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 Breast cancer is characterized by significant disease-related and treatment-related 
symptoms.  The objectives of this study were to identify classes of women experiencing 
similar symptom trajectories while undergoing chemotherapy for breast cancer and to 
determine if demographic, clinical, and symptom variables are associated with specific 
subgroups. 
 Through a secondary analysis, Latent Growth Mixture Modeling (LGMM) was 
used to examine potential subgroups of women experiencing similar symptom patterns.  
Daily symptom severity data for 10 symptoms reported by 166 women during cycles 2 
and 3 were analyzed.  The women’s mean age was 53 and most were Caucasian with 
Stage II disease.  Factors related to subgroup membership were explored for association 
with subgroups using independent-samples t tests, ANOVA, and chi-square analysis. 
 The multisymptom model did not reveal distinct subgroups of women with 
similar symptom profiles.  A 3-class solution was found for fatigue and 2-class models 
were found for disturbed sleep, depressed mood, and anxiety.   
Education was the only associated demographic factor with women with no 
college more likely to be in the moderate anxiety group (p=.03).  Type of chemotherapy 
was the only associated clinical variable with women who received doxorubicin more 
likely to be in higher severity classes for fatigue (p=.01), depressed mood (p<.01), and 
anxiety (p=.04).  More hours spent lying down was associated with membership in the 
higher fatigue (p=.02) and anxiety (p=.03) classes.
iv 
 
A variety of other symptoms were associated with worsening or higher severity 
symptom classes for each of the four symptoms in one or both treatment cycles.  Higher 
overall symptoms in cycle 2 were associated with the higher severity subgroups for all 
four symptoms in cycle 3. 
 Limitations were found using LGMM with daily symptom data and caution is 
warranted in interpreting study results.  Further research with longitudinal data, advanced 
statistical methods, and large samples is needed.  Findings suggest symptoms are 
common and co-occur.  Clinicians should be aware that symptoms at higher severity 
levels persist over cycles and require intensified management earlier to reduce continuing 
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Statement of the Problem 
Adequate symptom relief is an important goal for patients and clinicians during 
treatment for cancer (Kayl & Meyers, 2006).  Not only are symptoms major contributors 
to decreased quality of life and ability to function and disease-related interference with 
employment, but they may also interrupt treatment and influence treatment effectiveness 
(Bradley, Neumark, Luo, & Schenk, 2007; Cleeland et al., 2003; Groenvold et al., 2007; 
Kayl & Meyers, 2006).  Prompt evaluation and management of symptoms reduces use of 
emergency room and hospitalization, cost of treatment, and patient distress (Cleeland et 
al., 2000; Lee et al., 2004).  In addition, prompt and effective prevention or treatment of 
symptoms may result in less interference with employment and ability to work (Beck et 
al., 2010).   
Breast cancer is characterized by significant disease-related and treatment-related 
symptoms, but with a generally favorable prognosis.  The American Cancer Society 
(2015) predicted that 229,060 women would be diagnosed with breast cancer in 2015, 
making breast cancer the most frequently diagnosed cancer for women.  The expected 5-
year survival rate for women with localized breast cancer is 89% (ACS, 2015).  While 
women diagnosed with breast cancer may have increased survival when compared to 






uncertainty and residual symptom burden from treatment effect.  Aggressive, multimodal 
and multi-agent treatment may be associated with significant toxicities and side effects 
that, when combined with tumor and disease-related symptoms, significantly diminish 
quality of life (Kayl & Meyers, 2006). 
Considerable evidence suggests variability in the trajectories, or change in 
symptom prevalence, severity, and distress, over the courses of chemotherapy treatment 
for breast cancer (Dodd, Cho, Cooper, & Miaskowski, 2010).   Describing heterogeneity, 
correlates, and outcomes of different symptom trajectories will lead to more effective 
therapeutic models for symptom management. There is a large body of literature devoted 
to the description of single symptoms and, more recently, symptom clustering.  To date, 
most studies have focused on relationships between variables, such as the occurrence or 
association of specific symptoms in combination or relationships between demographic 
and clinical variables and symptom presentation (Dodd et al., 2010).  Prevalence is often 
studied as opposed to severity or distress.  Additionally, determination of which 
symptoms should be included in an analysis is often based on which symptoms are the 
more prevalent symptoms, not which symptoms are the more severe or distressing 
symptoms.  Methods for determining which symptoms to study are often a priori, using 
the literature and guided by theory.  While this method is practical, important symptoms 
that may be severe or distressing could remain inadvertently understudied.  More recent 
analyses have focused on identifying homogeneous classes of persons who share a 
common symptom trajectory profile (Dodd et al., 2010; Miaskowski et al., 2006; Pud et 
al., 2008).  Understanding trajectories of symptoms that occur in individuals may 






profiles, which may inform the development of better targeted interventions aimed at the 
reduction of symptoms during treatment. 
Recently, this topic has received increased attention, although well-designed 
longitudinal studies of breast cancer symptoms are rare (Dodd et al., 2010; Kayl & 
Meyers, 2006; Lee et al., 2004).  There is a growing body of literature devoted to 
describing symptom trajectories in women with breast cancer, but because the symptom 
experience is complicated and highly individualized, studies that develop trajectories 
based on daily symptom severity reporting and attempt to distinguish classes on the basis 
of personal and clinical variables are needed (Cleeland, Fisch & Dunn, 2011).  The 
purpose of this study was to examine patient-reported symptoms experienced daily by 
women with breast cancer over multiple cycles of chemotherapy, identifying classes of 
women experiencing similar symptom trajectories.    
Specific Aims 
Aim 1 
 To determine the trajectories and profile classes associated with the severity of 10 
symptoms (fatigue, pain, disturbed sleep, depressed mood, anxiety, nausea and vomiting, 
diarrhea, distress associated with changing appearance, sore mouth, and trouble thinking) 
reported by women undergoing cycles 2 and 3 of chemotherapy for breast cancer. 
 RQ 1.1: What are the trajectories of the severity of individual symptoms reported 
by women undergoing chemotherapy for breast cancer during cycle 2 and during cycle 3?
 RQ 1.2: What are the trajectory profile classes, if any, associated with the severity 
of individual symptoms reported by women undergoing chemotherapy for breast cancer 






 RQ 1.3: Do the profile classes associated with the severity of individual 
symptoms differ between cycle 2 and cycle 3 of chemotherapy? 
Aim 2 
 To identify multisymptom trajectory profile classes of patients undergoing cycles 
2 and 3 of chemotherapy for breast cancer. 
 RQ 2.1: What multisymptom profile classes can be identified in a cohort of 
women undergoing chemotherapy treatment for breast cancer during cycle 2 and during 
cycle 3? 
 RQ 2.2: Do the multisymptom profile classes differ between cycle 2 and cycle 3 
of chemotherapy? 
Aim 3 
 To determine if membership in differing multisymptom trajectory profiles is 
determined by various demographic, clinical, and symptom variables? 
 RQ 3.1: To what extent are differing symptom trajectory profiles associated with 
variations in age, chemotherapy regimen, stage of disease, marital status, employment, 
education, and the presentation of other symptoms at moderate to severe severity? 
Aim 4 
 To determine if differing multisymptom trajectory profiles are associated with 
variations in change in functional status, days of missed work, and hours spent lying 
down reported by women undergoing cycles 2 and 3 of chemotherapy for breast cancer. 
 RQ 4.1: To what extent are differing symptom trajectory profiles associated with 
variations in change in functional status, days of missed work, and hours spent lying 







 This section provides an overview of symptoms associated with breast cancer, 
including a description of prevalent symptoms, antecedents to symptoms, co-occurring 
symptoms, consequences of symptoms, and subgroups of individuals with similar 
symptom experiences.  Reports that focused on symptoms across varying cancer 
diagnoses and specific to breast cancer were included to support the identified aims and 
research questions.  Pertinent studies from 1986 to 2016 were identified through a 
systematic search in the Cumulative Index to Nursing and Allied Health and PubMed.  
Symptoms 
 Symptoms are self-reported, subjective phenomena that indicate a change in 
normal functioning, sensation, or appearance due to disease (Rhodes & Watson, 1987).  
Symptom reports describe the intensity, timing, level of distress, quality, and clustering 
of symptoms as well as the relationship between symptoms and demographic, clinical, 
and outcome variables (Dodd, Miaskowski, & Paul, 2001; Kim, McGuire, Tulman, & 
Barsevick, 2005; Lenz, Pugh, Milligan, Gift, & Suppe, 1997; Rhodes & Watson, 1987).  
The trajectory of cancer symptoms, or change in the presence and severity of the 
symptom over time, is dynamic throughout the course of treatment and survival (Payne, 
2002).  Cancer symptoms may have multiple etiologies, and may occur in response to 
disease-related tumor burden or treatment-related side effects, such as the acute and 
sometimes chronic effects of surgery, chemotherapy, or radiation (Payne, Piper, 
Rabinowitz, & Zimmerman, 2006). 
Wood, Nail, Gilster, Winters, and Elsea (2006) suggest that cancer symptoms are 






the absence of detectable tumor burden, such as in women with breast cancer undergoing 
adjuvant therapy after tumor resection.  Treatment-related symptoms usually begin at the 
onset of treatment, persist throughout treatment, and slowly decline thereafter, although 
treatment-related symptoms may persist at some level through survivorship (Wood et al., 
2006).   
Generally, challenges in the study of symptoms include difficulty determining 
whether symptoms are the result of tumor burden effects or treatment-related effects, 
obtaining serial data in longitudinal designs, and controlling for confounding variables, 
such as comorbidities, pharmacological agents, and the use of other symptom 
management strategies (Wood et al., 2006).  Confounding variables, particularly 
pharmacological agents, prove difficult to control for when patients engage in both self-
prescribed and medically prescribed therapies for symptom management.  For example, 
patients experiencing sleep disturbance may utilize therapies such as meditation, napping, 
exercise, and medications, including those that are both over-the-counter and prescription 
strength, to increase sleep time and quantity.  It may be difficult to capture and control for 
all of these therapies in a study of sleep disturbance. 
Symptoms in patients with breast cancer are often related to the effects of 
treatment as opposed to the effects of tumor burden, as the breast tumor itself does not 
typically cause symptoms.  Because of this, symptoms present during treatment of breast 
cancer may be attributed to the effects of treatment alone.  This allows for a unique 
setting in which treatment-related symptoms may be studied with minimal interference 
from disease-related symptoms (Kim, Barsevick, Tulman, & McDermott, 2008).  As a 






periods of treatment, such as cycles of chemotherapy or radiation, or postsurgical 
intervals. 
Over time, the science of cancer-related symptoms has become increasingly 
complex.  Reports range from simple cross-sectional studies of symptom prevalence to 
correlations between symptoms and antecedents and consequences to studies of co-
occurring symptoms to longitudinal studies of the trajectories of individual and multiple 
symptoms.  More recently, reports describe classes of individuals who experience similar 
trajectories and correlates of those trajectories using newer statistical modeling methods.   
Prevalent Symptoms in Breast Cancer  
There is an abundance of literature supporting a high prevalence of disturbing 
symptoms during chemotherapy in women with breast cancer.  The prevalence, possible 
etiologies, and trajectories of highly prevalent symptoms, including fatigue, sleep 
disturbance, pain, nausea and vomiting, trouble thinking, and mood disturbance, are 
discussed below. 
Fatigue 
 Fatigue is a complex, multidimensional symptom that patients may subjectively 
describe as weakness, weariness, sleepiness, tiredness, lack of energy, exhaustion, 
lethargy, or malaise (Bower et al., 2000; Winningham et al., 1994).  Fatigue is the most 
commonly reported and most distressing symptom associated with chemotherapy in the 
broader cancer literature (Payne, 2002; Payne et al., 2006).  The prevalence of fatigue in 
women with breast cancer varies across reports from 13% to 100% (Bender, Ergun, 
Rosenzweigh, Cohen, & Sereika, 2005; Bower et al., 2011; Browall, Persson, Ahlberg, 






Johansson, Fall-Dickson, Bakos, & Kennedy, 1999; Given, Given, Azzouz, & Stommel, 
2001; Jacobsen et al., 1999; Kim et al., 2008; Liu et al., 2009; Nieboer et al., 2005; So et 
al., 2009; Tchen et al., 2003).  The specific mechanisms underlying cancer-related fatigue 
are unknown, although proposed theories included pro-inflammatory cytokines, HPA 
axis dysregulation, circadian rhythm desynchronization, skeletal muscle wasting, and 
genetic dysregulation (National Comprehensive Cancer Network, 2010).  Cancer-related 
fatigue may result from depression, sleep disturbance, side effects of chemotherapy, 
endocrine imbalances, anemia, decreased ability to process nutrients, and increased 
energy requirements (Kim et al., 2005; National Comprehensive Cancer Network, 2010; 
Ware, Kosinski, & Keller, 1996).  Women with breast cancer report higher levels of 
fatigue when compared with women with no cancer history both before and after 
initiation of chemotherapy (Bower et al., 2001; Broeckel, Jacobsen, Horton, Balducci, & 
Lyman, 1998; Jacobsen et al., 1999; Nieboer et al., 2005; Payne et al., 2006).  Cancer 
patients often experience the highest levels of fatigue 48 hours after chemotherapy 
treatment, and while fatigue increases with the initiation of treatment, it does not appear 
to increase over time following the first cycle (Barsevick et al., 2004; Byar, Berger, 
Bakken, & Cetak, 2006; Jacobsen et al., 1999; Neiboer et al., 2005; Payne, 2002; Payne 
et al., 2006; Wilmoth, Coleman, Smith, & Davis, 2005).  In addition, fatigue increases 
after chemotherapy initiation and may persist for years following completion of breast 
cancer treatment (Berger & Higginbotham, 2000; Jacobsen et al., 1999; Payne et al., 








Significant disturbances in sleep are reported by cancer patients, including 
difficulty falling asleep and staying asleep (National Comprehensive Cancer Network, 
2011).  Over half of women (58-99%) report difficulty obtaining quality sleep during and 
following treatment for breast cancer (Beck et al., 2010; Bender et al., 2005; Berger & 
Higginbotham, 2000; Bower et al., 2011; Fortner et al., 2002; Given et al., 2001; Kim et 
al., 2008; Lee et al., 2005; Janz et al., 2007).  Sleep disturbance in women with breast 
cancer may be associated with the use of antiemetic protocols, including steroids, and the 
presence of menopausal symptoms, including hot flashes (Prigozin, Uziely, & Musgrave, 
2010).  Beck et al. (2010) reported that 65% of women begin chemotherapy for breast 
cancer with a history of poor sleep in the month proceeding therapy initiation.  In their 
sample, women had the poorest sleep quality on the first night following chemotherapy 
(Beck et al., 2010).  During chemotherapy treatment for breast cancer, the frequency and 
duration of nighttime awakening and reports of difficulty falling asleep and falling back 
asleep after awakening increase above normal limits (Berger & Higginbotham, 2000; 
Fortner et al., 2002).   
Pain 
Pain occurs in approximately 33% of patients undergoing treatment and 75% of 
patients with advanced disease for cancer generally (National Comprehensive Cancer 
Network, 2011).  Up to 70% of women receiving treatment for breast cancer experience 
pain (Bender et al., 2005; Gaston-Johansson et al., 1999; Given et al., 2001; So et al., 
2009).  Pain may be associated with treatment, with tumor, or unrelated to either and may 






Network, 2011).  More specifically, women with breast cancer may experience post-
surgical pain, neuropathic pain related to chemotherapy treatment, pain as a result of 
radiation-induced dermatitis, or pain related to sensorial alterations in the chest wall, arm, 
and axilla following surgery (Gaston-Johansson et al., 1999).  
Nausea and Vomiting 
 Despite advances in antiemetic pharmacologic agents, over half of all cancer 
patients suffer from nausea and vomiting during chemotherapy treatment (Lee et al., 
2005; Molassiotis, Yam, Yung, Chan, & Mok, 2002).  Up to 80% of women with breast 
cancer experience gastrointestinal symptoms (Browall et al., 2009; Kim et al., 2008; Lee 
et al., 2005; Tchen et al., 2003).  The pathways involved in the development of nausea 
and vomiting are complex and some mechanisms are not well understood, but may 
include neurotransmitters and neural pathways, the vomiting center in the brain stem, the 
chemoreceptor trigger zone, and chemicals (Molassiotis et al., 2002).  Of importance, 
women may experience a variety of types of nausea and vomiting, including anticipatory 
nausea, influenced by nonpharmacological factors such as demographic characteristics 
and anxiety, acute nausea and vomiting, or nausea that presents during the immediate 
days following chemotherapy administration, and/or delayed nausea and vomiting, which 
typically presents several days after chemotherapy administration (Lee et al., 2005; 
Molassiotis et al., 2002). 
Trouble Thinking 
 The symptoms of trouble thinking, which may include difficulty with 
concentration and memory, are prevalent among women receiving treatment for breast 






Cognitive changes may initiate with chemotherapy administration and continue through 
this use of hormonal therapies, including aromatase inhibitors (Downie et al., 2006; 
Merriman et al., 2015).  Cognitive dysfunction may be mediated by estrogen deprivation, 
a hormone that promotes synaptic and neural plasticity in the brain (Merriman et al., 
2015).  Chemotherapeutic agents and aromatase inhibitors may result in reduction of 
estrogen, and consequently, changes in cognitive function (Merriman et al., 2015). 
Mood Disturbance 
From the broader cancer literature, all patients experience some level of mood 
disturbance associated with a cancer diagnosis and treatment, and up to 40% of patients 
experience significant distress (National Comprehensive Cancer Network, 2010).  The 
symptoms of mood disturbance and their reported prevalence in women with breast 
cancer include depression (24-54%) (Bower et al., 2011; Gaston-Johansson et al., 1999; 
Kim et al., 2008; Liu et al., 2009; So et al., 2009) and anxiety (6-74%) (Bender et al., 
2005; Browall et al., 2009; So et al., 2009).  Mood disturbance may be related to anxiety, 
diagnostic testing, worries about disease progression, concern about an inability to 
perform usual functions, and concerns about the future (Gaston-Johansson et al., 1999).  
Chemotherapy may reduce a patient’s ability to function both physically and cognitively 
and increase morbidity, leading to increased mood disturbance (Gaston-Johansson et al., 
1999).  Additionally, symptoms of mood disturbance, including depressed mood and 









 Understanding potential antecedents to symptom expression may assist clinicians 
in targeting individuals at risk for the development of symptoms.  A brief summary of 
each demographic antecedent (age, marital status, employment, education status, and 
income) and each clinical factor antecedent (stage of disease and chemotherapy regimen) 
is provided in Table 1.1.   
While age does not appear as an antecedent to either fatigue or pain (Browall et 
al., 2008; deJong, Candel, Schouten, Abu-Saad, & Courtens, 2004; deJong, Kester, 
Schouten, Abu-Saad, & Courtens, 2006; Goldstein et al., 2012; Huang, Chen, Liang, & 
Miaskowski, 2014; Jacobsen et al., 1999; Von Ah, Kang, & Carpenter, 2008), increasing 
age may predict the presence of disturbed sleep, although reports are conflicting (Beck et 
al., 2010; Browall et al., 2008; Colagiuri et al., 2011; Onselen et al., 2012).  Beck et al. 
(2010) found that younger women experienced higher quality of sleep based on several 
sleep measures, including time in bed, total sleep time, and higher sleep percent.  
Additionally, Colagiuri et al. (2011) found that older age predicted sleep difficulty as 
measured by self-report.  In contrast, Browall et al. (2008) described a lack of correlation 
between age and disturbed sleep.  This difference in findings may be explained by 
differing samples, where Beck et al. (2010) and Colagiuri et al. (2011) studied women 
with ages ranging from 28-75 years and 26-70 years, respectively, and Browall et al. 
(2008) focused on older women only, with ages ranging from 55-77 years.  If disturbed 
sleep may be predicted by the presence of menopausal symptoms, including hot flashes, 
studies including samples of both premenopausal and postmenopausal women would be 






Table 1.1 Antecedents of Symptoms in Women With Breast Cancer 
 
Antecedent Symptom Evidence 
Age Fatigue 0 (deJong et al., 2004) b 
0 (deJong et al., 2006) b 
0 (Von Ah, Kang, & Carpenter, 2008) b 
0 (Jacobsen et al., 1999) b 
0 (Browall et al., 2008) b 
0 (Goldstein et al., 2012) b 
0 (Huang et al., 2014) b 
Disturbed Sleep + (Beck et al., 2010) b 
0 (Browall et al., 2008) b 
+ (Colagiuri et al., 2011) 
0 (Onselen et al., 2012) 
Depressed Mood 0 (Browall et al., 2008) b 
- (Gold et al., 2016) b 
Anxiety 0 (Browall et al., 2008) b 
- (Gold et al., 2016) b 
Pain 0 (Browall et al., 2008) b 
Nausea and Vomiting 0 (Browall et al., 2008) b 
- (Molassiotis et al., 2002) b 
Marital Status Fatigue Divorced women more fatigued than 
women living with a partner (deJong et 
al., 2004) b 
Married women more fatigued (Huang 
et al., 2013) b 
Married women receiving Doxorubicin 
experience later fatigue when compared 
to non-partnered women (deJong et al., 
2006) b 
0 (Jacobsen et al., 1999) b 
Disturbed Sleep 0 (Colagiuri et al., 2011) 
0 (Onselen et al., 2012) b 
Employment Fatigue 0 (deJong et al., 2004) b 
0 (deJong et al., 2006) b 
0 (Huang et al., 2014) b 
Disturbed Sleep Unemployment associated with 
disturbed sleep (Onselen et al., 2012) b 
Depressed Mood 0 (Gold et al., 2016) b 










Table 1.1 continued 
 
Antecedent Symptom Evidence 
Education Status Fatigue 0 (deJong et al., 2004) b 
+ (Huang et al., 2013) b 
0 (deJong et al., 2006) b 
0 (Von Ah et al., 2008) b 
0 (Jacobsen et al., 1999) b 
0 (Goldstein et al., 2012) b 
Sleep Disturbance  0 (Beck et al., 2010) b 
0 (Colagiuri et al., 2011) 
+ (Onselen et al., 2012) 
Depressed Mood 0 (Gold et al., 2016) b 
Anxiety 0 (Gold et al., 2016) b 
Income Fatigue 0 (Von Ah et al., 2008) b 
0 (Jacobsen et al., 1999) b 
Disturbed Sleep 0 (Colagiuri et al., 2011) 
Depressed Mood 0 (Gold et al., 2016) b 
Anxiety 0 (Gold et al., 2016) b 
Stage of Disease Fatigue 0 (deJong et al., 2004) b 
0 (Von Ah et al., 2008) b 
0 (Jacobsen et al., 1999) b 
Sleep Disturbance 0 (Beck et al., 2010) b 
0 (Colagiuri et al., 2011) 
0 (Onselen et al., 2012) b 
Nausea and Vomiting Later stage predicts increased nausea 
and vomiting (Molassiotis et al., 2002) b 
Chemotherapy 
Regimen 
Fatigue 0 (Berger, 1998) b 
0 (Berger & Farr, 1999) b 
CMF stable fatigue during treatment 
with late effect fatigue, Doxorubicin 
increase in fatigue at initial 
measurement (deJong et al., 2004) b 
CMF lower fatigue peak than 
Doxorubicin, Cyclophosphamide late 
fatigue peak (de Jong et al., 2006) b 
a +, antecedent positively correlated with symptom, -, antecedent negatively correlated with symptom, 0, 
no relationship between antecedent and symptom identified 








Additionally, reports of the relationship between age and mood disturbance and age and 
nausea and vomiting are similarly conflicting.  For example, while Gold et al. (2016) 
found that younger women experienced increased depressed mood and anxiety when 
compared to older women, Browall et al. (2008) found no association between age and  
mood disturbance.  Again, Browall et al. (2008), with a sample of older women only, did 
not identify differences between younger and older women in these symptoms.  While 
Browall et al. (2008) found no relationship between age and nausea and vomiting, 
Molassiotis et al. (2002) found that younger age was predictive of increased acute nausea 
and vomiting.     
 Marital status as a predictor variable of symptoms in breast cancer is reported 
with mixed findings.  While deJong et al. (2004) found that divorced women were more 
fatigued when compared to women living with a partner, Huang et al. (2013) found that 
married women were more fatigued when compared to nonmarried women.  
Additionally, Jacobsen et al. (1999) found no relationship between marital status and 
fatigue and Colagiuri et al. (2011) and Onselen et al. (2012) found no relationship 
between marital status and disturbed sleep.   
 Lack of employment is associated with increases in disturbed sleep (Onselen et 
al., 2012).  Employment status is not reported to influence fatigue or mood disturbance in 
women with breast cancer (deJong et al., 2004; deJong et al., 2006; Gold et al., 2016; 
Huang et al., 2014; Onselen et al., 2012). 
 Education status as an antecedent of symptoms in breast cancer is also reported 
with conflicting findings.  While Huang et al. (2013) found that women with higher 






education status and fatigue (deJong et al., 2004; deJong et al., 2006; Goldstein et al., 
2012; Jacobsen et al., 1999; Von Ah et al., 2008).  Huang et al. (2013) studied a sample 
of women with a large variability of educational levels, and suggest that a lack of 
association between educational status and fatigue in other studies may be attributable to 
homogeneity in educational status among the samples of other studies, where most 
women had at least some college education.  Onselen et al. (2012) found that increased 
education was associated with increased sleep disturbance and suggest that this 
relationship may be mediated by higher levels of distress related to increased knowledge 
about disease and treatment.  Alternatively, others have found no relationship between 
education status and sleep disturbance (Beck et al., 2010; Colagiuri et al., 2011).  
Additionally, Gold et al. (2016) found no relationship between educational status and the 
symptoms of mood disturbance. 
 A relationship between income and either fatigue or mood disturbance has not 
been found in women with breast cancer (Gold et al., 2016; Jacobsen et al., 1999; Von 
Ah et al., 2008).  Similarly, income has not been associated with disturbed sleep in 
women with breast cancer (Colagiuri et al., 2011). 
 Stage of disease has not been related to the presence of either fatigue or sleep 
disturbance (Beck et al., 2010; Colagiuri et al., 2011; deJong et al., 2004; Jacobsen et al., 
1999; Onselen et al., 2010; Von Ah et al., 2008).  Molassiotis et al. (2002) found that 
later stage of disease predicted increased nausea and vomiting and suggest that the 
additive effects of nausea and vomiting may be attributable to progressive illness. 
 Finally, chemotherapy regimen has been studied as a potential antecedent of 






(1998) and Berger and Farr (1999) found that levels of fatigue 48 hours after each of the 
first 3 chemotherapy treatments were not significantly different when comparing cohorts 
of women who received CMF, Doxorubicin with Cyclophosphamide, and CAF.  In a 
longitudinal study of the trajectory of fatigue, deJong et al. (2004) found that women 
receiving CMF reported stable fatigue during chemotherapy with late effect fatigue and 
women receiving Doxorubicin reported increases in fatigue just after chemotherapy 
receipt.  In another longitudinal study of the trajectory of fatigue, deJong et al. (2006) 
reported significant differences in the course of fatigue between those receiving CMF and 
those receiving Doxorubicin, with fatigue peaking at a later time for those receiving 
Cyclophosphamide.  Differing findings concerned with the relationship between 
chemotherapy regimen and fatigue may be related to methodological differences among 
the studies, including the design and measurement time-points.    
Co-Occurring Symptoms 
 Symptoms may co-occur in women during treatment for breast cancer.  The 
collective consequence of simultaneous multiple symptoms may result in increased 
impairment when compared to the consequence of a single symptom (Barsevick, 2007; 
Dodd et al., 2001; Kim et al., 2008; Lee et al., 2004).  The study of multiple symptoms 
simultaneously allows for the identification of shared symptom trajectories, symptom 
burden, and symptom mechanisms (Cleeland et al., 2003).  A brief summary of co-
occurring symptoms, focused on fatigue, disturbed sleep, depressed mood, anxiety, pain, 
nausea and vomiting, and trouble thinking, is provided in Table 1.2.  The reported 
symptom co-occurrences were found through correlational studies and studies of 











Fatigue Disturbed Sleep + (Berger & Higginbotham, 2000) b 
+ (Ancoli-Israel et al., 2006) 
+ (Jacobsen et al., 1999) b 
+ (Broeckel et al., 1998) 
+ (Berger & Farr, 1999) b 
+ (Liu et al., 2012) b 
+ (Bower et al., 2011) 
+ (Berger, 1998) b 
+ (Goldstein et al., 2012) b 
+ (Berger et al., 2007) 
+ (Berger et al., 2010) 
+ (Bender et al., 2005) b 
+ (Onselen et al., 2012) b 
+ (Kim et al., 2008) b 
+ (Liu et al., 2009) b 
0 (Prigozin et al., 2010) 
Depressed Mood + (Huang et al., 2013) b 
+ (Von Ah et al., 2008) b 
+ (Jacobsen et al., 1999) b 
+ (Ancoli-Israel et al., 2006) 
+ (Byar et al., 2006) b 
+ (Niebor et al., 2005) b 
+ (Bower et al., 2011) 
+ (Gaston-Johansson, et al., 1999) 
+ (Goldstein et al., 2012) b 
+ (Bender et al., 2005) b 
+ (Kim et al., 2008) b 
+ (Liu et al., 2009) b 
+ (Prigozin et al., 2010) 
Anxiety + (Byar et al., 2006) b 
+ (Dragomir & Fodoreanu, 2013) 
+ (Bender et al., 2005) 
+ (Prigozin et al., 2010) 
Pain + (Jacobsen et al., 1999) b 
+ (Niebor et al., 2005) b 
+ (Gaston-Johansson, et al., 1999) 
+ (Bender et al., 2005) b 
+ (Kim et al., 2008) b 
0 (Prigozin et al., 2010) 
Nausea and Vomiting + (Jacobsen et al., 1999) b 
+ (Molassiotis et al., 2002) b 











Fatigue, cont. Trouble Thinking + (Jacobsen et al., 1999) b 
+ (Merriman et al., 2015) b 
+ (Bender et al., 2005) 
+ (Kim et al., 2008) b 
0 (Prigozin et al., 2010) 
Disturbed Sleep Fatigue + (Berger & Higginbotham, 2000) b 
+ (Ancoli-Israel et al., 2006) 
+ (Jacobsen et al., 1999) b 
+ (Broeckel et al., 1998) 
+ (Berger & Farr, 1999) b 
+ (Liu et al., 2012) b 
+ (Bower et al., 2011) 
+ (Berger, 1998) b 
+ (Goldstein et al., 2012) b 
+ (Berger et al., 2007) 
+ (Berger et al., 2010) 
+ (Bender et al., 2005) b 
+ (Onselen et al., 2012) b 
+ (Kim et al., 2008) b 
+ (Liu et al., 2009) b 
0 (Prigozin et al., 2010) 
Depressed Mood + (Ancoli-Israel et al., 2006) 
+ (Colagiuri et al., 2011) 
+ (Berger et al., 2010) 
+ (Bender et al., 2005) b 
+ (Kim et al., 2008) b 
+ (Liu et al., 2009) b 
0 (Prigozin et al., 2010) 
Anxiety + (Colagiuri et al., 2011) 
+ (Bender et al., 2005) b 
0 (Prigozin et al., 2010) 
Pain + (Fortner et al., 2002) 
+ (Bender et al., 2005) b 
+ (Kim et al., 2008) b 
0 (Prigozin et al., 2010) 
Nausea and Vomiting 0 (Prigozin et al., 2010) 
Trouble Thinking + (Bender et al., 2005) b 
+ (Kim et al., 2008) b 












Depressed Mood Fatigue + (Von Ah et al., 2008) b 
+ (Jacobsen et al., 1999) b 
+ (Ancoli-Israel et al., 2006) 
+ (Byar et al., 2006) b 
+ (Niebor et al., 2005) b 
+ (Bower et al., 2011) 
+ (Gaston-Johansson, et al., 1999) 
+ (Goldstein et al., 2012) b 
+ (Prigozin et al., 2010) 
+ (Bender et al., 2005) b 
+ (Kim et al., 2008) b 
+ (Liu et al., 2009) b 
Disturbed Sleep + (Ancoli-Israel et al., 2006) 
+ (Colagiuri et al., 2011) 
+ (Bender et al., 2005) b 
+ (Kim et al., 2008) b 
+ (Liu et al., 2009) b 
0 (Prigozin et al., 2010) 
Anxiety + (Gold et al., 2016) b 
+ (Prigozin et al., 2010) 
+ (Bender et al., 2005) b 
Pain + (Gaston-Johansson, et al., 1999) 
+ (Bender et al., 2005) b 
+ (Kim et al., 2008) b 
0 (Prigozin et al., 2010) 
Nausea and Vomiting 0 (Prigozin et al., 2010) 
Trouble Thinking + (Merriman et al., 2015) b 
+ (Bender et al., 2005) 
+ (Kim et al., 2008) b 
0 (Prigozin et al., 2010) 
Anxiety Fatigue + (Byar et al., 2006) 
+ (Dragomir & Fodoreanu, 2013) 
+ (Bender et al., 2005) b 
0 (Prigozin et al., 2010) 
Disturbed Sleep + (Colagiuri et al., 2011) 
+ ( Bender et al., 2005) b 
0 (Prigozin et al., 2010) 
Depressed Mood + (Gold et al., 2016) b 
+ (Prigozin et al., 2010) 
+ (Bender et al., 2005) b 
Pain + (Bender et al., 2005) b 











Anxiety, cont. Nausea and Vomiting + (Molassiotis et al., 2002) b 
0 (Prigozin et al., 2010) 
Trouble Thinking + (Merriman et al., 2015) b 
+ (Bender et al., 2005) b 
0 (Prigozin et al., 2010) 
Pain Fatigue + (Jacobsen et al., 1999) b 
+ (Niebor et al., 2005) 
+ (Gaston-Johansson, et al., 1999) 
+ (Bender et al., 2005) b 
+ (Kim et al., 2008) b 
0 (Prigozin et al., 2010) 
Depressed Mood + (Gaston-Johansson, et al., 1999) 
+ (Bender et al., 2005) b 
+ (Kim et al., 2008) b 
0 (Prigozin et al., 2010) 
Disturbed Sleep + (Fortner et al., 2002) 
+ (Bender et al., 2005) b 
+ (Kim et al., 2008) b 
0 (Prigozin et al., 2010) 
Anxiety + (Bender et al., 2005) 
0 (Prigozin et al., 2010) 
Nausea and Vomiting 0 (Prigozin et al., 2010) 
Trouble Thinking + (Bender et al., 2005) b 
+ (Kim et al., 2008) 
0 (Prigozin et al., 2010) 
Nausea and 
Vomiting 
Fatigue + (Jacobsen et al., 1999) b 
+ (Molassiotis et al., 2002) b 
0 (Prigozin et al., 2010) 
Disturbed Sleep 0 (Prigozin et al., 2010) 
Depressed Mood 0 (Prigozin et al., 2010) 
Anxiety + (Molassiotis et al., 2002) b 
0 (Prigozin et al., 2010) 
Pain 0 (Prigozin et al., 2010) 













Trouble Thinking Fatigue + (Jacobsen et al., 1999) b 
+ (Merriman et al., 2015) b 
+ (Bender et al., 2005) b 
+ (Kim et al., 2008) b 
0 (Prigozin et al., 2010) 
Disturbed Sleep + (Bender et al., 2005) b 
+ (Kim et al., 2008) 
0 (Prigozin et al., 2010) 
Depressed Mood + (Merriman et al., 2015) b 
+ (Bender et al., 2005) b 
+ (Kim et al., 2008) b 
0 (Prigozin et al., 2010) 
Anxiety + (Merriman et al., 2015) b 
+ (Bender et al., 2005) b 
0 (Prigozin et al., 2010) 
Pain + (Bender et al., 2005) b 
+ (Kim et al., 2008) b 
0 (Prigozin et al., 2010) 
0 (Merriman et al., 2015) b 
Nausea and Vomiting 0 (Prigozin et al., 2010) 
a +, co-occurring symptoms positively correlated, 0, no relationship between two symptoms identified 








Fatigue is commonly reported to co-occur with other symptoms in women with 
breast cancer, including disturbed sleep (Ancoli-Israel et al., 2006; Bender et al., 2005; 
Berger, 1998; Berger & Farr, 1999; Berger & Higginbotham, 2000; Berger, Farr, Kuhn, 
Fischer, & Agrawal, 2007; Berger, Wielgus, Hertzog, Fischer, & Farr, 2010; Bower et al.,  
2011; Broeckel et al., 1998; Goldstein et al., 2012; Jacobsen et al., 1999; Kim et al., 
2008; Liu et al., 2009; Liu et al., 2012; Onselen et al., 2012). Only one report was found  
where fatigue did not co-occur with disturbed sleep when the correlation of symptoms 
were studied in women with breast cancer (Prigozin et al., 2010).  Symptoms of mood 
disturbance often co-occur with fatigue in women with breast cancer, including depressed 
mood (Ancoli-Israel et al., 2006; Bender et al., 2005; Bower et al., 2011; Byar et al., 
2006; Gaston-Johansson et al., 1999; Goldstein et al., 2012; Huang et al., 2013; Jacobsen 
et al., 1999; Kim et al., 2008; Liu et al., 2009; Niebor et al., 2005; Prigozin et al., 2010; 
Von Ah et al., 2008) and anxiety (Bender et al., 2005; Byar et al., 2006; Dragomir & 
Fodoreanu, 2013; Prigozin et al., 2010).  Additionally, pain is reported to co-occur with 
fatigue in all but one study of women with breast cancer where both symptoms were 
included in analyses of correlations or clusters (Bender et al., 2005; Gaston-Johansson et 
al., 1999; Jacobsen et al., 1999; Kim et al., 2008; Niebor et al., 2005).  Only Prigozin et 
al. (2010) reported on a lack of a strong correlation between pain and fatigue in their 
analysis.  The relationship between nausea and vomiting with fatigue is reported with 
conflicting findings.  While Jacobsen et al. (1999) and Molassiotis et al. (2002) found 
these two symptoms strongly correlated in breast cancer, Prigozin et al. (2010) did not.  
Trouble thinking has also been reported to co-occur with fatigue in several studies of the 






1999; Kim et al., 2008; Merriman et al., 2015), with only Prigozin et al. (2010) reporting 
a lack of strong correlation between these two symptoms. 
 In addition to the relation to fatigue described earlier, disturbed sleep has been 
reported to co-occur with several other symptoms in women with breast cancer.  
Depressed mood (Ancoli-Israel et al., 2006; Bender et al., 2005; Berger et al., 2010; 
Colagiuri et al., 2011; Kim et al., 2008; Liu et al., 2009) and anxiety (Bender et al., 2005 ; 
Colagiuri et al., 2011) are reported to correlate with disturbed sleep in women with breast 
cancer.  Only Prigozin et al. (2010) did not find a strong relationship between symptoms 
of mood disturbance and disturbed sleep.  Additionally, pain (Bender et al., 2005; Fortner 
et al., 2002; Kim et al., 2008) and trouble thinking (Bender et al., 2005; Kim et al., 2008) 
are reported to co-occur with disturbed sleep, in all reviewed studies, with the exception 
of Prigozin et al. (2010).  Prigozin et al. (2010) also reported on a lack of strong 
correlation between nausea and vomiting and disturbed sleep. 
 The symptoms of mood disturbance (depressed mood and anxiety) are reported to 
co-occur (Bender et al., 2005; Gold et al., 2016; Prigozin et al., 2010).  The co-
occurrence of depressed mood and anxiety with fatigue and disturbed sleep are 
previously described.  Depressed mood is also reported to co-occur with pain (Bender et 
al., 2005; Gaston-Johansson et al., 1999; Kim et al., 2008) and trouble thinking (Bender 
et al., 2005; Kim et al., 2008; Merriman et al., 2015).  In addition, anxiety is reported to 
co-occur with pain (Bender et al., 2005), nausea and vomiting (Molassiotis et al., 2002), 
and trouble thinking (Bender et al., 2005; Merriman et al., 2015).  Prigozin et al. (2010) 
found an insignificant correlation between depressed mood and pain, depressed mood and 






nausea and vomiting, and anxiety and trouble thinking. 
 As previously described, pain is reported to co-occur with fatigue, disturbed sleep, 
depressed mood, and anxiety.  Pain is also reported to co-occur with trouble thinking 
(Bender et al., 2005; Kim et al., 2008), although Prigozin et al. (2010) did not find a 
strong correlation between these two symptoms.  Additionally Prigozin et al. (2010) did 
not find a strong correlation between pain and nausea and vomiting.  Finally, nausea and 
vomiting is reported to co-occur with fatigue and anxiety as previously described, but not 
with disturbed sleep, depressed mood, pain, or trouble thinking (Prigozin et al., 2010).   
Consequences 
 
 Symptoms may influence outcomes, including changes in quality of life and 
functional status, changes in activity level, loss of employment, and interruption of 
treatment (Bradley et al., 2007; Cleeland et al., 2003; Kayl & Meyers, 2006).  A brief 
summary of three potential consequences, changes in functional status and activity level 
and hours spent lying down, is provided in Table 1.3.   
 Decline in functional status is associated with several symptoms in women with 
breast cancer, including fatigue (Ancoli-Israel et al., 2006; Berger & Higginbotham, 
2000; Downie et al., 2006; Huang et al., 2013), disturbed sleep  (Ancoli-Israel et al., 
2006; Beck et al., 2010; Colagiuri et al., 2011; Fortner et al., 2002; Onselen et al., 2012), 
depressed mood (Ancoli-Israel et al., 2006; Gold et al., 2016; Ng et al., 2015), anxiety 
(Gold et al., 2016; Ng et al., 2015), and nausea and vomiting (Lee et al., 2005).  
Additionally, fatigue, disturbed sleep, and nausea and vomiting are reported to correlate 
with decline in activity level during treatment in women with breast cancer (Berger, 






Table 1.3 Consequences of Symptoms in Women With Breast Cancer 
Consequence Symptom Evidence 
Functional Status Fatigue - (Berger & Higginbotham, 2000) b 
- (Huang et al., 2013) b 
- (Ancoli-Israel et al., 2006) 
- (Downie et al., 2006) 
Disturbed Sleep - (Beck et al., 2010) b 
- (Ancoli-Israel et al., 2006) 
- (Colagiuri et al., 2011) 
- (Fortner et al., 2002) 
- (Onselen et al., 2012) b 
Depressed Mood - (Ancoli-Israel et al., 2006) 
- (Ng et al., 2015) b 
- (Gold et al., 2016) b 
Anxiety - (Ng et al., 2015) b 
- (Gold et al., 2016) b 
Nausea and Vomiting - (Lee et al., 2005) b 
Activity Level Fatigue - (Berger & Higginbotham, 2000) b 
- (deJong et al., 2004) b 
- (Jacobsen et al., 1999) b 
- (Berger & Farr, 1999) b 
- (Berger, 1998) b 
Disturbed Sleep - (Colagiuri et al., 2011) 
Nausea and Vomiting - (Lee et al., 2005)b
Hours Lying Down Nausea and Vomiting + (Lee et al., 2005) b 
a +, consequence positively correlated with symptom, -, consequence negatively correlated with symptom, 
0, no relationship between consequence and symptom identified 







et al., 2004; Jacobsen et al., 1999; Lee et al., 2005).  Increased nausea and vomiting is 
associated with increased hours spent lying down (Lee et al., 2005). 
Subgroup Studies in Breast Cancer 
 Despite the abundance of reports of co-occurring symptoms within breast cancer, 
there are several inconsistencies in the methods used to determine whether symptoms co-
occur.  One inconsistency is the method used to determine which symptoms to include in  
the analysis.  Across the breast cancer literature, four symptoms: pain, psychological 
distress, fatigue, and sleep disturbance, are consistently reported as significant and 
distressing and are often reported as co-occurring.  In contrast, there are limited reports 
on the co-occurrence other highly prevalent and distressing symptoms, including 
cognitive impairment, menopausal symptoms, and gastrointestinal symptoms.  These 
other symptoms are commonly left out of correlational and symptom cluster studies. 
Reports cite the use of expert panels, the use of minimal available data in secondary 
analyses, or simply neglect to describe the a priori method used to determine which 
symptoms to study (Bender et al., 2005; Dodd et al., 2010; Gaston-Johansson et al., 1999; 
Glaus et al., 2006; Liu et al., 2009; So et al., 2009).  When studying symptom clusters, an 
analysis that allows the symptoms that are actually reported by the participants in the 
sample to guide the determination of which symptoms to include in studies of co-
occurrence is optimal.   
Another inconsistency in the symptom literature is a lack of common statistical 
approaches used to identify co-occurring symptoms (Dodd et al., 2010).  Multiple 
approaches are reported, including correlational studies, regression, factor analysis, and 






predictors of outcomes, such as symptoms and describe how dependent and independent 
variables are related, including co-occurring symptoms (Jung & Wickerama, 2007).  
Important advancements in statistical modeling, such as cluster analysis, finite mixture 
analysis, latent class analysis, and growth mixture modeling, have allowed for the 
identification of homogeneous classes that share a common profile or pattern on several 
factors of interest, such as symptom presentation (Colder, Richardson, Campbell, Ruel, & 
Flay, 2002; Muthen & Muthen, 2000).  These approaches focus on the relationships 
among individuals and the goal is to classify individuals into distinct groups, where 
individuals within a group are more similar than individuals between groups (Jung & 
Wickerama, 2007).  The identification of classes of individuals, sometimes called 
subgroups, may help to identify at-risk individuals who may benefit from specific 
targeted symptom management during treatment (Dodd et al., 2001).    
Table 1.4 presents a brief overview of several recent reports where classes of 
women with breast cancer displaying similar symptom experiences were identified using 
various approaches, including pattern-based, cluster analysis, latent class analysis, and 
mixture modeling.  For each reviewed study, the statistical methods, a description of the 
identified classes, and any correlates associated with class membership are summarized.  
A brief discussion of Cluster Analysis and Latent Class Analysis is presented, followed 
by a discussion of the usefulness of Latent Growth Mixture Modeling techniques in 
subgroup studies.  
Cluster Analysis   
Among studies in breast cancer, a longitudinal study of the symptoms of pain, 






Table 1.4 Subgroup Studies in Breast Cancer 
Analysis Reference Symptom Sample Size Measurement Times Classes Correlates 
Pattern-Based Deshields, Tibbs, 
Fan, & Taylor 
(2006) 
Depression n=84 Patterns Determination 
applied to CES-D 
threshold placement at 
end-of-treatment 
baseline, and 3 and 6 
months  
5: Never Depressed 
(60.7%), Become 
Depressed (3.6%), 
Recover (9.5%), Stay 
Depressed (11.9%), 
Vacillate (14.3%) 
-Become Depressed class had 
more children at home 
-Vacillate class had fewer 
children at home  
-Never Depressed class had 












n=112 Hierarchical Clusters 
Analysis applied to 
symptom scores at 
baseline, end of CTX, 
and one year post-
treatment  
4: All Low (52.2%), 
Mild (5.3%), Moderate 
(34.0%), All High 
(8.5%) (at baseline);  
4: All Low (39.3%), 
Mild (22.3%), Moderate 
(27.7%), All High 
(10.6%) (at end of CTX 
treatment);  
3: Mild (76.6%), 
Moderate (16.0%), All 
High (3.2%) (at one-
year) 
-All High class reported poorer 







n=133 Hierarchical Clusters 
Analysis applied to 
MSAS scores at 
baseline, end of CTX 
2: High Symptoms 
(33.8%), Low Symptoms 
(66.2%) 
-High Symptoms class more 
likely to have stage I disease 
-High Symptoms class more 
likely to report greater 
symptom prevalence and 











n=391  Latent Class Analysis 
applied to symptom 
scores the week 
following CTX 
3: All Low (35.8%), All 
Moderate (48.3%), All 
High (15.9%) 
 
-All High class had a lower 
functional status, higher 
comorbidity profile, higher 
symptom burden, poorer 







Table 1.4 continued 
 
Analysis Reference Symptom Sample Size Measurement Times Classes Correlates 






n=171  Finite Mixture Model 
applied to 
psychological distress 
during the first year 
after diagnosis using 5 
time-points (intercept at 
diagnosis)  
4: No Distress (36%), 
Recovery (33%), Late 
(15%), Chronic (15%) 
 -Recovery class and Chronic 
class had lower sense of 







n=287 Finite Mixture 
Modeling applied to 
SF-36  (MCS) 
measured at 4, 7, 13, 
19, 31, 43, 55 months 
post-diagnosis 
4 for MCS: Traj1 
(12.2%), Traj2 (26.5%), 
Traj3 (18.1%), Traj4 
(43.2%) 
4 for PCS: Traj1 
(19.5%), Traj2 (2.1%), 
Traj3 (23.3%), Traj4 
(55.1%) 
-Personal and social resources 
at the beginning of study 
distinguished different classes 
of MCS and PCS 





n=323 Finite Mixture 
Modeling applied to 
symptom scores at 
diagnosis,4, 8 months  
3: Depression, 5: 
Distress, 2: Anxiety  
-Most Distressed class had 
younger women, women 
without a partner, less 
education, chemotherapy 
Dunn et al. 
(2015) 
Depression n=398 Growth Mixture 
Modeling applied to 
CES-D prior to and 
monthly for 6 months 
after surgery 
4: Resilient (38.9%), 
Subsyndromal (45.2%), 
Delayed (11.3%), Peak 
(4.5%) 
-Subsyndromal class younger 
than women in Resilient class 
-Subsyndromal, Delayed, and 
Peak classes had higher mean 
trait and state anxiety scores 
prior to surgery compared to 
Resilient  
Lam et al. (2010) Psychological 
Distress 
n=285 Growth Mixture 
Modeling applied to 
Chinese Health 
Questionnaire scores at 
baseline postsurgery 
and 1,4,8-months after 




-Resilient class had less 
distress  
-Resilient class had less 
problems with satisfaction 
with treatment decisions 
-Age, education, occupation, 
stage of disease associated 






Table 1.4 continued 
 
Analysis Reference Symptom Sample Size Measurement Times Classes Correlates 








(Lam et al., 
2010) 
Multivariate analyses 
applied to anxiety, 
depression, cancer 
distress, and social 
morbidity at 6-year  





Recovery classes had higher 6-
year anxiety  
-Chronic class had higher 
depression  
 Wang, Chang, 




n=124 Growth Mixture 
Modeling applied to 
PTG scores at day 1, 
and 3,6,12 months after 
surgery 
4: Stable high (27.4%), 
High Decreasing 
(39.4%), Low Increasing 
(16.9%), Low 
Decreasing (16.9%) 
-Low Deceasing class more 
NA, more anxiety, worse MCS 
-High Decreasing class 
negative associates between 
PTG and NA, depression and 
anxiety 




n=398 Growth Mixture 
Modeling applied to  
sleep disturbance scores 
monthly for 6 months 
following surgery  




-High class had younger age, 
lower KPS, higher SCQ, hot 
flashes 
-Decreasing class had CTX -
Mastectomy or breast 
reconstruction  
-Decreasing & High classes 
had higher fatigue 
-High class had higher trait 
anxiety, state anxiety, CES-D  




n=335 Growth Mixture 
Modeling applied to 
Spielberger State-Trait 
Anxiety Inventories and 
CES-D scores at prior 
to and 6 months after 
surgery 
4: Higher Anxiety and 
Subsyndromal (44.5%), 
Lower and Anxiety and 
Resilient (32.5%), 
Higher Anxiety and 
Resilient (11.6%), Lower 
Anxiety and 
Subsyndromal (9.3%) 
-Higher Anxiety and 
Subsyndromal class younger  
-Higher Anxiety and Resilient 
and Higher Anxiety and 
Subsyndromal classes more 
non-white -Both 
Subsyndromal classes lower 
KPS scores  
-Higher Anxiety and  
Subsyndromal class lower 






with similar symptom trajectories (Dodd et al., 2010).  Over three measurement times, 
baseline, post-treatment, and 1-year follow-up, a class with all low symptoms, a class 
with mild symptoms, a class with moderate symptoms, and a class with all high 
symptoms were fitted using cluster analysis.  All four classes were found at baseline and 
post-treatment, and only the low symptoms class was not found at 1-year follow-up.  The 
all high symptoms class reported poorer functional status and QOL when compared to the 
other classes.  Gwede et al. (2008) also used Cluster Analysis to fit two classes, high and 
low symptoms over two measurement times, baseline and end of chemotherapy.  The 
high symptoms class was more likely to have less advanced staging and report greater 
symptom prevalence and poorer QOL following treatment.  A disadvantage of cluster 
analysis in subgroup studies is the assumption that classification is perfectly reliable, 
while in reality, classes based on longitudinal trajectories of symptoms are likely to have 
more ambiguous boundaries.  Therefore, conclusions about antecedents and 
consequences to these classifications may be erroneous (Colder et al., 2002).  
Importantly, cluster analysis only allows for studying one dimension of change in a 
variable, where, for example, symptoms severity and distress associated with a symptom 
could not be simultaneously studied (Colder et al., 2002).  Additionally, this method does 
not allow for the easy identification of individual change in symptom experience over 
time, or the ability to follow an individual’s growth model and map it to a class trend.   
 Latent Class Analysis 
 Langford et al. (2016) used latent class analysis (LCA) to identify classes of 
women with breast cancer who experienced a common symptom presentation of four 






chemotherapy administration.  Three classes were identified: low, moderate, and all high.  
Potential antecedents and consequences to class membership were studied, and 
participants in the all high class had a lower functional status, higher comorbidity profile, 
higher symptom burden, and poorer quality of life.  Importantly, LCA was used to 
determine classes of women who experienced a common symptom presentation in a 
cross-sectional design, at a single measurement time following chemotherapy 
administration.  LCA does not allow for modeling trajectories over time.  When studying 
classes of individuals with similar symptom experiences, a statistical method that allows 
for the statistical inference of trajectories of individuals and modeling of classes based on 
change over time is optimal. 
Latent Growth Mixture Modeling 
Conventional latent growth modeling allows for modeling of individual 
differences in growth on an outcome, providing latent growth factor means and variances.  
Latent growth mixture modeling (LGMM) further allows for the identification of discrete 
classes of individuals on the basis of common trajectories of growth, wherein each latent 
class has its own model of growth.  The categorical latent variables represent the category 
or class that describes groups of individuals who are homogeneous within that class and 
are heterogeneous across classes (Muthen & Muthen, 2000).   Classes are defined on the 
basis of different trajectories of change.  The goal of LGMM is to add classes stepwise 
until the model shows the smallest number of latent classes that can describe the 
associations among a set of observed measures (Muthen & Muthen, 2000).  Further, the 
probability of membership in a class and variances within the classes are estimated for 






Finally, LGMM may relate the probability of class membership to antecedents and may 
relate the probability of a given consequence based on class membership (Muthen & 
Muthen, 2000).   
There are a few studies that have used LGMM, and similar methods of Finite 
Mixture Modeling, to identify distinct classes of women with breast cancer experiencing 
similar symptom trajectories during various time points ranging from diagnosis through 
end of treatment and into survivorship.  Among studies of the symptoms of mood 
disturbance, depressed mood and anxiety, there are several that have applied these 
methods to measures of these symptoms over time with varying findings (Bidstrup et al., 
2015; Dunn et al., 2015; Gold et al., 2016; Helgeson et al., 2004; Henselmans et al., 
2010; Lam et al., 2010; Wang et al., 2014).  Henselmans et al. (2010), Lam et al. (2010), 
and Gold et al. (2016) described four classes of psychological distress that were similar in 
trajectories, but different class count percentages.  Helgeson et al. (2004) described four 
classes for physical adjustment and four classes for psychological adjustment over 
several years of follow-up.  Dunn et al. (2015) described four classes of depression and 
Bidstrup et al. (2015) described three classes of depression, five classes of distress, and 2 
classes of anxiety.  Finally, Wang et al. (2014) described four classes of posttraumatic 
growth during the 1st year after surgery for breast cancer.  Varying findings may be 
attributed to differences in sample demographics, differing measurement time points, and 
differences in the instruments used to measure varying symptoms.  Additionally, Onselen 
et al. (2012) used LGMM to describe three classes explaining the trajectories of disturbed 
sleep.   






using LGMM allows model specification that includes potential antecedents, covariates, 
and consequences of class membership, including demographic and clinical variables.  
For example, Lam et al. (2010) described four classes of the trajectory of psychological 
distress: resilient, chronic, recovered, and delayed-recover classes.  Distinguishers of 
class membership were determined, finding that those in the resilient class had less 
distress from symptoms and less problems with satisfaction with treatment decisions.  In 
this sample, age, stage of disease, education, and occupation were also associated with 
class membership, suggesting a potential risk profile that clinicians could apply in 
practice (Lam et al., 2010).  While the methods described in these papers assist in the 
development of future studies and the results are promising, much work is needed to 
replicate findings in the symptoms of mood disturbance and disturbed sleep and study 
additional prevalent symptoms experienced by women with breast cancer, such as 
fatigue, pain, and nausea and vomiting.   
Summary 
 
 In summary, prevalent and distressing symptoms reported by women receiving 
treatment for breast cancer include fatigue, disturbed sleep, depressed mood, anxiety, 
pain, nausea and vomiting, and trouble thinking.  Demographic and clinical variables 
may act as antecedents to symptom presentation.  Symptoms co-occur in women 
undergoing treatment for breast cancer and are associated with consequences, such as 
decreases in functional status, quality of life, and activity.  Newer approaches to studying 
classes of women with similar symptom experiences, including LGMM, enhance the 
scientific understanding of the symptom trajectories unique to individuals and the 







Several theoretical frameworks exist that underpin cancer-related symptom 
research.  Four of the more relevant frameworks to symptom cluster research include the 
Theory of Unpleasant Symptoms, the Symptom Management Model, the Symptom 
Interaction Framework, and Sickness Behavior (Barsevick, 2007; Dodd et al., 2001).   
The Theory of Unpleasant Symptoms describes the complex and 
multidimensional nature of the symptom experience with three major components: the 
actual symptoms, influencing factors that assist in the development of the symptoms, 
such as tumor burden and treatment, and the consequences of the symptoms, such as 
declining functional status or inability to continue employment (Lenz et al., 1997).  In 
addition, each symptom is conceptualized to be a multidimensional experience, involving 
the dimensions of intensity, timing, and quality.  Among the influencing factors are 
physiologic factors, such as normally functioning bodily systems, pathology, trauma, and 
level of energy.  Finally, consequences or outcomes may include functional performance 
outcomes or cognitive activity outcomes (Lenz et al., 1997).   
While the Theory of Unpleasant Symptoms presents a more linear process of 
antecedents, symptoms, and consequences, the Symptom Management Model describes 
an interrelationship between the symptom experience, symptom management strategies, 
and patient outcomes (Dodd et al., 2001).  The symptom experience is the individual’s 
perception of the dimensions of a symptom.  Symptom management strategies refer to 
changing methods for coping with and decreasing the symptom and the symptom 
outcome.  Symptom outcomes refer to symptom status, functional status, emotional state, 







The Symptom Interaction Framework describes synergistic relationship or 
interaction among symptoms and argues for the possibility of a common underlying 
etiology (Parker, Kimble, Dunbar, & Clark, 2005).  Sickness Behavior refers to a 
constellation of behavioral and physiologic responses, possibly a symptom cluster, first 
observed in animals after administration of pro-inflammatory cytokines (Cleeland et al., 
2003).  Studies in humans reveal a similar response to inflammatory cytokines released in 
response to infection that act in the brain to induce common symptoms of sickness, such 
as loss of appetite, sleepiness, withdrawal, fever, aching, and fatigue (Kelley et al., 2003).  
Both the Symptom Interaction Framework and Sickness Behavior point to a common 
causal mechanism for the presence of multiple symptoms. 
All of these theories acknowledge and signify the multiplicative nature of the 
concurrence of multiple symptoms (Lenz & Pugh, 2008).  Additionally, these models 
describe the existence of factors that may influence the development of a symptom 
cluster, suggesting the potential for a common etiology, and how a symptom cluster may 
influence outcomes.  None of these models describe how to identify symptoms that co-
occur in classes of individuals with varying frequency and severity during chemotherapy 
treatment.  This study utilized constructs shared across the four theories: the 
multiplicative nature of symptoms and the existence of antecedents and consequences to 
symptoms.  In addition to these ideas, this study assumed that symptoms co-occur in 
individuals in such a way that those individuals can be subclassified based on their 
unique symptom trajectories.  The methodological approach captured the unique 






among symptoms within class membership.  This study further examined whether class-
membership was predicted by antecedents such as age, chemotherapy regimen, or stage 
of disease, that uniquely precede the development of a symptom trajectory, and whether 
class-membership preceded the development of outcomes, such as variation in functional 
status, days of missed work, or hours spent laying down (see Figure 1.1). 
Significance of the Study 
While prolongation of life and achieving a disease-free state is the primary goal of 
cancer therapy, clinicians must be aware of the symptoms associated with tumor burden 
and cancer treatment, the mechanisms that support symptoms, and approaches for 
managing symptoms (Wood et al., 2006).  Not only are symptoms contributors to 
decreased quality of life and ability to function, but they may also interrupt treatment and 
influence treatment effectiveness (Beck et al., 2010; Bradley et al., 2007).  Prompt 
evaluation of symptoms reduces use of emergency room and hospitalization, cost of 
treatment, and patient distress (Byar et al., 2006; Cleeland et al., 2000). 
Through examining the growth of symptoms during the course of breast cancer 
chemotherapy using latent growth mixture modeling (LGMM), this study provides a 
significant contribution to the current body of symptom literature.  A unique contribution 
of this study is the richness of the symptom data available for analysis.  Ten symptoms 
with daily reporting were studied in an exploratory method.  All symptoms were used to 
define the model, as opposed to predetermining a few symptoms based on the literature.  
This allowed for an exploratory analysis.  The trajectory of multiple symptoms was 
simultaneously modeled to identify latent classes of individuals who exhibited similar 







Figure 1.1 Theoretical framework. 
with class membership, allowing for the examination of predictors of the different class 
trajectories, suggesting potential etiological factors that may be involved in the various 
symptom trajectories.  Finally, the latent classes themselves were used as potential 
correlates of outcomes to allow for predetermination of individuals at risk for poor health 
outcomes. 
Identification of groups of patients who experience a similar multisymptom 
profile trajectory, along with potential antecedents and consequences to that particular 
multisymptom profile trajectory, will allow clinicians the ability to identify at-risk 
individuals prior to and throughout the treatment process.  Identifying at-risk individuals 






early chemotherapy cycles and knowing which of these profiles exhibit poor outcomes 
may allow clinicians to intervene or modify treatment to prevent poor outcomes.   
Research Design and Methods 
 This study was a secondary analysis of data collected as part of two longitudinal, 
randomized controlled trials that tested the use of an automated telephone-linked-care 
system for monitoring symptoms and intervening in the presence of symptoms during 
chemotherapy: “Telephone-linked Care for Cancer Symptoms Management (TLC-
Chemo Alert),” which was funded by the NIH/DHHS (R01 CA89474 Mooney, PI) and 
“Symptom Care @ Home (SCH),” which was funded by the NIH/DHHS (R01 
CA120558 Mooney, PI).  Additionally, data were included from a nonrandomized, 
longitudinal study utilizing the same automated telephone-linked-care system for data 
collection of the presence of symptoms during chemotherapy: “Symptom Care by Phone 
(SCP2)” (Mooney, PI).  
Description of Parent Studies 
Study 1: Telephone-linked Care for Cancer Symptoms Management (TLC-Chemo Alert)  
 The purpose of the TLC-Chemo Alert trial, henceforth referred to as Study 1, was 
to test the efficacy of the telephone-linked-care automated system in the symptom 
management of adults receiving chemotherapy as compared to a control group of daily 
telephone data collection without alerts.  The methods, including a description of the 
TLC automated system, are further described by Mooney, Beck, Friedman, Farzanfar, 
and Wong (2014).  Participants were randomly assigned to an intervention group or a 
control group.  All participants, regardless of group assignment, were instructed to 






to report on the severity of and distress associated with ten symptoms: pain, fatigue, 
nausea/vomiting, fever, trouble sleeping, anxiety, depressed mood, sore mouth, diarrhea, 
and constipation.  Participants were asked whether symptoms were present during the 
past 24 hours and, if present, they rated severity and distress on a Likert scale (0-10) for 
all symptoms with the exception of fever.  If fever was reported, participants entered the 
highest temperature numerically and distress associated with fever was measured.  For 
the experimental group, two thresholds were set to alert the participant’s healthcare 
provider and team, either an alert when a symptom was rated as greater than or equal to 5 
or 7 (depending on the symptom) and trend alerts based on a pattern of moderate to 
severe levels reported over three out of the past 7 days.  The control group used the same 
TLC automated system to report on the presence of symptoms and rated those symptoms 
in the same manner as the experimental group.  No provider alerts were generated for the 
control group, although participants in both groups were advised to notify their provider 
for any concerns about their symptoms.  There was no effect for the main hypothesis that 
the experimental group would have less symptom severity, symptom distress, and 
symptom interference with normal activities when compared to the control group.  
Therefore, data from all participants in Study 1 with a breast cancer diagnosis, regardless 
of study group, were utilized in this secondary analysis.   
 The sample for Study 1 was stratified within each of 11 provider teams.  All 
patients who met the eligibility criteria were invited to participate.   
Criteria for inclusion (participants from Study 1): 
 Histological diagnosis of cancer 






least 6 months 
 Reported at least one symptom of moderate or greater intensity during 
their first chemotherapy cycle 
 18 years of age or older 
 Able to speak and read English or Spanish 
 Physically and mentally able to participate 
 Care under the direction of one of  the 11 designated provider teams 
 Access to a telephone on a daily basis  
Criteria for exclusion (participants from Study 1): 
 Receiving concurrent radiation therapy or biotherapy agents 
 For Study 1, participants were recruited from four ambulatory oncology clinics in 
two states in the U.S., including a community cancer center in the southeast, two 
community practices in the west, and a clinical cancer center in the west.  Eleven 
provider teams (oncologists and nurses) consented to participate in the study.  Potential 
study subjects were identified from the patient roster for each of the 11 provider teams, 
and eligibility criteria was reviewed.  Each eligible, potential participant was sent a letter 
of introduction, describing the study in detail.  Potential participants were given a phone 
number to call if they had questions and a prepaid postcard to send in if they did not wish 
to participate in a screening interview.  A screening telephone interview was conducted 
with potential participants to explain the study, answer questions, obtain verbal informed 
consent, background socio-demographic information, eligibility criteria, and set up study 
visit appointments.  Eligibility based on experience of poorly controlled symptoms during 






patient was asked to rate the highest level of severity and distress experienced on each 
symptom and their overall degree of interference with normal activities during the first 
cycle of chemotherapy.  For those eligible patients who gave verbal informed consent 
during the phone call, an appointment was made with a research assistant to obtain 
written informed consent, enroll the subject in the study, and demonstrate the telephone 
data collection system. 
 A total of 250 participants were accrued in Study 1.  Of the total n (250), 223 
participants completed the study through cycle 3, of which, 94 were diagnosed with 
breast cancer.   
Study 2: Symptom Care @ Home (SCH) 
 The purpose of Study 2 was to test the efficacy of the an integrated, computer- 
based symptom monitoring system combined with self-care strategies and Nurse 
Practitioner delivered, guideline-based symptom care in decreasing symptom severity and 
distress and interference with functional performance.  Participants were randomized to 
an experimental intervention group or a control group.  All participants participated in a 
daily call with the automated SCH system, the same system used in Study 1, expanded to 
include four new components.  First, participants were asked to report on the presence of 
11 symptoms: fatigue, trouble sleeping, nausea and vomiting, pain, feeling blue or down, 
feeling nervous or anxious, distressed over appearance, diarrhea, constipation, sore 
mouth, fever, and trouble thinking or concentrating.  For all symptoms, when present, 
participants were asked to rate the severity of and distress associated with the symptoms 
on a Likert scale (0-10), with the exception of fever.  If fever was present, participants 






Additionally, the Study 2 experimental participants were given self-care symptom 
management suggestions by the SCH system, automated provider alerts for uncontrolled 
symptoms, and unrelieved symptoms at moderate or greater levels generated an alert to 
the study Nurse Practitioner who initiated follow-up care.  For the 11 symptoms, 29 
different responses generated an alert, for either a severity rating of 5 or greater or a 
pattern of responses, such as a symptom reported at moderate or greater levels during 3 of 
the past 7 days.  Participants in the usual care group were not given self-care strategies 
nor had unrelieved symptoms alerted to their provider or managed by the study Nurse 
Practitioner, but were reminded to call their healthcare provider for symptom concerns.  
Preliminary data analysis suggests that there were differences in reported symptoms 
between the groups, with a potential main effect of the intervention on symptom severity, 
distress, or interference with functional performance.  For that purpose, only data 
collected from participants randomized to the control group were utilized in this 
secondary analysis. 
The sample for Study 2 was stratified from six provider practices.  All patients 
who met the eligibility criteria were invited to participate. 
Criteria for inclusion (participants from Study 2): 
 Histological diagnosis of cancer 
 A life expectancy of at least 3 months  
 Cognitively able to participate 
 Beginning a new course of chemotherapy planned for a minimum of 3 
cycles 






 Able to speak and read English 
 Care under the direction of 1 of the 6 provider practices 
 Access to a telephone on a daily basis  
Criteria for exclusion (participants from Study 2): 
 Receiving concurrent radiation therapy or biotherapy agents  
For Study 2, potential participants were recruited from four oncology practices at 
a cancer center in the western United States and two oncology practices at a public 
hospital in the southern United States.  Six provider practices consented to participate in 
the study.  Potential study subjects were identified from patient rosters for each provider 
practice.  The eligibility criteria were verified by data from the medical record and review 
by the medical team.  Potential participants were approached at their treatment planning 
visit or by phone prior to the first chemotherapy visit.  During initial contact, the research 
assistant explained the study, answered questions, obtained verbal informed consent, 
obtained socio-demographic background information, verified eligibility, and set up a 
study entry visit.  For those eligible patients who gave verbal informed consent, a study 
entry appointment was arranged where staff obtained written informed consent, obtained 
initial study measures, opened random assignment, explained the telephone data 
collection system, and answered questions.   
A total of 358 participants were accrued in Study 2, 178 were randomized to the 
control group and 180 to the experimental group.  Of the total n (358), 156 participants 







Study 3: Symptom Care by Phone (SCP2) 
The purpose of Study 3 was to develop a database of genotype/phenotypes of 
cancer treatment related symptoms and toxicities for at least 400 individuals receiving 
cancer chemotherapy.  The objective of this study was to collect descriptive information 
about the phenotype and to have banked DNA for the genotype.  Participants were 
recruited to participate in a daily call with the automated SCH system, where they were 
asked to report on severity of and distress associated with the same eleven symptoms as 
those reported in SCH.  Sampling procedures were continued from Study 2 and 
conducted in the same manner.  At the time of this secondary analysis, 38 participants 
were accrued in Study 3.  Of the total n (38), 29 were diagnosed with breast cancer. 
Measures 
 
All 3 parent studies utilized similar instrumentation, but included varying 
symptoms.  Demographic and disease-related data were collected at baseline from the 
participant and from the medical record in all three studies.  Demographic data included 
age, gender, race/ethnicity, employment status, education, and socioeconomic status.  
Disease factors included primary cancer diagnosis, extent of disease, and details of the 
chemotherapy protocol.    
For Study 1, both experimental and control groups used the TLC data collection 
system, which assessed prevalence on 10 selected symptoms and the overall degree of 
interference with normal activities during the past 24 hours.  If a symptom was present, 
the patient was asked a series of specific questions about the symptom and how they were 
currently managing it.  The TLC Conversation was as follows: 






 Patient entered password and TLC retrieved file and extended personal 
salutation 
 TLC asked whether patient had experienced each of the 10 specific 
symptoms during past 24 hours  
 TLC asked presence, severity and distress data for each of the 10 
symptoms, with the exception of fever, which, if present, TLC asked for 
the highest temperature and distress associated with it.   
 For each symptom present, TLC asked questions specific to that symptom 
 If more than 1 symptom was present, the system cycled back to the next 
symptom 
 TLC asked the overall degree of symptom interference with normal 
activities  
 TLC asked if any patient or provider-initiated contact (notification of 
study team if yes) 
 Personal message from provider team (rotated among 7 messages) 
 Closing, TLC reminded participant about calling healthcare team with any 
concerns 
For the Study 2 control group and Study 3 participants, the daily SCH data 
collection system was used to assess, over the previous 24 hours, prevalence of 11 
symptoms and the overall degree of interference with normal activities.  If a symptom 
was present, the patient was asked a series of specific questions about the symptom and 
how they were currently managing it.  Study 3 was conducted in the same manner.  The 






 Greeting; asked patient for personal password 
 Patient entered password and SCH retrieved file and extended personal 
salutation 
 SCH asked whether patient had experienced each of the 11 specific 
symptoms during past 24 hours or whether they were too ill to talk on the 
phone in the SCH study 
 SCH asked presence, severity and distress data for each of the 11 
symptoms, with the exception of fever, which, if present, SCH asked for 
the highest temperature and distress associated with it.   
 For each symptom present, SCH asked questions specific to that symptom 
 If more than one symptom was present, the system cycled back to the next 
symptom 
 SCH asked the overall degree of symptom interference with normal 
activities and amount of time spent lying down 
 Personal message from provider team (rotated among seven messages) 
 Closing, SCH reminded participant about calling healthcare team with any 
concerns 
In all studies, participants were instructed to call the automated system number by 
noon each day, and if the patient forgot, the automated system called the participant to 
obtain the daily ratings, decreasing the potential for missing data.  For Study 1, the call 
compliance for participants with breast cancer (n=94) was 70.1%.  For Study 2, the call 
compliance for participants with breast cancer in the control group (n=89) was 91.4%.  






Single-item indicators were used to assess each symptom to eliminate the 
potential for diluted impact of particular symptom seen in summative symptom measures 
(Mooney et al., 2014).  Participants were asked, “During the past 24 hours did you 
experience (symptoms)?”  A no response was scored as zero and a yes response led to 
questions using a 1 to 10 Likert scale for the severity associated with that particular 
symptoms.   
 In Study 1, functional status was measured using the 12-Item Short-Form Health 
Survey, SF-12 (Version 2).  In Study 2 and Study 3, functional status was measured using 
the 36-Item Short-Form Health Survey, SF-36 monthly during study participation.  The 
SF-36 is a health survey composed of 36 questions that document, through a 5-scale 
profile, both physical and mental functioning and well-being.  The SF-12 is a shorter 
subset of the SF-36, composed of 12 items.  The SF-12 was developed after it was 
determined that the SF-36 physical and mental component summary scales capture about 
85% of the reliable variance in the full SF-36.  The SF-12 assumes that these two 
outcome measures are satisfactory for most purposes.  Additionally, this reproduction of 
these two components in the SF-12 is accurate enough to warrant the use of published 
norms for SF-36 summary measures in interpreting SF-12 summary measures (Ware et 
al., 1996).  Both scales are widely used and have reported reliability and validity across 
many patient populations (Mchorney, Ware, Lu, & Sherbourne, 1993; McHorney, Ware, 
Lu, & Sherbourne, 1994; Ware et al., 1996).  
 A daily measure of days of missed work was asked for those participants in Study 
2 and Study 3 who reported being employed.  A daily measure of hours spent lying down 






In all studies, baseline data were collected prior chemotherapy cycle 2 (in Study 
1) and chemotherapy cycle 1 (in Study 2 and Study 3).  Daily symptom data were 
collected using the automated system during cycles 2 and 3 for Study 1 and during cycles 
1, 2, and 3 for Study 2 and Study 3.   In all studies, monthly functional status was 
collected.   
Sample 
 All participants in Study 1 and Study 3 with a breast cancer diagnosis who met 
the eligibility criteria and all participants in Study 2 with a breast cancer diagnosis who 
met the eligibility criteria and were randomized to the control group were included in this 
secondary analysis.  Participants were excluded from the sample if they did not complete 
the parents study through cycles 2 and 3 of chemotherapy.  For the current study, 279 
women with breast cancer were combined from the three parent studies.  Eighty women 
were not included who were randomized to the intervention group for Study 2.  One-
hundred sixty-six women who completed study measures through cycles 2 and 3 of 
chemotherapy were identified.  For cycle 2, 165 of those women reported on symptom 
severity at least 3 days during chemotherapy and for cycle 3, 155 of those women 
reported on symptom severity at least 3 days during chemotherapy (see Figure 1.2).  
Because growth mixture modeling requires multiple measurement time points, only 
women with at least 3 days of symptoms severity (0-10) over the first 14 days of the 
cycle were included in the models.  For cycle 2, only 1 woman was excluded for this 
reason and for cycle 3 only 10 women were excluded as a result of less than three daily 
calls.  These same women were excluded from tests of distinguishers of class 



























Figure 1.2 Sampling procedures. 
  
Eligible with Breast Cancer  
Study 1 (n = 94) 
Study 2 (n = 156) 
Study 3 (n = 29) 
Women who 
completed Cycles 2 
and 3 Study 1 
(n = 82) 
Control Group Only 
Study 2 
(n = 89) 
Women who 
completed Cycles 2 
and 3 Study 3 
(n = 25) 
Women who 
completed Cycles 2 
and 3 Study 2 
(n = 59) 
Final Sample 
(n = 166) 
Reported symptom 
severity at least three 
times during the first 14 
days of cycle 2 
(n = 165) 
Reported symptom 
severity at least three 
times during the first 14 
days of cycle 3 






not assigned a predicted class membership in the original models.    
The total sample size for this secondary analysis was 165 women in cycle 2 and 
155 women in cycle 3.  Although this sample size is relatively small, it was adequate to 
apply the proposed statistical analysis.  A limitation of the proposed analysis methods 
(growth mixture modeling) is the requirement for multiple measurement time points; at 
least three time points is preferred (Andruff, Carraro, Thompson, Gaudreau, & Louvet, 
2009). With this comes the requirement for a larger sample size to increase power and 
allow for the assumed attrition rates.  There is no general rule for determining sample size 
applicable to all situations in growth modeling; however, the Monte Carlo method has 
been recommended (Muthen & Muthen, 2002).  Assuming the missing data from the 
sample are random, the Monte Carlo method would estimate a sample size requirement 
between 150 and 250 participants (Muthen & Muthen, 2002).  Regardless, given the 
nature and limitations of a secondary analysis, the data for 166 participants were 
available and included in this study.  Because growth mixture modeling requires multiple 
measurement time points, only women with at least 3 days of symptoms severity (0-10) 
over the first 14 days of the cycle were included in the models.  For cycle 2, only 1 
woman was excluded for this reason and for cycle 3 only 10 women were excluded as a 
result of less than 3 daily calls.  These same women were excluded from tests of 
distinguishers of class membership including clinical, demographic, and symptom 









 Data included in this study were daily symptom severity reports on eight 
symptoms common to all three parent studies (fatigue, pain, disturbed sleep, depressed 
mood, anxiety, nausea, diarrhea, and sore mouth) and two symptoms unique to Study 2 
and Study 3 (distress associated with changing appearance and trouble thinking) for the 
first 14 days of cycles 2 and 3 of chemotherapy for all participants.  Additionally, 
functional status measures, as measured by the SF-12 in Study 1 and the SF-36 in Study 2 
and Study 3, were included.  Days of missed work and hours spent lying down were used 
for participants in Study 2 and Study 3.  
 Data from all studies were cleaned and combined into one SPSS file for analysis 
purposes.  The data for this secondary analysis had an initial data cleaning in the course 
of the analysis and dissemination of the primary studies.  Additionally, outliers and 
extreme cases were identified prior to initiating data analysis. 
 This secondary analysis was reviewed by the Institutional Review Board (IRB) at 
the University of Utah.  Subjects were identified only by their original study 
identification number.  All computer files were password protected.     
Analysis 
 
The Software Statistical Package for the Social Sciences (SPSS), version 23.0 was 
used for data management and data analysis and MPlus, version 6.0 was used for data 
analysis.  The data were cleaned and transformed to a person-period data set, where each 
individual has multiple records, one for each period in which he or she was observed 
(Singer & Willet, 2003).  The person-period data set contained a subject identifier, a time 






on a Likert scale 0-10 and functional status scores measured by SF-12/36), and correlate 
variables (demographic and disease-related variables).  Alpha was set at 0.05 to reduce 
type I error.   
Means, standard deviations, and evaluation of distributions were described for 
sample data, including age, ethnicity, marital status, employment, education status, 
income, stage of disease, and chemotherapy regimen.   
Specific Aim 1 
 Specific aim 1 was to determine the trajectories and profile classes associated 
with the severity of 10 symptoms (fatigue, pain, disturbed sleep, depressed mood, 
anxiety, nausea, diarrhea, sore mouth, distress associated with changing appearance, and 
trouble thinking) reported by women undergoing cycles 2 and 3 of chemotherapy for 
breast cancer. 
 Research Question 1.1: What are the trajectories of the severity of individual 
symptoms reported by women undergoing chemotherapy for breast cancer during cycle 2 
and cycle 3? 
 To accommodate for varying cycle lengths, only data collected during the first 14 
days of each cycle for all measures were included in the analysis.  The prevalence of each 
symptom (fatigue, disturbed sleep, depressed mood, anxiety, pain, nausea/vomiting, sore 
mouth, and diarrhea) within the entire sample and of two individual symptoms (distress 
associated with changing appearance and trouble thinking) within a subsample of 
participants from Study 2 and Study 3 over the first 14 days of cycles 2 and 3 of 
chemotherapy was determined.  Additionally, the prevalence of these sample symptoms 






each symptom was reported at a level 0, reported at a level 1-10, and reported at a level 
4-10 for each individual symptom over the first 14 days of cycles 2 and 3 of 
chemotherapy were also determined.       
 An exploratory analysis was conducted to describe how individuals in the data set 
changed over time on each symptom using graphical visualization and conventional 
growth mixture modeling for each cycle of chemotherapy (cycle 2 and cycle 3 
separately).  This analysis provided an intercept, slope, and quadratic term that described 
the baseline measure and rate of change for each symptom, as well as profile classes that 
describe groups of individuals who have a similar intercept, slope, and quadratic term for 
each individual symptom.  First, an aggregate model with an intercept, slope, and 
quadratic function for each symptom was described.  Second, a latent class model with 
classes that have unique intercepts, slopes, and quadratic terms for each symptom were 
described.   
Simple regression models are designed for cross-sectional data, and provide an 
intercept and slope that represents the relationship between a correlate and an outcome 
variable.  The model is fitted to the sample data and population parameters are estimated, 
i.e., the intercept, slope, and variances.  A “goodness-of-fit” statistic is provided that 
quantifies the correspondence between the fitted model and the sample data.  In a well-
fitted model, the estimated population parameters can be used to draw conclusions about 
the direction and magnitude of the effect of the correlate variable.  Alternatively, analysis 
of longitudinal data requires the use of growth modeling, or statistical models that 
embody two types of research questions: questions about within-person change and 






question of how each individual’s pain changes over the course of chemotherapy, the 
within-person change.  Then the model must address the question of how individuals’ 
pain trajectories vary by some observed or unobserved correlate variable, the between-
person change.  The assessment of both within-person and between-person change 
requires the model to have components at two levels: the level-1 submodel that describes 
the within-person change and the level-2 submodel that describes the between-person 
change.  Combined, these two submodels form the multilevel statistical model.  
Conventional growth modeling allows for the examination of within-person and between-
person change simultaneously, allowing for the mathematical representation of 
population behaviors (Singer & Willet, 2003).  
Empirical growth plots were formed by plotting each person’s symptom severity 
score versus time for each of the 10 symptoms.  Data points indicated the severity of the 
individual symptom reported by the participant for each day during the first 14 days of 
the cycle of chemotherapy (cycle 2 and cycle 3 separately).  Cycle length (the number of 
data points) was set at 14 days.  Inspection of graphs allowed for a visual evaluation of 
the within-person trajectories of the severity of each symptom.   
Taking the example of pain, plots were formed for each individual in the sample 
that demonstrated the individual’s pain score over the time of measurement, one data 
point for each measurement time (see Figure 1.3).  Nonparametric smoothed trajectories 
were superimposed on the individual empirical growth plots to begin to understand the 
variability, direction, and functional form of the symptom trajectory. 
In keeping the example of pain, for each individual empirical growth plot of pain, 






      
 
Figure 1.3 Example of plots of pain severity score for 4 participants over 5 days of one 
cycle (days 1-5).  Days 1-5 are included in these plots to simplify the example.  The 
actual visualization included data points for each day 1-14 during the cycle of 
chemotherapy (one graph for each participant for cycle 2 and for cycle 3), instead of only 







































measurement time (see Figure 1.4). Interindividual differences in change on individual 
symptoms over time were explored by plotting the entire set of smoothed individual  
trajectories on a single graph.  The observed data (or plots) were omitted to decrease 
clutter and allow for easier visualization of the variability in trajectories.  An average 
change trajectory for the entire group was added to the graph to help compare individual 
change with group change.  The average change trajectory was calculated by determining 
time-specific means for the symptom of interest, plotting these means, and then applying 
the same nonparametric smoothed trajectory to the plot. 
Continuing with the example of the plots of 4 participant’s pain severity over days 
1-5 of a chemotherapy cycle, the 4 participant’s trajectories were combined on a single 
graph with an average change trajectory superimposed (see Figure 1.5). 
The mathematical form of growth for each symptom was determined using 
conventional polynomial growth models.  The level-1 submodel hypothesized about the 
shape of each person’s true trajectory of change over time.  Individual growth 
parameters, intercept, slope, and quadratic terms, were calculated for each person in the 
sample.  The individual growth intercept represented the “starting point” for the 
individual on the measure of interest, in this case, initial pain score.  The individual 
growth slope represented the rate of change for the individual on the measure of interest, 
in this case, the rate of change in the individual’s pain score.  In the level-1 submodel, 
individuals had their own intercept, slope, and possibly quadratic term, and thus their 
own trajectory.  Individual growth trajectories for each symptom were displayed 
graphically by plotting the regression line for each individual in the sample on a single 






       
              
Figure 1.4 Example of plots of pain severity score for 4 participants over 5 days of one 
cycle (days 1-5) with a smoothed trajectory line superimposed.  The actual visualization 
included plots for each day 1-14 during the cycle of chemotherapy (one graph for each 
participant for cycle 2 and for cycle 3), instead of just days 1-5 shown here.  Pain severity 





Figure 1.5 Example of set of smoothed trajectories of pain severity for 4 participants over 
5 days of one cycle (days 1-5) on a single graph.  The actual visualization included plots 
for each day 1-14 during the cycle of chemotherapy (one graph for each participant for 
cycle 2 and for cycle 3), instead of just days 1-5 shown here.  Pain severity is located to 

















































Next, the level-2 submodel for interindividual change on each symptom was 
studied.  The level-2 submodel mathematically displayed the variability in individuals.  
The level-2 submodel provided an intercept and slope that represented the variability in 
the individual intercepts, or the average true initial status, and the average true rate of 
change in the variable of interest.  This model was used to describe the average trajectory 
of each symptom over the 2 cycles of chemotherapy.  Model determination was by 
maximum likelihood methods, or the determination of population parameters (intercept 
and slope and possibly a quadratic or cubic function) that maximize the probability of 
observing a particular set of data.  In other words, the intercept, slope, and/or quadratic 
term were calculated for each symptom that maximized the probability of observing the 
data retrieved from the sample.  The model started with an intercept-only model and then 
a slope was added to the model.  If the slope was significantly different from zero, it was 
included in the model.  Next, a quadratic function was added to the model using 
maximum likelihood estimates.  If the quadratic function differs significantly from zero, 
it was included.  A cubic function was tested in the same fashion.  The model that best fit 
each symptom was selected on the basis of model chi square test, CFI, and RMSEA 
(Muthen, 2004). 
 For example, our individual pain plots showed a best fit line that demonstrated the 
individual pain intercept and the rate of change in the individual’s pain score (the level-1 
submodel) (see Figure 1.6).  Next the population intercept and slope on pain were 
determined (the level-2 submodel) (see Figure 1.7). 
 This model was used to describe the average trajectory of the eight individual 






       
 
 
Figure 1.6 Example of plots of pain severity score for 4 participants over 5 days of one 
cycle (days 1-5) with best fit line superimposed.  An individual pain intercept and rate of 
change (slope) could be calculated with this line.  Pain severity is located to the y-axis 





Figure 1.7 Example of the collection of best fit trajectories across all 4 participants and an 
average change trajectory line (dashed) over 5 days of one cycle (days 1-5) of 
chemotherapy.  Population intercept and slope could be determined on this average 




















































anxiety, pain, nausea/vomiting, sore mouth, and diarrhea) and a subsample of only data 
gathered from participants in Study 2 and Study 3 for two symptoms unique to those  
parent studies (distress associated with changing appearance and trouble thinking).   
Research Question 1.2: What are the trajectory profile classes, if any, associated 
with the severity of individual symptoms reported by women undergoing chemotherapy 
for breast cancer during cycle 2 and cycle 3? 
After identifying the best growth model for each symptom with quantified 
intercepts, slopes, and possibly quadratic and/or cubic functions, the number of latent 
classes for each symptom was determined on the basis of means of the growth factors, 
using Latent Growth Mixture Modeling (LGMM). An unobserved categorical variable, 
the latent class variable, was added to the model to represent the latent classes (Colder et 
al., 2002).  Each latent class corresponded to a subpopulation that had its own set of 
parameter values (intercept and slope).  Variances and covariances of these growth 
factors within each class were also estimated to allow for within-class heterogeneity 
(Colder et al., 2002; Collins & Lanza, 2010; Muthen & Muthen, 2000).  While the growth 
curve analysis used to address Research Question 1.1 produced growth factors and 
variance components for the entire sample on the symptom of interest, LGMM estimated 
a new latent categorical variables that identified distinct classes on the basis of 
differences in any combination of their intercepts, slopes, and within-class variances in 
intercepts and slopes (Dunn et al., 2008).  A unique feature was that this method used a 
formal statistical procedure to test whether the hypothesized trajectories actually emerged 
from the data rather than assumed the existence of a particular number of trajectories or 






The simplest assumption, a single-class model was hypothesized first.  Then 
classes were added to the model to determine the solution (the number of classes) that 
best fit the data.  Intercepts, slopes, and possibly quadratic or cubic functions were 
determined for each class.  Models were evaluated on the Bayesian information criterion 
(BIC), used to evaluate improvement in model fit when additional classes were added.  
Smaller BIC values suggested a better model fit (Colder et al., 2002; Muthen & Muthen, 
2000).  If the addition of a class resulted in a reduction in the BIC value relative to the 
BIC from the previous model (without the added class), then the new model was 
considered an improvement and the class was retained.  The addition of classes continued 
until the BIC did not decrease with the addition of a class.   
Model selection was determined by multiple additional criteria, including the “K” 
versus “K-1” class models to determine whether a model with K classes fit the data better 
than a model with “K-1” classes with the parametric bootstrapped likelihood ratio 
(BLRT) and Vuong-Lo-Mendell-Rubin Likelihood Ratio Tests (VLMR) (Dunn et al., 
2011; Jung & Wickerama, 2008; Nylund, Asparouhov, et al., 2007; Nylund, Bellmore, et 
al., 2007).  Additionally, entropy, a summary measure of classification based on the 
probability of membership in each class for each individual that ranges from 0 to 1.0, was 
used to evaluate the models (Colder et al., 2002).  The closer entropy values were to 1.0, 
the better the classification.  Finally, the best-fitting model was examined for the number 
of subjects in each class (greater than 5% of the sample) and graphed visually to 
determine if the predicted trajectories made clinical and theoretical sense (Onselen et al., 
2012).   






of random starting values to avoid local solutions in GMM (Jung & Wickerama, 2008).  
Missing data were accommodated by MPlus version 6.0 through use of Full Information 
Maximum Likelihood and the use of the Expectation-Maximization algorithm (Dunn et 
al., 2011; Onselen et al., 2012). 
In keeping with the example of pain over the first 5 days of a cycle of 
chemotherapy, classes were fitted to the model that demonstrated a unique slope and 
intercept for pain (see Figure 1.8).  Intercept referred to a baseline measure of pain and 
slope referred to the rate of change of pain over time during the first 14 days of each 
cycle.  The class referred to a group of individuals within the sample who had a similar 
growth in their pain trajectory, or in other words, a similar slope and intercept for pain. 
This individual symptom growth mixture modeling provided classes that 
displayed homogenous trajectories across each symptom that were heterogeneous from 
other classes.  For example, a potential result might include a class that reported a 
moderate intercept and increasing severity of pain during the first 14 days of cycle 2; a 
class that reported a low intercept and a stable severity of pain during the first 14 days of 
cycle 2; and a class that reported a low intercept and an increasing severity of pain during 
the first 14 days of cycle 2.  For each of these 3 classes, a unique intercept and slope for 
pain were calculated that demonstrated the baseline measure and rate of change for pain 
as reported by the participants in the class. 
This model was used to describe the latent trajectory classes associated with the 8 
individual symptoms common to all three parent studies (fatigue, disturbed sleep, 
depressed mood, anxiety, pain, nausea/vomiting, sore mouth, and diarrhea) and a 








Figure 1.8 Form of growth for pain (example of linear form of growth for single 
symptom with 5 time points of interest).  The class referred to a grouping of individuals 
with similar slopes and intercepts.  Referring back to Figure 1.5, IDs 1 and 2 logically fell 
into a same class, as their trajectories were almost parallel, suggesting a similar slope.  
IDs 3 and 4 represented 2 other classes, as one had a more flat trajectory (stable pain over 










unique to those parent studies (distress associated with changing appearance and trouble 
thinking). 
Research Question 1.3: Do the profile classes associated with the severity of  
individual symptoms differ between cycle 2 and cycle 3 of chemotherapy? 
Posterior probabilities and class assignments for each individual were saved into 
an output text file and extracted into the data set to be used for further analysis (Jung & 
Wickerama, 2008).  Crosstabs were used to compare predicted class memberships 
extracted from the individual symptom growth mixture models between the two cycles of 
chemotherapy to test for movement in individuals to different classes between cycles. 
Specific Aim 2 
Specific aim 2 was to identify multisymptom trajectory profile classes of patients 
undergoing cycles 2 and 3 of chemotherapy for breast cancer. 
 Research Question 2.1: What multisymptom profile classes can be identified in a 
cohort of women undergoing chemotherapy treatment for breast cancer during cycle 2 
and cycle 3? 
After establishing the number of trajectory classes for each of the symptoms, 
latent classes were modeled on the basis of growth trajectories from multiple symptoms 
that display growth trajectories of interest, or those trajectories with significant variability 
over time (see Figure 1.9).  These models represent the multisymptom models.  
Interesting growth trajectories included those symptoms with an average trajectory of 
slope that is significantly different from zero and/or those symptoms that had at least two 
latent classes that represent the average. For each cycle, a cross-tabulation was created 








Figure 1.9 Example of plots of pain severity and diarrhea severity scores for two groups 
of 4 participants over 5 days of one cycle (days 1-5).  The collection of best fit 
trajectories across all 4 participants and an average change trajectory line (dashed) for 
pain is on the left.  The collection of best fit trajectories across all 4 participants and an 
average change trajectory line (dashed) for diarrhea is on the right.  Population intercept 
and slope could be determined on this average change trajectory line.  The trajectory for 
pain has an increasing slope, suggesting variability in pain across the population over 
time.  The trajectory for diarrhea has a flatter slope, suggesting less variability in diarrhea 
across the population over time.  In this case, diarrhea would not be included in the latent 
growth mixture analysis, while pain would be included.  Pain and diarrhea severity are 

































individual symptom models.  The cross-tabulation was used to estimate latent classes in 
the multisymptom model.  An initial 1-class model was tested, and subsequent classes 
were added in descending order on the basis of cell-sizes in the cross-tabulation to 
determine the best model fit.  Evaluation of the model was based on criteria as described 
above.  While conventional growth modeling estimated a mean growth curve under the 
assumption that all individuals in the sample come from a single population, LGMM 
estimated a mean growth curve for each class (Colder et al., 2002).  This multisymptom 
model provided classes that displayed homogenous trajectories across multiple symptoms 
that were heterogeneous from other classes.  For example, a potential result might include 
a class that reports a high severity of pain, fatigue, and depressed mood; a class that 
reports low severity of pain, fatigue, and depressed mood; and a class that reports 
moderate severity of pain, fatigue, and depressed mood (see Figure 1.10).  For each of 
these 3 classes, a unique intercept and slope for each symptom  is calculated that 
demonstrates the baseline measure and rate of change for each symptom as reported by 
the participants in that class. 
Specific Aim 3 
 
 Specific aim 3 was to determine if membership in differing individual symptom 
trajectory classes is determined by various demographic, clinical, and symptom variables. 
 Research Question 3.1: To what extent are differing symptom trajectory classes 
associated with variations in age, chemotherapy regimen, stage of disease, marital status, 
employment, education, and the presentation of other symptoms at moderate to severe 
levels?  















the predicted classes for the individual symptoms were examined for potential 
antecedents (age, marital status, employment, education status, income, stage of disease, 
and chemotherapy regimen) using independent-samples  t tests and ANOVA for tests of 
mean differences and chi-square for tests of association among categories.  Additionally, 
it was determined whether the number of days with a summative score of fatigue, 
disturbed sleep, depressed mood, anxiety, pain, and nausea and vomiting at moderate to 
severe levels during cycle 2 was an antecedent to individual symptom class membership 
during cycle 3 using independent-samples t tests and ANOVA.  Differences among the 
predicted classes for the individual symptoms was also examined for potential co-
occurring symptoms at moderate to severe levels using independent-samples  t tests and 
ANOVA.  While it is preferred to examine potential antecedents and co-occurring 
symptoms of the growth in different latent classes by incorporating these variables into 
increasingly complex structural models, this requires larger samples, especially when 
class counts may be small in the selected model (Dunn et al., 2011).  Because our sample 
size was relatively small, posterior probabilities and class assignments for each individual 
were saved into an output text file and extracted into the data set to be used for further 
analysis in tests of mean differences across the classes on antecedents and co-occurring 
symptoms outside the model.  Class membership then became a correlate for these 
variables (Jung & Wickerama, 2008).  Because chi-square tests assume that each cell has 
an expected frequency of five or more, small cell sizes were accounted for with Fisher’s 
exact chi-square.  This technique allowed for tests of association among categories when 
cell sizes had an expected frequency of five or less (Green & Salkind, 2008). 






class membership using independent-samples t tests, ANOVA and chi-Square.  
Chemotherapy regimen was constrained to two theoretically relevant variables of interest, 
whether or not the individual received Doxorubicin and whether or not the individual 
received Taxane separately.  Adjustments were not made for missing data on the 
demographic and clinical variables.  Therefore, the sample for each of these individual 
analyses was dependent on the largest set of complete data across groups (Langford et al., 
2016). 
 The overall symptom severity during cycle 2 was included as a potential 
antecedent of individual symptom class membership during cycle 3 using independent-
samples t tests and ANOVA.  Overall symptom severity for cycle 2 was calculated by 
combining the number of days where participants scored 4 or higher on severity of 
fatigue, disturbed sleep, depressed mood, anxiety, pain, and nausea.  The total number of 
moderate to severe days for these symptoms combined was then compared to the 
extracted class membership for the individual symptoms in cycle 3 using independent-
samples t tests and ANOVA.  Follow-up post hoc contrasts were conducted to evaluate 
pairwise differences among the means for significant differences in class membership 
during cycle 3 based on overall symptom severity during cycle 2.  In cases where equal 
variances were not assumed, the Dunnett’s C test was used, which does not assume equal 
variances among the factor levels.   
 Tests of mean differences across classes on the number of moderate to severe 
days reported for several symptoms were conducted using independent-samples t tests 
and ANOVA.  Summative scores for each symptom included the number of days subjects 






and nausea and vomiting individually within each cycle.  These summative scores were 
then compared to class membership for the individual symptoms in cycle 2 and 3.  In 
cases where classes did not display homogeneity of variance, the Welch statistic, a robust 
test that allows violation of this assumption, was used.  Where appropriate, follow-up 
post hoc contrasts were conducted to evaluate pairwise differences among the means for 
significant differences in class membership on the dependent variable of interest.  In 
cases where equal variances were not assumed, the Dunnett’s C test was used, which 
does not assume equal variances among the factor levels.   
Specific Aim 4 
 Specific aim 4 was to determine if differing multisymptom trajectory profiles are 
associated with variations in change in functional status, days of missed work, and hours 
spent lying down reported by women undergoing cycles 2 and 3 of chemotherapy for 
breast cancer. 
Research Question 4.1: To what extent are differing symptom trajectory profiles 
associated with variations in change in functional status, days of missed work, and hours 
spent lying down as reported by women undergoing chemotherapy for breast cancer? 
 After identifying the latent class solutions that best fit the data, differences among 
the predicted classes for the individual symptoms were examined for important outcomes 
using independent-samples t tests and ANOVA for tests of mean differences.  As 
described above, predicted class memberships were extracted from the model and used 
for further analysis in tests of mean differences across the classes on covariates outside 
the model.  Because Study 1 measured functional status with the SF-12 and Study 2 and 






the regression analysis.  First, baseline functional status (pre-cycle 2) scores for the 
sample from each parent study were compared to the norm for the SF-36 to ensure the 
two samples were relatively similar in distribution to the population norm.  If the sample 
mean and standard deviation were not significantly different from the norm for the SF-36, 
then the sample scores for each study were used and z-scores were calculated.  Next, the 
baseline functional status score and the post-cycle 3 functional status score were used to 
compute a change score for each participant.  The change score was then converted to a 
z-score, and the z-scores were used to test for mean differences among the trajectory 
classes to determine whether individual symptom classes are associated with variations in 
change in functional status over cycles 2 and 3 of chemotherapy.   
 Daily measures of hours spent lying down were averaged for each individual.  
Days of missed work were summed for all employed participants for each cycle 2 and 3.  
Tests of mean differences across the predicted classes were conducted on the average 
hours spent lying down and summed days of missed work using independent-samples t 






Table 1.5 Summary of the Analysis 
 
Specific Aim Research Question Statistical Analysis 
Aim 1 Determine the 
trajectories and profile classes 
associated with the severity of 
ten symptoms (fatigue, pain, 
disturbed sleep, depressed 
mood, anxiety, nausea, 
diarrhea, distress associated 
with changing appearance, sore 
mouth, and trouble thinking) 
reported by women undergoing 
cycles 2 and 3 of 
chemotherapy for breast 
cancer. 
 
1.1 What are the 
trajectories of the 
severity of individual 
symptoms reported by 
women undergoing 
cycles 2 and 3 of 
chemotherapy for 
breast cancer? 
1.2 What are the profile 
classes, if any, 
associated with the 
severity of individual 
symptoms reported by 
women undergoing 
cycles 2 and 3 of 
chemotherapy for 
breast cancer? 
1.3 Do the profile classes 
associated with the 
severity of individual 
symptoms differ 
between cycle 2 and 
cycle 3 of 
chemotherapy?  
 
1.1 Single Symptom 
Latent Growth 
Mixture Analysis 
1.2 Latent Growth 












Table 1.5 continued 
 
Specific Aim Research Question Statistical Analysis 
Aim 2 Identify multisymptom 
trajectory profile classes of 
patients undergoing cycles 2 





2.1 What symptom profile 
classes can be identified in 
a cohort of women 
undergoing chemotherapy 
treatment for breast cancer 
during cycle 2 and during 
cycle 3? 
2.2 Do the multisymptom 
profile classes differ 
between cycle 2 and cycle 
3 of chemotherapy? 
 
2.1 Multisymptom 





Aim 3 Determine if 
membership in differing 
multisymptom trajectory 
profiles is determined by 
various demographic, clinical, 




3.1 To what extent are 
differing symptom 
trajectory profiles 
associated with variations 
in age, chemotherapy 
regimen, stage of disease, 
marital status, 
employment, education, 
and the presentation of 
other symptoms at 
moderate to severe 
severity? 
Independent-samples  t 
tests, ANOVA and chi-
square 
Aim 4 Determine if differing 
multisymptom trajectory 
profiles are associated with 
variations in change in 
functional status, days of 
missed work, and hours spent 
lying down reported by women 
undergoing cycles 2 and 3 of 
chemotherapy for breast 
cancer. 
 
4.1 To what extent are 
differing symptom 
trajectory profiles 
associated with variations 
in change in functional 
status, days of missed 
work, and hours spent 
lying down as reported by 
women undergoing 
chemotherapy for breast 
cancer? 
Independent-samples  t 









Overview of Dissertation 
 The dissertation is organized into 5 chapters.  This chapter introduces the problem 
statement with specific aims, provides background and review of the relevant literature, 
and details the methods used in this study.  Chapters 2, 3, and 4 are written in manuscript 
format.  Chapter 2 discusses the results of the Latent Growth Mixture Models for the 
individual symptoms and the multisymptom models.  Chapter 3 presents the results of the 
studies of associations between various demographic, clinical, and symptom variables 
with symptom class membership extracted from the selected models for fatigue and 
disturbed sleep.  Chapter 4 presents the results of the studies of associations between 
various demographic, clinical, and symptom variables with symptom class membership 
extracted from the selected models for the symptoms of mood disturbance. Chapter 5 
provides a synthesis of the findings across all four specific aims of this study, the 
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IDENTIFICATION OF DISTINCT CLASSES OF WOMEN 
WITH BREAST CANCER BASED ON  
SYMPTOM TRAJECTORIES 







The purpose of this study was to examine 10 patient-reported symptoms 
experienced daily by women with breast cancer over multiple cycles of chemotherapy, 
exploring potential classes of women experiencing similar symptom trajectories. 
A secondary analysis was conducted utilizing data collected from women (n=166) 
undergoing chemotherapy for breast cancer during cycles 2 and 3 and who self-reported 
on the severity of 10 symptoms through daily phone calls to an automated system.  Latent 
Growth Mixture Modeling was used to identify classes of women experiencing similar 
symptom trajectories. 
 Participants ranged in age between 24 and 80 years (mean age 52.91 years), were 
mostly Caucasion (91.46%) and the largest proportion of the sample was diagnosed with 
stage II breast cancer (40.36%).  Fatigue, disturbed sleep, depressed mood, and anxiety 
were commonly reported at moderate to severe levels (4 or greater on a 10 point scale) 
during the two cycles of chemotherapy.  The multisymptom model did not reveal distinct 
subgroup classes; however, 4 individual symptoms did have distinct subgroups including 
a 3-class solution that was determined to be the best fit for fatigue and 2-class solutions 
that were selected for disturbed sleep, depressed mood, and anxiety.  For the other 6 
symptoms, no distinct subgroups were identified. 
Three classes of fatigue were identified, including those with mild improving 
fatigue (59% of women in cycle 2 and 64% in cycle 3), low moderate improving to mild 
fatigue (30% of women in cycle 2 and 25% in cycle 2), and high moderate improving 
fatigue (11% of women in both cycles).  Two classes of disturbed sleep were identified, 
including mild improving disturbed sleep (89% of women in cycle 2 and 81% in cycle 3) 





worsening disturbed sleep during cycle 3 (19% of women).  For depressed mood, 2 
classes were identified, with the majority (91% of respondents in cycle 2 and 94% in 
cycle 3) reporting a minimal level of depressed mood and a small class with a moderate 
level of depressed mood (9% of respondents in cycle 2 and 6% in cycle 3).  Two latent 
trajectories of anxiety were also revealed, including a minimal anxiety class (95% of 
respondents in cycle 2 and 92% in cycle 3) and a moderate anxiety class (5% of 
respondents in cycle 2 and 8% in cycle 3).   
 For fatigue, disturbed sleep, depressed mood, and anxiety, a class of women 
reported symptoms at moderate levels during both cycles, suggesting that clinicians 
should carefully review symptom patterns early in the course of treatment to identify 
women experiencing moderate to severe symptoms.  These women are likely to continue 
with higher symptom presentation throughout the cycle of chemotherapy and may benefit 
from intensifying symptom intervention.  Consideration should be given to the limitations 
of LGMM in identifying distinct subgroups with a modest sample size and daily 
symptom reporting with patterns that included days with zero severity.  
Introduction 
Breast cancer is the most frequently diagnosed cancer for women, but has a 
relatively high 5-year survival rate of 89% for women with localized cancer (American 
Cancer Society, 2015).  While women diagnosed with breast cancer may have increased 
survival when compared to other cancers, they often face significant symptoms during 
and following treatment (Bradley, Neumark, Luo, & Schenk, 2007).  Aggressive, 
multimodal and multi-agent treatment may be associated with significant toxicities and 





diminish quality of life, ability to function, interfere with activity and employment, 
interrupt treatment and, consequently, influence treatment effectiveness (Bradley et al., 
2007; Cleeland et al., 2003; Kayl & Meyers, 2006). 
Symptoms are self-reported, subjective phenomena that indicate a change in 
normal functioning, sensation, or appearance due to disease (Rhodes & Watson, 1987). 
Considerable evidence suggests variability in the trajectories, or change in symptom 
prevalence and severity over the course of chemotherapy treatment for breast cancer 
(Dodd, Cho, Cooper, & Miaskowski, 2010).  Describing heterogeneity, correlates, and 
outcomes of different symptom trajectories allows clinicians to target women who may 
be at higher risk for increased symptom burden and poor outcomes related to the 
symptom experience.  There is a large body of literature devoted to the description of 
single symptoms and symptom clustering.  There is evidence to support the existence of 
common groups and trajectories of symptoms that occur during treatment for cancer 
(Miaskowski et al., 2006).  To date, most studies have been focused on symptom 
prevalence and the occurrence or association of specific symptoms in combination (Dodd 
et al., 2010).  While useful for understanding the presence of symptoms overall within 
samples and at meaningful single time points, these studies do not account for individual 
change in symptom presentation over time (Henly, Wyman, & Findorff, 2011).  
Determination of which symptoms are included in an analysis is often based on which 
symptoms are the more prevalent symptoms, not which symptoms are more severe.  
While this method is practical, important symptoms that may be severe or distressing 
could remain inadvertently understudied.   





longitudinal statistical modeling techniques have allowed for newer methodological 
approaches to studying classes of symptom trajectories, identifying homogeneous classes 
of persons who share common symptom trajectories (Dodd et al., 2010; Henly et al., 
2011; Lam et al., 2010; Onselen et al., 2012; Pud et al., 2008; Wang, Chang, Chen, Chen, 
& Hsu, 2014).  Conventional latent growth modeling allows for modeling of individual 
differences in growth on an outcome, providing latent growth factor means and variances.  
Latent growth mixture modeling (LGMM) further allows for the identification of discrete 
classes of individuals on the basis of common trajectories of growth, wherein each latent 
class has its own model of growth.  The categorical latent variables represent the class 
that describes groups of individuals who are homogeneous within that class and are 
heterogeneous across classes (Muthen & Muthen, 2000).  The goal of LGMM is to add 
classes stepwise until the model shows the smallest number of latent classes that can 
describe the associations among a set of observed measures (Muthen & Muthen, 2000).  
One benefit of LGMM over other methods of class identification is that the probability of 
membership in a class and variances within the classes are estimated for each individual, 
accounting for unreliability of classification (Colder, Richardson, Campbell, Ruel, & 
Flay, 2002).  Finally, LGMM provides the probability of class membership, which can 
then be used to study correlate variables and may relate the probability of a given 
outcome based on class membership (Muthen & Muthen, 2000).  
LGMM has been applied to symptom data for women with breast cancer during 
various stages of the disease and treatment, identifying classes of women with similar 
trajectories for depression, psychosocial distress, and trouble sleeping individually and a 





et al., 2011; Lam et al., 2010; Langford et al., 2016; Onselen et al., 2012).  Based on 
symptom prevalence, evaluated monthly before, during, and following chemotherapy, 
these studies have identified 3-5 classes of distinct trajectories of the symptoms of 
interest (Dunn et al., 2011; Lam et al., 2010; Langford et al., 2016; Onselen et al., 2012).  
While this topic has received increased attention, well-designed longitudinal studies of 
breast cancer symptoms are needed to replicate findings and continue studying individual 
and multisymptom trajectory classes (Dodd et al., 2010; Dunn et al., 2011; Henselmans et 
al., 2010; Lam et al., 2010; Lee et al., 2004; Onselen et al., 2012).  Additionally, no study 
has modeled the self-reported severity of symptoms using daily measures during distinct 
cycles of chemotherapy.  The purpose of this study was to examine self-reported 
symptom severity experienced daily by women with breast cancer over multiple cycles of 
chemotherapy, exploring potential classes of women experiencing similar symptom 
trajectories, and to examine whether the classes differ between 2 cycles.  Understanding 
trajectories of symptoms that occur in individuals may elucidate potential targets, or at-
risk individuals, and common etiologies for symptoms profiles, which may inform the 
development of targeted interventions aimed at the reduction of symptoms during 
treatment. 
Methods 
Participants and Setting 
 This study was a secondary analysis of longitudinal data pooled from three trials 
of a symptom monitoring and behavioral intervention in women undergoing 
chemotherapy for breast cancer.  Study 1 and Study 2 tested the use of an automated 





of symptoms during chemotherapy.  Study 3 was an observational study utilizing the 
same automated telephone-linked-care system for data collection.  Each of the studies 
used the same data collection methods, the telephone-linked-care automated system, 
further described by Mooney, Beck, Friedman, Farzanfar, and Wong (2014).    
 For Study 1, participants were recruited from four ambulatory clinics in two states 
in the United States, including a community cancer center in the southeast, two 
community practices in the west, and a clinical cancer center in the west.  For Studies 2 
and 3, participants were recruited from two academic, multidisciplinary practice settings 
in the Midwest and the western United States.  While in both Study 1 and Study 2, 
participants were randomly assigned to a usual care group or a symptom management 
intervention group, preliminary data analysis suggests differences in reported symptoms 
between the control and intervention groups in study 2 only.  Therefore, data from all 
eligible participants in Study 1 with a breast cancer diagnosis, regardless of study group, 
and only data collected from eligible participants randomized to the control in Study 2 
were utilized in this secondary analysis.  Study 3 involved no intervention and data from 
all eligible participants was utilized in this secondary analysis.  Because data from cycle 
1 was not available for Study 1, we chose to include data from cycles 2 and 3 for this 
secondary analysis.  Only women who reported on at least 3 days during the cycle of 
chemotherapy were included in the study sample to allow for application of the analysis 
methods.   
A cohort of 259 women with breast cancer were pooled from the 3 parent studies, 
94 from Study 1, 156 from Study 2 and 29 from Study 3.  Thirteen women who did not 





the intervention group for Study 2 were excluded.  This yielded a total data set of 166 
women, of which 165 completed measures on at least 3 days during cycle 2 and 155 
completed measures on at least 3 days during cycle 3.      
Measures 
All 3 parent studies utilized similar instrumentation.  We collected demographic 
and disease-related data at study entry from the participant and from the medical record.  
Demographic data included age, gender, race and ethnicity, marital status, education, 
employment, and income.  Disease factors included primary cancer diagnosis, extent of 
disease at diagnosis, and details of chemotherapy protocol.  Rather than summative 
symptom measures, we used single-item indicators to assess each symptom to better 
appreciate changes in specific symptoms.  Single-item indicators have acceptable 
reliability and validity in symptom studies (Cleeland & Mendoza, 2011; Mooney et al., 
2014).   The investigator-developed instrument employed conditional branching such that 
participants were first asked, “During the past 24 hours did you experience (symptoms)?”  
A no response was scored as zero and a yes response yielded a question asking the 
participant to score the symptom severity using a 1 (low) to 10 (high) Likert scale.  
Symptoms assessed included fatigue, disturbed sleep, depressed mood, anxiety, pain, 
nausea/vomiting, sore mouth, and diarrhea across all three parent studies.  Two additional 
symptoms, distress associated with changing appearance and trouble thinking, were 
assessed in Studies 2 and 3.  A subsample, consisting of participants enrolled in those 2 






This secondary analysis was reviewed by the Institutional Review Board (IRB) at 
the University of Utah.  Subjects were identified only by their original study 
identification number.  All participants signed a written, informed consent upon initiation 
of participation in the original studies. 
Statistical Analysis 
 MPlus, version 6.0, was used for mixture model analyses and the Software 
Statistical Package for the Social Sciences (SPSS), version 23.0, was used for data 
management and analysis of the demographics.  Alpha was set at 0.05 and no adjustments 
were made for multiplicity in this hypothesis-generating study.   
 Descriptive statistics and frequency distributions were generated on the sample 
characteristics.  To accommodate for varying cycle lengths, only data from the first 14 
days of each cycle were included in the analysis.  The prevalence of individual symptoms 
during the first 14 days of each cycle was determined.  An exploratory analysis was 
conducted to describe how individuals in the data set changed over time on each 
symptom; using graphical visualization and conventional growth modeling (cycle 2 and 
cycle 3 separately).  This analysis provided an intercept and slope that describe the 
baseline measure and rate of change for each symptom during each cycle.  Cycles were 
studied individually to capture potential differences in the symptom trajectories of 
consecutive cycles.  
After establishing the growth form for each of the 10 symptoms, latent classes 
were modeled on the basis of growth trajectories from multiple symptoms.   Latent 





individuals’ symptom experience that are heterogeneous from other classes.  Using the 
more prevalent symptoms in our sample, an exploratory method was employed, building 
the effort towards a multisymptom latent growth curve, adding first fatigue and disturbed 
sleep, followed by symptoms of mood disturbance, pain, and nausea.  An initial 1-class 
model was tested, and subsequent classes were added in ascending order to determine the 
best model fit.  Each latent class corresponded to a subpopulation that has its own set of 
parameter values (intercept and slope) (Singer & Willett, 2003).  Step-wise models were 
evaluated on the Bayesian information criterion (BIC), used to evaluate improvement in 
model fit with the addition of classes.  Smaller BIC values suggested a better model fit 
(Colder et al., 2002; Muthen & Muthen, 2000).  If the addition of a class resulted in a 
reduction in the BIC value relative to the BIC from the previous model (without the 
added class), then the new model was considered an improvement and the class was 
retained.  The addition of classes continued until the BIC did not decrease with the 
addition of a class.  Additionally, entropy was used to evaluate the probabilities of 
membership in each class for each individual.  Entropy is a summary measure of 
classification based on these probabilities that ranges from 0 to 1.0 (Colder et al., 2002).  
The closer entropy values are to 1.0, the better the classification.  Finally, the best-fitting 
model was examined for the number of subjects in each class (greater than 5% of the 
sample) and graphed visually to determine if the predicted trajectories were clinically and 
theoretically relevant (Onselen et al., 2012).   
After identifying the potential multisymptom latent classes, the number of latent 
classes for each individual symptom was determined on the basis of means of the growth 






A total of 166 women with breast cancer participated in the study.  Patient 
demographic and clinical characteristics are summarized in Table 2.1.  Participants 
ranged in age between 24 and 80 years (mean age 52.91 years, SD = 10.8).  The majority 
of participants were White (91.46%), married (75%), and not currently working (62.8%).  
The largest proportion of the sample was diagnosed with Stage II disease (40.36%) and 
had at least some education beyond high school (75.3%).  All study participants were 
receiving the second and third cycles of a multicycle chemotherapeutic regimen.  Data 
regarding dose density and use of anti-emetic agents were not available.  
Prevalence and Trajectories of Individual Symptoms 
Call compliance was 78.4% of days during the first 14 days of cycle 2 and 78.0% 
of days during the first 14 days of cycle 3.  The prevalence of individual symptoms 
during each cycle and the prevalence of moderate to severe levels of symptoms during 
the first 14 days of each cycle are reported in Table 2.2.  The percent of days reported of 
total cycle days with severity of zero, severity of 1-10, and severity of 4-10 (moderate to 
severe levels) are also presented in Table 2.2.   Symptoms were common during both 
cycles and reported at moderate to severe levels.  Fatigue was the most prevalent 
symptom, reported by 92.7% and 94.9% of women in each cycle 2 and 3, respectively.  
Disturbed sleep, pain, nausea and vomiting, depressed mood, and anxiety were also 
highly prevalent.  Growth factors for the 1-class model for each symptom are presented 






Table 2.1 Sample Demographic and Clinical Characteristics (n =166) 
 
Characteristic Mean SD 
Age (in years) 52.90 10.8 
Characteristic n % 
Ethnicity 
   Non-Hispanic 
   Hispanic 










   Partnered 
   Nonpartnered 










   Full-time 
   Part-time 
   Not Employed 












   High school          
   Some College  
   Associate Degree 
   Bachelor Degree 
   Postgraduate  
















   Less than  $9,999 
   $10,000-29,999 
   $30,000-49,000 
   $50,000-69,000 
   $70,000 or More      
   Unknown 

















Stage of Disease 
   Stage I 
   Stage II 
   Stage III 
   Stage IV 













Chemotherapy Regimen   
   Cyclophosphamide with Doxorubicin 68 41.0% 
   Docetaxel 23 13.9% 
   Cyclophosphamide with Methotrexate and 5-FU 16 9.6% 
   Docetaxel with Carboplatin 13 7.8% 
   Cyclophosphamide with Docetaxel 12 7.2% 
   Cyclophosphamide with Doxorubicin and 
Docetaxel 9 5.4% 
   Cyclophosphamide with Doxorubicin and 5-FU 6 3.6% 
   Cyclophosphamide with 5-FU 4 2.4% 






Table 2.2 Symptom Prevalence and Mean Number of Days at Moderate to Severe Levels 
 
Symptom Cycle 






than 0 at 
Least Once 
Mean no. Days 











than 3 at 
Least Once 
Mean no. Days 



















Fatigue a 2 153 (92.7%) 7.53 (3.69), 1-14 115 (69.7%) 5.09 (3.47), 1-14 659 (36.4%) 1,152 (63.6%) 585 (32.3%) 3 148 (94.9%) 7.09 (3.93), 1-14 105 (67.3%) 4.95 (3.70), 1-14 654 (38.4%) 1,050 (61.6%) 520 (30.5%) 
Disturbed 
Sleep a 
2 126 (76.4%) 3.63 (2.56), 1-13 103 (62.4%) 2.87 (2.07), 1-13 1,354 (74.8%) 457 (25.2%) 296 (16.3%) 
3 110 (70.5%) 3.40 (2.64), 1-13 85 (54.5%) 2.46 (1.76), 1-11 1,330 (78.1%) 374 (21.9%) 209 (12.3%) 
Pain a 2 124 (75.2%) 4.55 (3.20), 1-14 75 (45.5%) 3.51 (2.95), 1-13 1,247 (68.9%) 564 (31.1%) 263 (14.5%) 3 104 (66.7%) 5.16 (3.74), 1-14 66 (42.3%) 4.15 (3.33), 1-14 1,167 (68.5%) 537 (31.5%) 274 (16.1%) 
Nausea and 
Vomiting a 
2 116 (70.3%) 3.90 (2.92), 1-13 78 (47.3%) 2.66 (2.28), 1-11 1,359 (75.0%) 542 (29.9%) 208 (11.5%) 
3 111 (71.2%) 4.05 (3.31), 1-14 63 (40.4%) 3.14 (2.63), 1-12 1,254 (73.6%) 450 (26.4%) 198 (11.6%) 
Diarrhea a 2 69 (41.8%) 2.13 (1.53), 1-8 30 (18.2%) 1.83 (0.87), 1-4 1,664 (91.9%) 147 (8.1%) 55 (3.0%) 3 49 (31.4%) 2.63 (1.82), 1-10 23 (14.7%) 2.17 (1.53), 1-6 1,575 (92.4%) 129 (7.6%) 49 (2.9%) 
Sore Mouth a 2 68 (41.2%) 3.62 (2.34), 1-11 38 (23.0%) 3.11 (2.29), 1-10 1,565 (86.4%) 246 (13.6%) 118 (6.5%) 3 68 (43.6%) 3.32 (2.61), 1-13 38 (24.4%) 2.66 (2.72), 1-13 1,478 (86.7%) 216 (12.7%) 91 (5.3%) 
Trouble 
Thinking b 
2 46 (27.9%) 2.67 (1.97), 1-11 28 (17.0%) 2.50 (2.19), 1-10 884 (93.2%) 64 (6.8%) 37 (3.9%) 
3 31 (19.9%) 3.26 (2.11), 1-9 21 (13.5%) 1.95 (1.07), 1-5 776 (94.1%) 46 (5.6%) 20 (2.4%) 
Appearance b 2 38 (23.0%) 3.32 (2.57), 1-12 25 (15.2%) 3.16 (2.37), 1-9 882 (93.0%) 66 (7.0%) 42 (4.4%) 3 15 (9.6%) 3.27 (3.97), 1-13 10 (6.4%) 3.50 (4.50), 1-12 801 (97.1%) 24 (2.9%) 17 (2.1%) 
Mood Disturbance Symptoms 
Depressed 
Mood a 
2 99 (60.0%) 3.60 (3.21), 1-13 70 (42.4%) 3.23 (2.84), 1-12 1,455 (80.3%) 356 (19.7%) 226 (12.5%) 
3 83 (53.2%) 3.47 (3.11), 1-14 55 (35.3%) 2.87 (2.86), 1-13 1,416 (83.1%) 288 (16.9%) 158 (9.3%) 
Anxiety a 2 77 (46.7%) 3.34 (3.17), 1-13 47 (28.5%) 2.91 (2.83), 1-11 1,544 (85.3%) 267 (14.7%) 147 (8.2%) 3 62 (39.7%) 3.56 (3.62), 1-13 40 (25.6%) 2.65 (2.56), 1-9 1,483 (87.0%) 221 (13.0%) 106 (6.2%) 
a n=165, cycle 2; n=156, cycle 3; 1811(78.4%) days reported cycle 2, 1704(78.0%) days reported cycle 3; 499(21.6%) days missing cycle 2, 480(22.0%) days missing cycle 3 
b n=84, cycle 2; n=75, cycle 3; 948 (80.6%) days reported cycle 2, 825 (79.6%) days reported cycle 3; 228 (19.4%) days missing cycle 2, 211 (20.4%) days missing cycle 3
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Table 2.3 Results of Latent Growth Mixture Analysis (n=165, n=156) 
 
Symptom Cycle Intercept Slope 
Quadratic 
Term 
Fatigue Cycle 2 2.69* 0.05 -0.01* Cycle 3 2.27* 0.19* -0.02* 
Disturbed Sleep Cycle 2 1.95* -0.22* 0.01* Cycle 3 1.01* -0.03 0.00 
Depressed Mood Cycle 2 0.93* 0.02 -0.00 Cycle 3 0.52* 0.13* -0.01* 
Anxiety Cycle 2 0.75* -0.04 0.00 Cycle 3 0.60* -0.01 -0.00 
Pain Cycle 2 1.14* 0.08 -0.01* Cycle 3 1.10* 0.11* -1.01* 
Nausea and 
Vomiting 
Cycle 2 1.63* -0.15* 0.00 
Cycle 3 0.89* 0.11* -0.01* 
Diarrhea Cycle 2 0.14* 0.05* -0.00* Cycle 3 0.25* 0.02 -0.00* 
Trouble 
Thinking 
Cycle 2 0.56* -0.09* 0.00 
Cycle 3 0.26* -0.01 0.00 
Sore Mouth Cycle 2 0.02 0.16* -0.01* Cycle 3 0.09* 0.10* -0.01 
Change in 
Appearance 
Cycle 2 0.87* -0.15* 0.01* 





Multisymptom Latent Growth Mixture Model 
 Multisymptom models did not converge and classes could not be discerned.  
Without convergence, no fit statistics were available to compare various models.   
Individual Symptom Latent Growth Mixture Models 
Multiclass latent growth mixture models were evaluated for the individual 
symptoms and fit indices are presented in Table 2.4.  Multiclass models were retained for 
fatigue, disturbed sleep, depressed mood, and anxiety.  For trouble thinking, the 2-class 
model converged, but was not retained because class counts were less than 5% for one 
class.  For diarrhea, nausea and vomiting, and pain, 2-class models converged, but the 
results were not trustworthy due to a nonpositive definite first-order derivative product 
matrix.  For sore mouth and distress with changing appearance, the best log likelihood 
value was not replicated for the 2-class model.  Models were not retained for trouble 
thinking, diarrhea, nausea, pain, sore mouth, and distress with changing appearances.    
For fatigue, a 3-class solution was selected with mild improving, low moderate 
improving to mild, and high moderate improving classes during both cycles.  Intercept, 
slopes, and quadratic terms for the individual symptom classes are presented in Table 2.5 
and trajectory graphs are presented in Figure 2.1.  The majority of women were in the 
mild improving fatigue class (59% for cycle 2 and 64% for cycle 3).  These individuals 
had a low fatigue severity level at day 1 of each cycle (2.25 ± 0.29, 1.76 ± 0.24).  
Individuals in the low moderate improving to mild fatigue class had a moderate fatigue 
severity level at day 1 of each cycle (3.21 ± 0.52, 2.52 ± 0.39) and individuals in the high 
moderate improving fatigue class had a severe level of fatigue at day 1 (5.66 ± 0.73, 5.43 













1 class -4,309.41 8,651.70 N/A N/A N/A 
2 class -3,954.18 7,948.98 .944 .988, .989 69%, 31% 
3 class -3,847.23 7,742.81 .944 .977, .950, .982 59%, 30%, 11% 
4 class -3,800.81 7,657.70 .943 .950, .960, .984, .935 
57%, 12%, 22%, 
10% 
1 class -4,062.06 8,156.06 N/A N/A N/A 
2 class -3,652.62 7,344.68 .963 .998, .968 72%, 28% 
3 class -3,570.33 7,187.62 .941 .986, .950, .960 64%, 25%, 11% 
4 class -3,538.36 7,131.18 .881 .935, .869, 1.000, .956 
53%, 22%, 22%, 
3% 
1 class -4,067.91 8,168.70    
2 class -3,906.86 7,854.34 .984 .997, .995 89%, 11% 
3 class -3,855.66 7,759.66 .958 .945, .989,.968 84%, 10%, 5% 
1 class -3,582.73 7,197.38    
2 class -3,441.79 6,923.02 .925 .981, .980 81%, 19% 
3 class -3,385.73 6,818.42 .962 .987, .995,.969 82%, 14%, 5% 
1 class -3,861.42 7,755.71 N/A N/A N/A 
2 class -3,470.9 6,982.42 .990 .997, .995 91%, 9% 
3 class -3,359.91 6,768.17 .987 .998, .992,.961 84%, 9%, 7% 
1 class -3,362.53 6,756.98 N/A N/A N/A 
2 class -2,827.07 5,792.57 1.000 1.000, 1.000 94%, 6% 
3 class -2,782.16 5,611.26 .998 1.000, .989, 1.000 94%, 5%, 2% 
1 class -3,509.86 7,052.60 N/A N/A N/A 
2 class -3,029.89 6,100.39 1.000 1.000, 1.000 95%, 5% 
3 class -2,918.53 5,887.40 .995 .992, 1.000 85%, 12%, 3% 
1 class -3,076.95 6,185.83 N/A N/A N/A 
2 class -2,621.09 5,281.63 .997 .999, 1.000 92%, 8% 



























1 class -2,454.71 4,942.29 N/A N/A N/A 
2 class -2,219.35 4,479.31 .997 .999, 1.000 98%, 2% 
1 class -2,003.35 4,038.62 N/A N/A N/A 
2 class -1,766.92 3,573.29 .994 1.000, .999 98%, 2% 
1 class -2,573.34 5,179.56 N/A N/A N/A 
2 class a -2,463.73 4,968.08 .985 .981, .999 89%, 11% 
1 class -2,106.29 4,244.52 N/A N/A N/A 
2 class a -1,925.72 3,890.88 .995 .999, .996 94%, 6% 
1 class -3,555.29 7,143.46 N/A N/A N/A 
2 class a -3,241.06 6,522.74 .990 1.000, .981 85%, 15% 
1 class -3,407.89 6,847.71 N/A N/A N/A 
2 class a -3,055.22 6,149.88 .980 .987, .997 84%, 16% 
1 class -4,281.51 8,595.90 N/A N/A N/A 
2 class a -4,047.23 8,135.08 .965 .988, .994 85%, 15% 
1 class -3,590.76 7,213.45 N/A N/A N/A 
2 class a -3,223.28 6,486.00 .975 .997, .982 81%, 19% 
1 class -3,267.50 6,567.88 N/A N/A N/A 
2 class b      
1 class -2,906.92 5,845.77 N/A N/A N/A 
2 class b      
1 class -1,663.20 5,425.06 N/A N/A N/A 
2 class b      
1 class -1,977.58 4,040.89 N/A N/A N/A 
2 class b      
a Results not trustworthy for parameters due to nonpositive definite first-order derivative product matrices. 
b The best log likelihood value was not replicated. 





Table 2.5 Growth Factor Means and Predicted Frequencies for Each Class 
 







Mild Improving 2.25* -0.26* 0.01* 97.94 
Low Moderate Improving to 
Mild 3.21* 0.32 -0.03* 51.46 
High Moderate Improving 5.66* 0.34 0.01 18.26 
Cycle 3 
Mild Improving 1.76* -0.12 0.00 106.24 
Low Moderate Improving to 
Mild 2.52* 0.65* -0.06* 41.50 
High Moderate Improving 5.43* 0.60* -0.06* 18.26 
Disturbed Sleep 
Cycle 2 
Mild Improving 1.74* -0.20* 0.01 145.85 
Moderate Worsening 3.76* -0.28 0.03 18.15 
Cycle 3 
Mild Improving 0.87* -0.07 0.00 133.65 
Mild Worsening 1.66* 0.14 0.00 31.35 
Depressed Mood 
Cycle 2 
Consistently Mild 0.78* -0.04 0.00 148.50 
Consistently Moderate 4.04* 0.22 -0.01 14.85 
Cycle 3 
Consistently Mild 0.27 0.13 -0.01 155.10 
Moderate Improving 4.82* 0.23 -0.02* 9.90 
Anxiety 
Cycle 2 
Consistently Mild 0.69* -0.10* 0.01* 156.75 
Consistently Moderate 4.90* 0.03 0.00 8.25 
Cycle 3 
Consistently Mild 0.34* -0.03 0.00 156.75 
Low Moderate Improving to 










     
 




























































































































































































































































































































































day 14 of each cycle.  In both cycles, 11% of participants were in the high moderate 
improving fatigue class.   
For disturbed sleep, depressed mood, and anxiety, 2-class solutions were retained.  
For disturbed sleep, two classes were identified: a mild improving disturbed sleep class 
and a moderate worsening disturbed sleep class during cycle 2 and a mild improving and 
a mild worsening disturbed sleep class during cycle 3.  The majority of subjects were in 
the mild improving disturbed sleep classes (89% for cycle 2 and 81% for cycle 3) and had 
a low severity of disturbed sleep at day 1 (1.74 ± 0.20, 0.87 ± 0.13) for each cycle and 
remained stable over the 14 days.  A smaller percentage of participants were in the 
worsening disturbed sleep classes (11% in cycle 2 and 19% in cycle 3) and  
had a higher severity of disturbed sleep at cycle day 1 in both cycles (3.76 ± 1.05, 1.66 
±0.49) that increased over the 14 days.  This class started with a slightly higher severity 
of disturbed sleep during cycle 2 when compared to cycle 3. 
 The majority of subjects were in the consistently mild depressed mood class (91% 
in cycle 2 and 94% in cycle 3) with a low severity of depressed mood on day 1 (0.78 ± 
0.16, 0.27 ± 0.09) which they maintained over the first 14 days of both cycles.  Nine 
percent of women during cycle 2 were in the consistently moderate depressed mood class 
and reported moderate severity on day 1 (4.04 ± 0.76), which they maintained over the 
first 14 days of both cycles.  During cycle 3, 6% of women were in the moderate 
improving depressed mood class and reported moderate severity on day 1 (4.82 ± 0.63), 
which improved slightly over the first 14 days of chemotherapy. 
 The majority of subjects were in the consistently mild anxiety classes (95% in 





0.13, 0.34 ±  0.07) that remained stable over the first 14 days of both cycles.  During 
cycle 2, 5% of women were in the consistently moderate anxiety class and reported 
moderate levels of anxiety on cycle day 1 (4.92 ± 1.70) that remained stable across the 
cycle.  During cycle 3, 8% of women were in the low moderate improving to mild 
anxiety class and reported moderate anxiety on cycle day 1 (3.53 ±  0.61) that improved 
to mild levels over the first 14 days of chemotherapy.  Women in the moderate anxiety 
class did report higher severity of anxiety in cycle 2 when compared to cycle 3. 
Discussion 
Results of this study contribute to a growing body of literature concerned with the 
trajectories of individual and multiple symptoms that are experienced by women 
receiving chemotherapy for breast cancer.  Three classes displaying homogenous 
trajectories of fatigue severity were identified: mild improving fatigue, low moderate 
improving to mild fatigue, and high moderate improving fatigue.  Two classes displaying 
homogenous trajectories of disturbed sleep were identified: mild improving disturbed 
sleep during both cycles and moderate worsening disturbed sleep during cycle 2 and mild 
worsening disturbed sleep during cycle 3.  Two classes of both depressed mood and 
anxiety were identified, including consistently mild depressed mood during both cycles 
and consistently moderate depressed mood during cycle 2 and moderate improving 
depressed mood during cycle 3.  Additionally, consistently mild anxiety classes were 
identified during both cycles and a consistently moderate anxiety class during cycle 2 and 
a low moderate improving to mild anxiety class during cycle 3 were described.  Classes 
were not identified for the other 6 symptoms and a multisymptom model was not 





available for analysis.  Ten symptoms with daily reporting on symptom severity rather 
than symptom prevalence alone over 2 cycles of chemotherapy were studied in an 
exploratory method. 
The lack of class identification for some individual symptoms and multiple 
symptoms in combination warrants some discussion.  Some of the symptoms, including 
sore mouth, trouble thinking, distress associated with changing appearance and diarrhea, 
were comparatively rare, reported overwhelming at a level zero.  Rare events may not 
have trajectories that can be modeled individually or in combination with other symptoms 
or may require a larger sample size and consideration of distributional assumptions in 
attempting to recover classes of women with homogenous trajectories.  The use of 
differing methodological approaches may allow for better explanations of these rare 
symptoms.  For example, cross-sectional designs using specific measurement time points 
and with specific chemotherapy regimens when these symptoms are expected to be 
present may better explain rare symptoms.   
With regards to pain and nausea and vomiting, a multiclass model using only the 
more prevalent symptoms, our study was likely underpowered given the modest sample 
size and large variability in the number of days with reported symptoms.  For nausea and 
vomiting and pain, it is possible that a 2-class model could represent the trajectories of 
these symptoms, but given the number of parameters needed for model estimation, the 
results were untrustworthy.  With a larger sample, these models might have been 
retained.  Additionally, a multiclass model with multiple symptoms may have been 
recovered with a larger sample.  Several recent reports suggest that symptoms may exist 





symptoms (Bender, Ergun, Rosenzweigh, Cohen, & Sereika, 2005; Berger & Farr, 1999; 
Berger & Higginbotham, 2000; Bower et al., 2011; Broeckel, Jacobsen, Horton, 
Balducci, & Lyman, 1998; Byar, Berger, Bakken, & Cetak, 2006; Dodd et al., 2010; 
Gaston-Johansson, Fall-Dickson, Bakos, & Kennedy, 1999; Jacobson et al., 1999; 
Langford et al., 2016; Liu et al., 2009; Liu et al., 2012; Molassiotis, Yam, Yung, Chan, & 
Mok, 2002; Osoba et al., 1997; Poon et al., 2013; So et al., 2009).  In our sample, the 
more prevalent symptoms, including fatigue, disturbed sleep, depressed mood, and 
anxiety, presented as hugely variable in the number of days these symptoms were 
reported and at varying levels.  While a mixture distribution may well-represent the 
diversity in these symptoms, we did not have the sample size needed to recover classes in 
a multisymptom model.  There is no general rule for determining sample size applicable 
to all situations in growth modeling; however, the Monte Carlo method is recommended 
(Muthen & Muthen, 2002).  Assuming the missing data from the sample are random, the 
Monte Carlo method estimated a sample size requirement between 150 and 250 
participants.  The sample in the study was borderline adequate to apply LGMM, and it is 
likely that given the number of days with zero on many symptoms and the large 
variability in the number of days with the more prevalent symptoms at varying levels, a 
larger sample was needed.     
Only one report of successful class identification with multiple symptoms in 
breast cancer was found in the literature, but with important differences methodologically 
from this study.  Langford et al. (2016) identified a multisymptom model using Latent 
Class Analysis (LCA) of the symptom cluster of pain, fatigue, sleep disturbance, and 





study, a larger sample of women (n=391) were evaluated the week after chemotherapy 
administration in a cross-sectional design and data were studied using LCA.  LCA does 
not allow individuals to vary within classes as LGMM does, and may have allowed for 
model convergence but with constraints.  Constraining the model may be useful in studies 
with smaller sample sizes and with a large number of data with a zero value, but comes 
with limitations inherent to not allowing individual growth to vary within the classes.   
  While any or all of these reasons may have contributed to the failure of the multi-
symptom LGMM to identify classes, further study is needed to clarify whether LGMM 
can be used to identify classes of women with similar severity trajectories on multiple 
symptoms.  It is possible that an increased variability in rare symptoms could be found 
with a larger sample.  Additionally, larger samples and model constraints may allow for 
identification of classes using multiple highly prevalent symptoms.  Future studies using 
complex longitudinal data sets to study cancer-related symptoms need to consider the 
variability within the data to be analyzed using these methods and account for the 
limitations inherent to LGMM.   
 In an exploratory modeling of the individual symptoms, a three-class model was 
retained for fatigue and two-class models were retained for disturbed sleep, depressed 
mood, and anxiety individually.  Fatigue was reported at a severity greater than zero by 
92.7% of women during cycle 2 and 94.9% of women during cycle 3, consistent with the 
prevalence of fatigue during chemotherapy found in other studies (Bender et al., 2005; 
Bower et al., 2011; Browall, Persson, Ahlberg, Karlsson, & Danielson, 2009; Downie, 
Fan, Houede-tchen, Yi, & Tannock, 2006; Gaston-Johannson et al., 1999; Given, Given, 





McDermott, 2008; Liu et al., 2009; Nieboer et al., 2005; So et al., 2009; Tchen et al., 
2003).  In contrast to previous studies, this analysis used fatigue severity rather than 
prevalence to model change.  The overall 1-class model predicted a fatigue level of 2.69 
on the first day of cycle 2 and 2.27 on the first day of cycle 3.  During both cycles, the 
fatigue severity remained stable across the first 14 days.  This finding is consistent with 
findings reported by Huang, Chen, Liang, and Miaskowski (2014), who found that 
average fatigue severity ranged from 1.92-3.09 over the 12 months following breast 
cancer surgery.   This 1-class model allows for little discussion of those women (69.7% of 
respondents in cycle 2 and 67.3% in cycle 3) who reported moderate to severe levels of 
fatigue (ranging from 4-10) during the two cycles of chemotherapy.   
 Three patterns of fatigue were described in the LGMM model, including mild 
improving fatigue (59% of respondents in cycle 2 and 64% in cycle 3), low moderate 
improving to mild fatigue (31% of respondents in cycle 2 and 25% in cycle 3), and high 
moderate improving fatigue (11% of respondents in both cycles) classes.  Across all three 
classes, the level of fatigue improved during the first 14 days of chemotherapy during 
both cycles, but was still present at day 14, consistent with previous findings that fatigue 
persists throughout treatment, but does not worsen over time (Byar et al., 2006; deJong, 
Candel, Schouten, Abu-Saad, & Courtens, 2004; Jacobsen et al., 1999; Payne, Piper, 
Rabinowitz, & Zimmerman, 2006; Sitzia & Huggins, 1998). Additionally, the intercepts 
and slopes and visualization of over the 2 cycles of chemotherapy suggest that fatigue in 
cycle 2 did not differ in pattern during cycle 3, similar to previously reported findings of 






Disturbed sleep was reported by 76.4% of women during cycle 2 and 70.5% of 
women during cycle 3.  While other studies have report that over half of women report 
difficulty obtaining quality sleep during and following treatment for breast cancer, those 
numbers were higher in our sample (Beck et al., 2010; Bender et al., 2005; Berger & 
Higginbotham, 2000; Bower et al., 2011; Fortner, Stepanski, Wang, Kasprowicz, & 
Durrence, 2002; Given et al., 2001; Janz et al., 2007; Kim et al., 2008; Lee, Dibble, 
Pickett, & Luce, 2005).  In the overall 1-class model, women reported disturbed sleep 
severity of 1.59 on the first day of cycle 2 and 1.01 on the first day of cycle 3, not 
representing well the women who experience a significant number of days with moderate 
to severe disturbed sleep.  Two patterns of disturbed sleep were described by the LGMM 
model, including a mild improving disturbed sleep class (89% of respondents in cycle 2 
and 81% in cycle 3) and a moderate worsening disturbed sleep class during cycle 2 (11% 
of respondents) and a mild worsening disturbed sleep class during cycle 3 (19% of 
respondents).  The severity of disturbed sleep improved slightly over time in the mild 
improving disturbed sleep class during both cycles, while the severity of disturbed sleep 
began at a moderate level and increased for the moderate worsening disturbed sleep class 
during cycle 2 and began at mild level and increased for the mild worsening disturbed 
sleep class during cycle 3.  This suggests that some women will experience progression 
in the severity of disturbed sleep over the course of the cycle.   
Sixty percent of women reported depressed mood during cycle 2 and 53.2% of 
women reported depressed mood during cycle 3.  During cycle 2, 46.7% of women 
reported anxiety and 39.7% of women reported anxiety during cycle 3.  The prevalence 





Gaston-Johansson et al., 1999; Kim et al., 2008; Liu et al., 2009; So et al., 2009).  During 
cycle 2, 42.2% of women reported moderate to severe levels of depressed mood and 
35.3% of women reported moderate to severe levels of depressed mood during cycle 3.  
During cycle 2, 28.5% of women reported moderate to severe levels of anxiety and 
25.6% of women reported moderate to severe levels of anxiety during cycle 3.  While a 
large number of women who reported moderate to severe levels of depressed mood 
during both cycles, the 1-class model for depressed mood indicated an average baseline 
severity of 0.93 during cycle 2 and 0.53 during cycle 3 that remained stable over time.  
The LGMM recovered two classes of depressed mood, a consistently mild depressed 
mood class during both cycles (91% of respondents in cycle 2 and 94% in cycle 3) and a 
consistently moderate depressed mood class during cycle 2 (9% of respondents) and a 
moderate improving depressed mood class during cycle 3 (6% of respondents).  While 
the consistently mild depressed mood class experienced a severity of less than 1 over 
both cycles, the moderate improving depressed mood class during cycle 2 and the 
moderate improving depressed mood class during cycle 3 experienced a significant 
severity of 4 or higher.  During cycle 3 only, the moderate improving depressed mood 
reported a decrease in the severity of depressed mood as the cycle progressed, but the 
severity remained at moderate levels.  The symptoms of mood disturbance have been 
reported to increase at initiation of chemotherapy, but generally remain stable during 
treatment (Nieboer et al., 2005).  This suggests that women who report higher levels of 
depressed mood at the beginning of the cycle maintain this symptom at moderate to 
severe levels through the end of the cycle.  While the 1-class model for anxiety indicated 





class model that fit the data with a consistently mild anxiety class during both cycles 
(95% of respondents in cycle 2 and 92% in cycle 3) and a consistently moderate anxiety 
class during cycle 2 (5% of respondents) and a low moderate improving to mild anxiety 
class during cycle 3 (8% of respondents).  Similar to depressed mood, the moderate 
classes reported a severity of anxiety of greater than 3 across both cycles, with severity 
levels slightly higher during cycle 2 when compared to cycle 3.  Only the low moderate 
improving to mild anxiety class reported improvement in the severity of anxiety during 
the first 14 days of chemotherapy. 
Recent findings of classes of symptom trajectories are conflicting with the results 
of this study.  Onselen et al. (2012) identified 3 classes of women with sleep disturbance 
during the 6 months following surgery for breast cancer, a low and high class, but also a 
decreasing class that represented 5.3% of their sample (n=398).  The conflicting findings 
may be a result of differing instrumentation and timing of measures, where Onselen et al. 
used a 21-item General Sleep Disturbance Scale measured monthly for 6 months 
following surgery, as opposed to the single-item severity measured daily over 2 cycles.  
Additionally, Onselen et al. constrained their models, setting the slope variances to zero 
to better estimate classes, potentially finding the third, decreasing class not found here.  A 
few recent reports of classes of trajectories of depression and psychological distress in 
women with breast cancer have found 4 or 5 class models as the best fit (Desheilds, 
Tibbs, Fan, & Taylor et al., 2006; Dunn et al., 2011; Helgeson, Snyder, & Seltman, 2004; 
Henselmans et al., 2010; Lam et al., 2010; Wang et al., 2014).   Differences in the number 
of trajectories identified may be due to methodological discrepancies, where, for 





time points following treatment and Dunn et al. (2015) modeled trajectories based on 
CES-D scores prior to and monthly for 6 months after surgery for breast cancer.  The use 
of the CES-D cut-points as opposed to the continuous severity single-item measure and 
the time points measured (every 3 months or monthly) would certainly elicit differing 
patterns of trajectories when compared to daily measures.  Finally, varying analysis 
methods used to identify classes may have also contributed to inconsistencies in findings. 
 The primary limitation of this study is related to sample sizing.  As previously 
discussed, a larger sample size may have elicited different results and potentially 
identified a multisymptom model.  Additionally, the sample was fairly homogenous in 
demographic variables, including marital status and ethnicity.  While data were collected 
from multiple sites across the United States, findings may not generalize to all 
populations of women receiving initial treatment for breast cancer. 
 This study was limited by the use of a single-item measure that may be prone to 
increased measurement error.  Although numerous sources cite good reliability and 
validity with use of single-item measure, some would argue that more than one item is 
needed in symptom studies (Cleeland & Mendoza, 2011; Mooney et al., 2014).  For 
practical purposes, these measures are useful in symptom studies and data were available 
for this secondary analysis using single-item measures (Cleeland & Mendoza, 2011; 
Mooney et al., 2014). 
 Particular care should be given to the nature of the data in our study and the 
usefulness of LGMM in modeling symptom trajectories with daily reporting.  In our 
identified models, and given the use of daily symptom severity reporting, it is likely that 





represent.  Additionally, a large number of days where women reported zero severity on 
symptoms may have decreased the aggregate means for the growth factors and means 
may not well-represent the actual severity of the symptoms.  Caution should be used in 
considering the existence of the classes identified in our models and the interpretation of 
the estimated growth parameters.  
Conclusions 
 Results of this study suggest that women receiving chemotherapy for breast 
cancer experience different, distinct trajectories of the severity of fatigue, disturbed sleep, 
depressed mood, and anxiety, all symptoms that have been previously reported as 
distressing and may have a negative effect on outcome measures such as treatment 
adherence, quality of life, and health during survivorship.  At the person-level, patterns 
emerge where a good number of individuals experience low symptoms, but there are also 
those at risk for moderate to severe levels.  Additionally, regardless of class membership 
and with the exception of the worsening disturbed sleep classes, the severity of symptoms 
remained fairly stable or even improved across the cycle of chemotherapy.  Clinicians 
should seek to identify those at risk for moderate or severe symptom trajectories with the 
awareness that unless there is an intervention, symptoms are likely to continue or 
possibly escalate through the cycle of chemotherapy.  Future research should focus on 
replication of this hypothesis-generating study, on identifying potential correlates of class 
membership and outcomes related to class membership to clarify the identification of 
those individuals who are likely to experience symptoms at a severe level during 





account for a high level of variability in symptom prevalence and severity, using large 
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ANTECEDENTS, CO-OCCURING SYMPTOMS, AND OUTCOMES OF  
DISTINCT TRAJECTORIES OF FATIGUE AND DISTURBED  
SLEEP IN WOMEN WITH BREAST CANCER 






 The purpose of this study was to examine if membership in differing symptom 
subgroups for fatigue and disturbed sleep in women receiving treatment for breast cancer 
is determined by demographic, clinical, or symptom characteristics.   
 A secondary analysis was utilized to examine data collected from 166 women 
undergoing chemotherapy for breast cancer, who self-reported on the severity of 10 
symptoms through daily phone calls to an automated system.  Independent-samples t tests 
and ANOVA tests of mean difference and chi-square tests of associations among 
categories were used to distinguish between subgroups of women previously determined 
to demonstrate distinct trajectories of fatigue and disturbed sleep on antecedents, co-
occurring symptoms, and outcome variables. 
Participants in this study had a mean age of 52.91 years, were mostly Caucasian 
(91.46%), and the largest proportion of the sample was diagnosed with Stage II disease 
(40.36%).  No demographic variables were associated with class membership for either 
fatigue or disturbed sleep.  Chemotherapy regimen predicted fatigue severity class, with 
those women who received a Doxorubicin containing regimen more likely to be in the 
higher severity classes (cycle 2:  = 7.75, p = .02; cycle 3: = 8.59, p = .01).  Higher 
severity fatigue class was associated with increased hours lying down during cycle 2 
(F(2,44) = 2.03,  p = .02).  Membership in higher severity fatigue classes was associated 
with increased disturbed sleep (cycle 2: F(2, 162) = 6.03, p < .001; cycle 3: Welch(2, 36) 
=9.21, p < .001), depressed mood (cycle 2: Welch(2, 40) = 8.77, p < .001; cycle 3: 
Welch(2, 34) =5.31, p = .01), nausea and vomiting (cycle 2: Welch(2, 41) = 5.95, p = .01; 




cycle 3: Welch(2, 35) =3.39, p < .01), and trouble thinking (cycle 3: F(2, 74) = 7.26, p < 
.01*).  Membership in the worsening disturbed sleep class was associated with fatigue 
(cycle 2: t(162) = 11.72, p < .01; cycle 3: t(153) = 4.67, p = .03), depressed mood (cycle 
2: Welch t(27) = 7.37, p = .01), and trouble thinking (cycle 3: t(75) = -2.02, p < .01).  The 
overall symptom severity during cycle 2 predicted fatigue and disturbed sleep class 
membership during cycle 3 (fatigue: F(1,153) = 28.90, p < .001; disturbed sleep: t(153) = 
15.47, p < .001). 
 While demographic variables did not distinguish class membership for fatigue or 
disturbed sleep, further study is needed to determine whether genetic or biological factors 
may.  The co-existence of symptoms during chemotherapy may distinguish trajectory 
classes for fatigue and disturbed sleep.  Symptom severity during an earlier cycle 
predicted class membership for fatigue and disturbed sleep during a subsequent cycle, 
suggesting that clinicians should be aware that women who experience significant 
symptoms during an earlier cycle may be at risk for severe symptoms during later cycles. 
Introduction 
 Individual symptoms and symptoms clusters are dynamic and may change over 
the course of treatment for breast cancer (Langford et al., 2016).   Common and 
debilitating cancer symptoms, including fatigue and disturbed sleep, may be more severe 
and distressing during active chemotherapy treatment (Langford et al., 2016; Payne, 
Piper, Rabinowitz, & Zimmerman, 2006).   
 Fatigue is the most common and a particularly distressing symptom for women 
receiving chemotherapy for breast cancer (Huang, Chen, Liang, & Miaskowski, 2014).  




life.  Importantly, high levels of fatigue may predict shorter recurrence-free and overall 
survival in breast cancer patients (Groenvold et al., 2007).  Additionally, insomnia, poor 
sleep quality, and increased daytime sleepiness are shown to cause severe distress in 
patients with breast cancer and are related to increased fatigue (Beck, et al., 2010; Berger 
& Higginbotham, 2000; Kuo, Chiu, Liao, & Hwang, 2006).  Not only are fatigue and 
sleep disturbance  major contributors to decreased quality of life, ability to function, and 
disease-related interference with employment, but these symptoms may also interrupt 
treatment and influence treatment effectiveness (Bradley, Neumark, Luo, & Schenk, 
2007).   
 Several demographic and clinical characteristics have been associated with 
fatigue and disturbed sleep prevalence and severity in women receiving chemotherapy for 
breast cancer.  While age does not appear to relate to fatigue, Beck et al. (2010) and 
Colagiuri et al. (2011) reported a positive relationship between age and disturbed sleep, 
where older women experienced increased disturbed sleep during chemotherapy 
(Browall, Ahlberg, Persson, Karlsson, & Danielson, 2008; deJong, Candel, Schouten, 
Abu-Saad, & Courtens, 2004; deJong, Kester, Schouten, Abu-Saad, & Courtens, 2006; 
Goldstein et al., 2012; Jacobsen et al., 1999; Von Ah, Kang, & Carpenter, 2008).  While 
deJong et al. (2004) reported that divorced women were more fatigued than women living 
with a partner, Huang et al. (2014) found that married women were more fatigued than 
nonmarried.  Additionally, Jacobsen et al. (1999) found no relationship between marital 
status and fatigue and Colagiuri et al. and Onselen et al. (2012) found no relationship 
between marital status and disturbed sleep.  Employment is not reported to relate to 




and stage of disease are not reported to relate with fatigue or sleep disturbance in women 
receiving chemotherapy for breast cancer (Beck et al., 2010; Colagiuri et al., 2011; 
deJong et al., 2004; Von Ah et al., 2008).  
 Outcome variables such as decreases in functional status are reported to associate 
with fatigue and sleep disturbance (Ancoli-Israel et al., 2006; Beck et al., 2010; Berger & 
Higginbotham, 2000; Colagiuri et al., 2011; Downie, Fan, Houede-tchen, Yi, & Tannock, 
2006; Fortner, Stepanski, Wang, Kasprowicz, & Durrance, 2002; Huang et al., 2014; 
Onselen et al., 2012).  Additionally, fatigue and disturbed sleep during chemotherapy for 
breast cancer have been reported to predict decreases in activity level (Berger, 1998; 
Berger & Farr, 1999; Berger & Higginbotham, 2000; Colagiuri et al., 2011; deJong et al., 
2004; Jacobsen et al., 1999).    
 Fatigue is reported to co-occur with several symptoms, including trouble sleeping 
(Ancoli-Israel et al., 2006; Bender Ergun, Rosenzweigh Cohen, & Sereika, 2005; Berger, 
1998; Berger & Farr, 1999; Berger, Farr, Kuhn, Fischer, & Agrawal, 2007; Berger & 
Higginbotham, 2000; Berger, Wielgus, Hertzog, Fischer, & Farr, 2010; Bower et al., 
2011; Broeckel, Jacobsen, Horton, Balducci, & Lyman, 1998; Goldstein et al., 2012; 
Jacobsen et al., 1999; Kim, Barsevick, Tulman, & McDermott, 2008; Liu et al., 2009; Liu 
et al., 2012; Onselsen et al., 2012), depressed mood (Ancoli-Israel et al., 2006; Bender et 
al., 2005; Bower et al., 2011; Byar, Berger, Bakken, & Cetak, 2006; Dragomir & 
Fodoreanu, 2013; Gaston-Johansson, Fall-Dickson, Bakos, & Kennedy et al., 1999; 
Goldstein et al., 2012; Huang et al., 2014; Jacobsen et al., 1999; Kim et al., 2008; Liu et 
al., 2009; Nieboer et al., 2005; Prigozin, Uziely, & Musgrave, 2010; Von Ah et al., 




Prigozin et al., 2010), pain (Bender et al., 2005; Gaston-Johansson et al., 1999; Jacobsen 
et al., 1999; Kim et al., 2008; Nieboer et al., 2005), nausea (Jacobsen et al., 1999; 
Miaskowski et al., 2014), and trouble thinking (Bender et al., 2005; Jacobsen et al., 1999; 
Kim et al., 2008; Merriman et al., 2015).  Only Prigozin et al. (2010) did not find a 
relationship between fatigue and potential co-occurring symptoms of pain, nausea and 
vomiting, and trouble thinking.  Besides the relation to fatigue described earlier, 
disturbed sleep has been reported to co-occur with depressed mood (Ancoli-Israel et al., 
2006; Bender et al., 2005; Berger et al., 2010; Colagiuri et al., 2011; Kim et al., 2008; Liu 
et al., 2009), anxiety (Bender et al., 2005; Colagiuri et al., 2011), pain (Bender et al., 
2005; Fortner et al., 2002;  Kim et al., 2008), and trouble thinking (Bender et al., 20052; 
Kim et al., 2008).  Again, Prigozin et al. did not find a strong relationship between 
disturbed sleep and several symptoms including depressed mood, anxiety, pain, trouble 
thinking, and nausea and vomiting. 
  Because of the significance of fatigue and disturbed sleep as debilitating 
symptoms for women receiving chemotherapy, a greater understanding of the trajectory 
of the development and progression of these symptoms is needed.  Using data across 
cycle 2 and 3 in women initiating chemotherapy treatment for newly diagnosed breast 
cancer, we previously identified three patterns of fatigue described by a Latent Growth 
Mixture Model (LGMM), including those with mild improving fatigue (59% of women 
in cycle 2 and 64% in cycle 3), low moderate improving to mild fatigue (30% of women 
in cycle 2 and 25% in cycle 2), and high moderate improving fatigue (11% of women in 
both cycles).  Two patterns of disturbed sleep were described by a LGMM model, 




and moderate worsening disturbed sleep during cycle 2 (11% of women) and mild 
worsening disturbed sleep during cycle 3 (19% of women).  The purpose of this analysis 
was to determine if antecedents, co-occurring symptoms, and outcomes are associated 
with class membership.  
Methods 
Participants and Setting 
 This was a secondary analysis of data collected as part of three longitudinal 
studies that used an automated telephone-linked-care system for monitoring symptoms 
during chemotherapy.  Participants in Study 1 were recruited from four ambulatory 
clinics in the southeast and western United States.  Participants in Study 2 and Study 3 
were recruited from two settings in the Midwest and western United States.  In both 
Study 1 and Study 2, participants were assigned to a usual care and a symptom 
management intervention group, but only those in Study 2 were found to have differences 
in reported symptoms between the control and intervention groups.  Study 3 involved no 
intervention and no group assignment.  All data from eligible participants in Study 1 and 
Study 3 and those in the usual care group in Study 2 were included in this secondary 
analysis.  Eligibility requirements for this secondary analysis included being a woman 
diagnosed with breast cancer at initial treatment with chemotherapy, completion of study 
measures through cycles 2 and 3, and reported data for at least 3 days during each cycle.   
 From the three parent studies, 259 women were identified as eligible.  93 women 
were excluded from the secondary analysis because they were either randomized to the 
intervention group in Study 2 or did not complete study measures through cycles 2 and 3.  




during cycle 2 and 155 of women who completed 3 days of measures during cycle 3. 
Measures 
 
All 3 parent studies used similar instrumentation.  Demographic and clinical data 
were collected at baseline and included age, gender, race/ethnicity, employment status, 
education, diagnosis, extent of disease, and chemotherapy protocol, whether the 
participant received a regimen containing Doxorubicin and whether the participant 
received a regimen containing Taxane separately.  The telephone-linked-care automated 
system is further described by Mooney, Beck, Friedman, Farzanfar, and Wong (2014).  
During a daily automated phone call, beginning with the first day of chemotherapy and 
continuing through the cycle, participants were asked “During the past 24 hours did you 
experience (symptoms)?”  Conditional branching was employed so that a no response 
was scored as zero and a yes response prompted the system to ask the participant to rate 
the severity of the symptom on a Likert scale of 1 to 10.  The use of single-item measures 
for studying symptoms is considered to have acceptable reliability and validity (Cleeland 
& Mendoza, 2011; Mooney et al., 2014).  Symptoms assessed included fatigue, disturbed 
sleep, depressed mood, anxiety, pain, nausea/vomiting, sore mouth, and diarrhea across 
all three parent studies.  Two additional symptoms, distress associated with changing 
appearance and trouble thinking, were assessed in Studies 2 and 3.  A subsample, 
consisting of participants enrolled in those 2 parent studies only, was used in analyses 
that included those 2 symptoms.  
 Hours spent lying down was collected daily and employed participants were 
asked whether they were able to go to work each day whether full or part-time employed.  




days of each cycle were used in the analysis, providing a consistent period of treatment 
across participants. 
This secondary analysis was reviewed by the Institutional Review Board (IRB) at 
the University of Utah.  Subjects were identified only by their original study 
identification number.  All participants signed a written, informed consent upon initiation 
of participation in the original studies. 
Statistical Analysis 
 The Software Statistical Package for the Social Sciences (SPSS), version 23.0 was 
used for data management and data analysis.  P values less than .05 were considered 
statistically significant and there was no adjustment for multiple comparisons as this was 
a hypothesis generating study.  
 Descriptive statistics and frequency distributions were generated on the sample 
characteristics.  After determining the best model fit for the data, including classes as 
previously reported, the model-predicted class membership for each individual was 
obtained using posterior probabilities.  While there is uncertainty in the model-predicted 
class assignment, high entropy and high posterior probabilities in the retained models 
suggest that model-predicted class assignments could be considered observed variables.  
Class membership assignment was then used to test for mean differences across the 
classes using independent-samples t tests and ANOVA and tests of associations among 
categories using chi-square on antecedents, co-occurring symptoms, and outcomes 
(deJong et al., 2004).  Small cell sizes were accounted for with use of the more 
conservative Fisher’s exact chi-square.  This technique allowed for tests of associations 




Salkind, 2008; Jung & Wickerama, 2008).  In cases where classes did not display 
homogeneity of variance, the Welch statistic, a robust test that allows violation of this 
assumption, was used (Green & Salkind, 2008).  Where appropriate, follow-up post hoc 
contrasts were conducted to evaluate pairwise differences in class membership on 
antecedents, co-occurring symptoms, and outcomes.  In cases where equal variances were 
not assumed, the Dunnett’s C test was used (Green & Salkind, 2008).  The analysis 
proceeded to answer 4 specific aims. 
 Aim 1 was to determine whether differing symptom trajectory profiles for fatigue 
and disturbed sleep are associated with variations in demographic and clinical 
characteristics.  Using the trajectory classes for fatigue and disturbed sleep, as previously 
described, and treating those as observed group variables in each of 2 cycles of treatment 
(cycle 2 and cycle 3), the association between the classes and age were examined using 
independent-samples t tests and ANOVA and the association between the classes and 
stage of disease, education, employment, marital status, and chemotherapy regimen were 
examined using chi-square.   
 Aim 2 was to determine whether differing symptom trajectory profiles for fatigue 
and disturbed sleep are associated with variations in outcomes, such as average hours 
spent lying down and days of missed work.  Daily measures of hours spent lying down 
during the first 14 days of each cycle separately were averaged for each individual for 
each cycle 2 and 3.  Days of missed work during the first 14 days of each cycle separately 
were summed for all employed participants.  To answer this aim, tests of mean 
differences across the classes were conducted on the outcome using independent-samples 




test of mean differences across the classes for days of missed work.   
 Aim 3 was to determine whether differing symptom trajectory profiles for fatigue 
and disturbed sleep are associated with variations in the severity of other symptoms, such 
as pain, trouble thinking, nausea, depressed mood, and anxiety.  Tests of mean 
differences across classes on the number of moderate to severe days reported for each 
symptom of interest were conducted using independent-samples t tests and ANOVA.  
Summative scores for each symptom included the number of days subjects scored 4 or 
higher on severity of fatigue, disturbed sleep, depressed mood, anxiety, pain, nausea and 
vomiting, and trouble thinking individually within the first 14 days of each cycle.  These 
symptoms were studied because they were both prevalent in the sample and previously 
reported to relate with fatigue and/or disturbed sleep.  These summative scores were then 
compared to class membership for fatigue and disturbed sleep in cycles 2 and 3 using 
independent-samples t tests and ANOVA.   
 Aim 4 was to determine whether differing symptom trajectory profiles for fatigue 
and disturbed sleep during cycle 3 were associated with variations in the overall symptom 
severity during cycle 2.  Overall symptom severity for cycle 2 included the number of 
days where subjects scored 4 or higher on severity of fatigue, disturbed sleep, depressed 
mood, anxiety, pain, and nausea and vomiting.  These symptoms were studied because 
they were both prevalent in the sample, with data from all participants, and previously 
reported to relate with fatigue and/or disturbed sleep.  The number of days with moderate 
to severe symptoms during cycle 2 was then compared to the extracted class membership 







The sample consisted of 166 women with breast cancer.  Demographic and 
clinical characteristics of the sample are summarized in Table 3.1.  Women ranged in age 
between 24 and 80 years (mean age 52.91, SD = 10.8).  The majority of women were 
white (91.46%), married (75%), and not currently working (62.8%).  The largest 
proportion of women were diagnosed with Stage II disease (40.36%) and 75.3% of 
women in the sample had some education beyond high school. 
The prevalence of individual symptoms in the sample during the first 14 days of 
each cycle and the prevalence of moderate/severe levels of symptoms during the first 14 
days of each cycle are reported in Table 3.2.  The most prevalent symptom was fatigue, 
followed by disturbed sleep, pain, nausea and vomiting, depressed mood, and anxiety.  
Diarrhea, trouble thinking, sore mouth, and distress associated with change in appearance 
were not highly prevalent or highly prevalent at moderate to severe levels.   
Aim 1 
 Results of the tests of mean differences and associations among categories across 
classes on the demographic variables are presented in Tables 3.3 for the fatigue classes 
and 3.4 for the disturbed sleep classes.  All test results were nonsignificant, with the 
exception of chemotherapy regimen.  Women who received Doxorubicin as part of their 
chemotherapy regimen were more likely to be in the high moderate improving fatigue 
class when compared to the mild improving fatigue class in both cycles 2 and 3.  
Aim 2 
 For fatigue and disturbed sleep, the independent-samples t tests and ANOVAs for 




Table 3.1 Sample Demographic and Clinical Characteristics (n =166) 
Characteristic Mean SD 
Age (in years) 52.90 10.8 
Characteristic n % 
Ethnicity 
   Non-Hispanic 
   Hispanic 










   Partnered 
   Nonpartnered 










   Full-time 
   Part-time 
   Not Employed 












   High school          
   Some College  
   Associate Degree 
   Bachelor Degree 
   Postgraduate  
















   Less than  $9,999 
   $10,000-29,999 
   $30,000-49,000 
   $50,000-69,000 
   $70,000 or More      
   Unknown 

















Stage of Disease 
   Stage I 
   Stage II 
   Stage III 
   Stage IV 













Chemotherapy Regimen   
   Cyclophosphamide with Doxorubicin 68 41.0% 
   Docetaxel 23 13.9% 
   Cyclophosphamide with Methotrexate and 5-FU 16 9.6% 
   Docetaxel with Carboplatin 13 7.8% 
   Cyclophosphamide with Docetaxel 12 7.2% 
   Cyclophosphamide with Doxorubicin and 
Docetaxel 9 5.4% 
   Cyclophosphamide with Doxorubicin and 5-FU 6 3.6% 
   Cyclophosphamide with 5-FU 4 2.4% 





Table 3.2 Symptom Prevalence and Mean Number of Days at Moderate to Severe Levels 
Symptom Cycle 






than 0 at 
Least Once 
Mean no. Days 











than 3 at 
Least Once 
Mean no. Days 



















Fatigue a 2 153 (92.7%) 7.53 (3.69), 1-14 115 (69.7%) 5.09 (3.47), 1-14 659 (36.4%) 1,152 (63.6%) 585 (32.3%) 3 148 (94.9%) 7.09 (3.93), 1-14 105 (67.3%) 4.95 (3.70), 1-14 654 (38.4%) 1,050 (61.6%) 520 (30.5%) 
Disturbed 
Sleep a 
2 126 (76.4%) 3.63 (2.56), 1-13 103 (62.4%) 2.87 (2.07), 1-13 1,354 (74.8%) 457 (25.2%) 296 (16.3%) 
3 110 (70.5%) 3.40 (2.64), 1-13 85 (54.5%) 2.46 (1.76), 1-11 1,330 (78.1%) 374 (21.9%) 209 (12.3%) 
Pain a 2 124 (75.2%) 4.55 (3.20), 1-14 75 (45.5%) 3.51 (2.95), 1-13 1,247 (68.9%) 564 (31.1%) 263 (14.5%) 3 104 (66.7%) 5.16 (3.74), 1-14 66 (42.3%) 4.15 (3.33), 1-14 1,167 (68.5%) 537 (31.5%) 274 (16.1%) 
Nausea and 
Vomiting a 
2 116 (70.3%) 3.90 (2.92), 1-13 78 (47.3%) 2.66 (2.28), 1-11 1,359 (75.0%) 542 (29.9%) 208 (11.5%) 
3 111 (71.2%) 4.05 (3.31), 1-14 63 (40.4%) 3.14 (2.63), 1-12 1,254 (73.6%) 450 (26.4%) 198 (11.6%) 
Diarrhea a 2 69 (41.8%) 2.13 (1.53), 1-8 30 (18.2%) 1.83 (0.87), 1-4 1,664 (91.9%) 147 (8.1%) 55 (3.0%) 3 49 (31.4%) 2.63 (1.82), 1-10 23 (14.7%) 2.17 (1.53), 1-6 1,575 (92.4%) 129 (7.6%) 49 (2.9%) 
Sore Mouth a 2 68 (41.2%) 3.62 (2.34), 1-11 38 (23.0%) 3.11 (2.29), 1-10 1,565 (86.4%) 246 (13.6%) 118 (6.5%) 3 68 (43.6%) 3.32 (2.61), 1-13 38 (24.4%) 2.66 (2.72), 1-13 1,478 (86.7%) 216 (12.7%) 91 (5.3%) 
Trouble 
Thinking b 
2 46 (27.9%) 2.67 (1.97), 1-11 28 (17.0%) 2.50 (2.19), 1-10 884 (93.2%) 64 (6.8%) 37 (3.9%) 
3 31 (19.9%) 3.26 (2.11), 1-9 21 (13.5%) 1.95 (1.07), 1-5 776 (94.1%) 46 (5.6%) 20 (2.4%) 
Appearance b 2 38 (23.0%) 3.32 (2.57), 1-12 25 (15.2%) 3.16 (2.37), 1-9 882 (93.0%) 66 (7.0%) 42 (4.4%) 3 15 (9.6%) 3.27 (3.97), 1-13 10 (6.4%) 3.50 (4.50), 1-12 801 (97.1%) 24 (2.9%) 17 (2.1%) 
Mood Disturbance Symptoms 
Depressed 
Mood a 
2 99 (60.0%) 3.60 (3.21), 1-13 70 (42.4%) 3.23 (2.84), 1-12 1,455 (80.3%) 356 (19.7%) 226 (12.5%) 
3 83 (53.2%) 3.47 (3.11), 1-14 55 (35.3%) 2.87 (2.86), 1-13 1,416 (83.1%) 288 (16.9%) 158 (9.3%) 
Anxiety a 2 77 (46.7%) 3.34 (3.17), 1-13 47 (28.5%) 2.91 (2.83), 1-11 1,544 (85.3%) 267 (14.7%) 147 (8.2%) 3 62 (39.7%) 3.56 (3.62), 1-13 40 (25.6%) 2.65 (2.56), 1-9 1,483 (87.0%) 221 (13.0%) 106 (6.2%) 
a n=165, cycle 2; n=156, cycle 3; 1811(78.4%) days reported cycle 2, 1704(78.0%) days reported cycle 3; 499(21.6%) days missing cycle 2, 480(22.0%) days missing cycle 3 




 Table 3.3 Tests of Mean Differences and Associations Among Categories for 
Antecedents and Outcomes of Fatigue Class Membership 
 




















p = .10 
Education     
 = 2.16, 
p = .99 
 Less than high 
school 
4 (4.3%) 1 (2.0%) 1 (5.3%) 
 High school 20 (21.5%) 8 (16.3%) 3 (15.8%) 
 Undergraduate 57 (61.3%) 33 (67.3%) 13 (68.4%) 
 Postgraduate 12 (12.9%) 7 (14.3%) 2 (10.5%) 
Marital Status      = 1.54, 
p = .85  Married 72 (75.8%) 37 (75.5%) 13 (68.4%)  Not Married 23 (24.2%) 12 (24.5%) 6 (31.6%) 
Employment      = 2.91, 
p = .58  Employed 32 (33.7%) 22 (44.9%) 6 (31.6%)  Not Employed 63 (66.3%) 27 (55.1%) 13 (68.4%) 
Stage     
 = 4.60, 
p = .80 
 I 13 (14.1%) 5 (10.0%) 2 (30.5%) 
 II 34 (37.0%) 25 (50.0%) 8 (42.1%) 
 III 24 (26.1%) 10 (20.0%) 4 (63.2%) 
 IV 21 (22.8%) 10 (20.0%) 5 (26.3%) 
Doxorubicin      = 7.75, 
p = .02*  Yes 41 (46.6%) 27 (57.4%) 14 (82.4%)  No 47 (53.4%) 20 (52.6%) 3 (17.6%) 
Taxane      = 3.01, 
p = .22  Yes 34 (38.6%) 14 (29.2%) 3 (17.6%)  No 54 (61.4%) 33 (70.2%) 14 (82.4%) 
Hours Spent 
Lying Down 




p = .02* 
Days Missed 
Work (n=20) 
 1.9 (1.52) 3.13 (2.03) 2.5 (2.12) F(2, 17) 
= 1.05, 






Table 3.3 continued 
 


















p = .88 
Education     
= 3.47, 
p = .75 
 Less than high 
school 
3 (3.2%) 1 (2.6%) 1 (5.6%) 
 High school 20 (21.5%) 5 (5.1%) 5 (27.8%) 
 Undergraduate 58 (62.4%) 26 (66.7%) 10 (55.6%) 
 Postgraduate 12 (12.9%) 7 (17.9%) 2 (11.1%) 
Marital Status     = 0.78, 
p = .74  Married 69 (72.6%) 29 (74.4%) 15 (83.3%)  Not Married 26 (27.4%) 10 (25.6%) 3 (16.7%) 
Employment      = 0.06, 
p = 1.00  Employed 36 (37.9%) 15 (41.0%) 7 (38.9%)  Not Employed 59 (62.1%) 24 (59.0%) 11 (61.1%) 
Stage     
= 7.69, 
p = .25 
 I 11 (11.3%) 6 (15.8%) 0 (0.0%) 
 II 37 (38.1%) 20 (52.6%) 9 (47.4%) 
 III 27 (27.8%) 5 (13.2%) 6 (33.3%) 
 IV 22 (22.7%) 7 (18.4%) 3 (16.7%) 
Doxorubicin     = 8.59, 
p = .01*  Yes 45 (46.9%) 22 (57.9%) 15 (83.3%)  No 51 (53.1%) 16 (42.1%) 3 (16.7%) 
Taxane     = 6.06, 
p = .05  Yes 38 (39.6%) 11(28.9%) 2 (11.1%)  No 58 (60.4%) 27 (71.1%) 16 (88.9%) 
Hours Spent 
Lying Down 




p = .70 
Days Missed 
Work (n=27) 
 1.33(1.50) 1.43(1.72) 2.20(1.65) F(2, 24) 
= 0.51, 






Table 3.4 Tests of Mean Differences and Associations Among Categories for 
Antecedents and Outcomes of Disturbed Sleep Class Membership 
 
Cycle 2 










p = .66 
Education    
= 1.08, 
p = .94 
 Less than high school 6 (4.4%) 0 (0.0%) 
 High school 26 (19.3%) 4 (16.0%) 
 Undergraduate 85 (63.0%) 18 (72.0%) 
 Postgraduate 18 (13.3%) 3 (12.0%) 
Marital Status    = 1.01, 
p = .61  Married 104 (75.9%) 17 (68.0%)  Not Married 33 (24.1%) 8 (32.0%) 
Employment    = 0.87, 
p = .64  Employed 48 (35.3%) 11 (44.0%)  Not Employed 88 (64.7%) 14 (56.0%) 
Stage    
= 3.80, 
p = .40 
 I 14 (10.4%) 6 (24.0%) 
 II 57 (42.2%) 10 (40.0%) 
 III 33 (24.4%) 4 (16.0%) 
 IV 31 (23.0%) 5 (20.0%) 
Doxorubicin     = 0.22, 
p = .66  Yes 68 (53.1%) 14 (58.3%)  No 60 (46.9%) 10 (41.7%) 
Taxane     = 0.25, 
p = .65  Yes 44 (34.4%) 7 (29.2%)  No 84 (65.6%) 17 (70.8%) 
Hours Spent 
Lying Down 
 10.66 (2.59) 9.87 (3.88) t( 28.1) = 
0.98, 
p = .33 
Days Missed 
Work (n=20) 
 2.44 (1.93) 2.50 (1.29) t(18) = 0.00, 






Table 3.4 continued 
 
Cycle 3 










p = .97 
Education    
 = 2.31, 
p = .62 
 Less than high school 5 (11.1%) 1 (5.9%) 
 High school 26 (57.8%) 2 (11.8%) 
 Undergraduate 12 (26.7%) 12 (70.6%) 
 Postgraduate 2 (4.4%) 2 (11.8%) 
Marital Status     = 2.25, 
p = .41  Married 103 (76.3%) 11 (61.1%)  Not Married 32 (23.7%) 7 (38.9%) 
Employment     = 0.29, 
p = 1.00  Employed 53 (39.3%) 7 (38.9%)  Not Employed 82 (60.7%) 11 (61.1%) 
Stage    
 = 1.83, 
p = .77 
 I 17 (12.7%) 2 (11.1%) 
 II 58 (43.3%) 7 (38.9%) 
 III 32 (23.9%) 3 (16.7%) 
 IV 27 (20.1%) 6 (33.3%) 
Doxorubicin    = 0.18, 
p = .67  Yes 72 (53.3%) 10 (58.8%)  No 63 (46.7%) 7 (41.2%) 
Taxane     = 0.50, 
p = .59  Yes 44 (32.6%) 7 (41.2%)  No 91 (67.4%) 10 (58.8%) 
Hours Spent 
Lying Down 
 10.69 (2.74) 9.65 (3.23) t(150) = 
1.48, 
p = .14 
Days Missed 
Work (n=27) 
 1.50(1.71) 1.60(1.52) t(25) = 0.01, 






exception of hours spent lying down during cycle 2 (see Tables 3.3 and 3.4).  During 
cycle 2, the number of hours spent lying down was statistically significantly higher in the 
high moderate improving fatigue class when compared to the mild improving fatigue 
class (p = .02).  Although not statistically significant in the ANOVA, examination of days 
missed work within each class for fatigue across both cycles suggests an upward trend in 
class mean, as days missed work increased with fatigue class severity. 
Aim 3 
 
Class membership for fatigue and disturbed sleep was compared with the number 
of moderate to severe days of individual symptoms using independent-samples t tests and 
ANOVA and results are presented in Tables 3.5 and 3.6.  Women in the high moderate 
improving fatigue class reported a greater number of days with moderate to severe 
disturbed sleep (p < .01* in cycle 2 and p < .01* in cycle 3) and nausea and vomiting (p < 
.01* in cycle 2 and p < .01*in cycle 3) during both cycles and anxiety (p = .03*) and 
depressed mood (p < .01*) during only cycle 2 when compared to women in the mild 
improving fatigue class.  Women in the high moderate improving fatigue class also 
reported a statistically significantly greater number of days with moderate to severe 
depressed mood (p = .001*, p = .010*) during both cycles when compared to women in 
the low moderate improving to mild fatigue class.  Additionally, women in the low 
moderate improving to mild fatigue latent trajectory class reported a statistically 
significantly greater number of days with moderate to severe disturbed sleep (p < .01*, p 
< .01*) when compared to women in the mild improving fatigue class during both cycles.  
Women in the low moderate improving to mild fatigue class also reported a greater 




Table 3.5 95% Confidence Intervals of Pairwise Differences Among the Mean Number 
of Days with Moderate to Severe Symptoms for Fatigue Class Membership 
 






p omnibus test 
Cycle 2 
Anxiety 
Welch(2, 40) = 
3.79, 
p = .03* 
Mild Improving .49 1.13    
Low Moderate .64 1.52 -.74 to .44   
High Moderate 3.10 4.14 .18 to 5.05** -.01 to 4.94  
Depressed Mood 
Welch(2, 40) = 
8.77, 
p < .001* 
Mild Improving .74 1.66    
Low Moderate 1.54 2.38 -.11 to 1.71   
High Moderate 4.11 3.77 1.12 to 5.61** .21 to 4.92**  
Disturbed Sleep F(2, 162) = 6.03, 
p < .001* 
Mild Improving 1.34 1.83    
Low Moderate 2.24 2.33 -1.76 to -.04**   
High Moderate 2.89 2.58 -2.79 to -.31** -1.98 to .67  
Pain 
Welch(2, 61) = 
4.64, 
p = .02* 
Mild Improving 1.34 2.62    
Low Moderate 2.38 2.87 -.13 to 2.21   
High Moderate 0.79 1.55 -1.66 to .55 .26 to 2.93**  
Nausea and Vomiting 
Welch(2, 41) = 
5.95, 
p = .01* 
Mild Improving 0.83 1.47    
Low Moderate 1.42 2.32 -1.46 to .28   
High Moderate 3.00 2.87 .45 to 3.88** -.28 to 3.44  
Trouble Thinking F(2, 80) = .37, 
p = .69 
Mild Improving 0.89 1.80    
Low Moderate 0.82 1.63    










Table 3.5 continued 
 






p omnibus test 
Cycle 3 
Anxiety  Welch(2, 35) =3.39,  p < .01* 
Mild Improving 0.38 1.18    
Low Moderate 0.92 2.09 -.32 to 1.41   
High Moderate 1.38 2.73 -.22 to 3.13** -.93 to 2.75  
Depressed Mood Welch(2, 34) =5.31, 
p = .01* 
Mild Improving 0.58 1.35    
Low Moderate 1.28 2.87 -.46 to 1.87**   
High Moderate 1.02 3.11 -3.74 to .64 .34 to 4.16  
Disturbed Sleep Welch(2, 36) =9.21, 
p < .001* 
Mild Improving 0.85 1.26    
Low Moderate 1.92 1.77 .32 to 1.83**   
High Moderate 2.83 2.92 .20 to 3.77** -.98 to 2.80  
Pain Welch(2, 36) =2.73, 
p = .08 
Mild Improving 1.29 2.26    
Low Moderate 2.33 3.22    
High Moderate 3.17 4.94    
Nausea and Vomiting Welch(2, 35) = 6.66, 
p < .01* 
Mild Improving 0.73 1.38    
Low Moderate 1.49 2.36 -.23 to 1.73   
High Moderate 3.78 3.90 .66 to 5.43** -.24 to 4.82  
Trouble Thinking F(2, 74) = 7.26, 
p < .01* 
Mild Improving 0.35 0.92    
Low Moderate 1.50 1.24 -2.16 to -.14*   
High Moderate 0.53 1.03 -.96 to .86 -2.39 to .19  
Total Cycle 2 Days Moderate or Severe Symptoms F(1,153) = 28.90, 
p < .001* 
Mild Improving 7.43 8.40    
Low Moderate 14.00 8.01 2.78 to 10.37*   





*p<.05 for omnibus test 
** The difference in means is significant at the .05 significance using Dunnett’s C 




Table 3.6 Tests of Mean Differences for Co-occurring Symptoms With Disturbed Sleep 
Class Membership 
 
Disturbed Sleep Class Mean Days SD p omnibus test 
Cycle 2 
Fatigue t(162) = 11.72, p < .01* 
Mild Improving 3.16 3.52  
Moderate Worsening 5.84 4.08  
Depressed Mood Welch t(27) = 7.37, p = .01* 
Mild Improving 1.07 2.01  
Moderate Worsening 3.12 3.69  
Anxiety t(162) = 2.66, p = .11 
Mild Improving 0.73 1.86  
Moderate Worsening 1.44 2.65  
Pain t(162) = 0.10, p = .75 
Mild Improving 1.58 2.55  
Moderate Worsening 1.76 3.23  
Nausea and Vomiting t(162) = 0.96, p = .33 
Mild Improving 1.20 1.93  
Moderate Worsening 1.64 2.71  
Trouble Thinking t(80) = 0.07, p = .79 
Mild Improving 0.84 1.79  
Moderate Worsening 1.00 1.32  
Cycle 3
Fatigue t(153) = 4.67, p = .03* 
Mild Improving 3.12 3.66  
Mild Worsening 5.17 4.67  
Depressed Mood Welch t(18.3) = 3.97, p = .06 
Mild Improving 0.82 1.88  
Mild Worsening 2.50 3.50  
Anxiety Welch t(18.5) = 2.68, p = .12 
Mild Improving 0.56 1.55  
Mild Worsening 1.61 2.66  
Pain t(152) = .47, p = .49 
Mild Improving 1.71 2.99  
Mild Worsening 2.22 2.98  
Nausea and Vomiting t(153) = 1.76, p = .19 
Mild Improving 1.19 2.22  
Mild Worsening 1.94 2.65  
Trouble Thinking t(75) = -2.02, p < .01* 
Mild Improving 0.46 1.00  
Mild Worsening 1.33 1.21  
Total Cycle 2 Days Moderate or Severe Symptoms t(153) = 15.47, p < .001* 
Mild Improving 9.80 9.44  





high moderate improving fatigue class.  Finally, women in the low moderate improving 
to mild fatigue class reported a greater number of days with moderate to severe trouble 
thinking (p < .01*) during cycle 3 only when compared to women in the mild improving 
fatigue class.   
Compared to their counterparts with mild improving disturbed sleep, the moderate 
worsening disturbed sleep trajectory class experienced statistically significantly more 
days with moderate to severe fatigue (p < .01*) and depressed mood (p = .01*) in cycle 2 
and the mild worsening disturbed sleep trajectory class experienced statistically 
significantly more days with moderate to severe fatigue (p = .03*) and trouble thinking (p 
< .01*) during cycle 3.  There was no association between membership in the worsening 
disturbed sleep trajectory class and nausea and vomiting, pain, or anxiety during either 
cycle.   
Aim 4 
 For both fatigue (F(1,153) = 28.90, p<.001*) and disturbed sleep (F(1, 153) = 
15.47, p<.001*), the overall symptom severity in cycle 2, the total number of days where 
subjects scored 4 or higher on severity of fatigue, disturbed sleep, depressed mood, 
anxiety, pain, and nausea and vomiting, was associated with class membership in cycle 3 
(see Tables 3.5 and 3.6).  For fatigue, means for the mild improving fatigue class (7.43, 
SD = 8.40), low moderate improving to mild fatigue class (14.00, SD = 8.01), and high 
moderate improving fatigue class (22.89, SD = 9.75) suggest that those in the low 
moderate improving to mild and high moderate improving classes for fatigue in cycle 3 
had statistically higher overall symptom severity in cycle 2 when compared to the mild 




fatigue in cycle 3 had statistically higher overall symptom severity in cycle 2 when 
compared to the low moderate improving to mild class. Means for the mild improving 
disturbed sleep class (9.80, SD = 9.44) and mild worsening disturbed sleep class (19.11, 
SD = 9.53) suggest that those in the mild worsening class during cycle 3 reported 
statistically higher overall symptom severity in cycle 2 when compared to the mild 
improving class. 
Discussion 
Identifying longitudinal patterns of symptoms is important because it can 
elucidate factors that contribute to distinct symptom trajectories. Various demographic 
and clinical characteristics were examined as possibly distinguishers of fatigue and 
disturbed sleep class membership.  None of the demographic or clinical characteristics 
were found to be associated with fatigue or disturbed sleep class membership, with the 
exception of chemotherapy regimen.  Our findings are consistent with several reports that 
age and fatigue are not related (Browall et al., 2008; deJong et al., 2004; deJong et al., 
2006; Goldstein et al., 2012; Jacobsen et al., 1999; Von Ah et al., 2008).  Although Beck 
et al. (2010) and Colagiuri et al. (2011) found a relationship between age and disturbed 
sleep, this relationship was not found in our sample, similar to findings reported by 
Browall et al. (2008) and Onselen et al. (2012).  Reports of the relationship between 
marital status and fatigue are inconsistent, where deJong et al. (2004) reported that 
divorced women were more fatigued than women living with a partner, and Huang et al. 
(2013) found that married women were more fatigued than nonmarried.  In our sample, 
there was no relationship between marital status and fatigue, similar to findings reported 
by Jacobsen et al. (1999).  The lack of relationship between marital status and disturbed 




that employment status does not predict fatigue is supported in the literature, Onselen et 
al. found an association between unemployment and disturbed sleep that we did not find 
in our sample (deJong et al., 2004; deJong et al., 2006; Huang et al., 2014).  The lack of 
association between stage of disease and either fatigue or disturbed sleep has been 
previously reported (Beck et al., 2010; Colagiuri et al., 2011; deJong et al., 2004; 
Jacobsen et al., 1999; Onselen et al., 2012; Von Ah et al., 2008).  Inconsistencies between 
our findings of the relationship between demographic and clinical characteristics and 
fatigue and disturbed sleep class membership may be related to a lack of sample variation 
on these demographics and a relatively small sample size in the present study.  Further 
research is needed to explore other personal characteristics that might be associated with 
distinct classes for fatigue and disturbed sleep, including molecular and genetic 
determinants (Cleeland et al., 2003; Miaskowski et al., 2014). 
 Women in this sample who received Doxorubicin as part of their chemotherapy 
regimen were more likely to be in the high moderate improving fatigue class when 
compared to the mild improving fatigue class.  The effects of chemotherapy type on 
fatigue severity have been reported with inconsistent findings.  Berger (1998) and Berger 
and Farr (1999) found that levels of fatigue 48 hours after each of the first 3 
chemotherapy treatments were not significantly different when comparing cohorts of 
women who received CMF, Doxorubicin with Cyclophosphamide, and CAF.  deJong et 
al. (2006) reported significant differences in the course of fatigue between those 
receiving CMF and those receiving Doxorubicin, with fatigue peaking at a later time for 
those receiving Cyclophosphamide.  In the present study, while Doxorubicin did have a 




dependent or related to other agents received in combination with Doxorubicin.  Across 
the sample, more than 12 different chemotherapy combinations were reported, making it 
difficult to adequately address the question of how chemotherapy affected class 
membership.  Regardless, with the effect of Doxorubicin on fatigue class found here, 
further study is needed to determine whether the use of Doxorubicin alone or in 
combination with other specific agents places women at risk for higher fatigue.   
 While days of missed work was not significantly associated with class 
membership, examination of the mean days of missed work for the three classes of 
fatigue severity suggests an upward trend in the number of days missed as fatigue 
severity increases (see Table 3.2).  Unfortunately, because only 37.2% of the sample was 
employed, there were only 20 participants for cycle 2 and 27 participants for cycle 3 with 
data available for days of missed work.  A larger cohort of employed participants may 
have revealed a significant relationship between fatigue severity class and days of missed 
work. 
 Increased hours spent lying down was associated with membership in the high 
moderate improving fatigue class (mean hours = 12.36, SD = 3.77) when compared to the 
mild improving fatigue class (mean hours = 10.00, SD = 2.54) during cycle 2 only.  This 
is consistent with other studies which have found that higher fatigue is associated with 
lower activity levels (Berger & Farr, 1999; Berger & Higginbotham, 2000; deJong et al., 
2004; Downie et al., 2006).  However, the upward trend and statistical association of 
hours spent lying down and fatigue severity class was not seen during cycle 3.  Further 
examination with larger samples may better highlight this association. 




presence of other symptoms at moderate to severe levels.  In both cycles, the number of 
days of moderate to severe levels of disturbed sleep was increased for those in the low 
moderate improving to mild and high moderate improving classes for fatigue when 
compared to those in the mild improving class for fatigue.  Several studies have reported 
a positive relationship between fatigue and sleep disturbance (Berger & Farr, 1999; 
Berger & Higginbotham, 2000; Bower et al., 2011; Broeckel et al., 1998; Jacobsen et al., 
1999; Liu et al., 2009; Onselen et al., 2012).  Liu et al. (2012) found that fatigue 
significantly related to sleep problems, but also that women with poor sleep during 
chemotherapy were already experiencing disturbed sleep at baseline and that sleep 
disturbance did not increase during chemotherapy while fatigue did.  This is consistent 
with findings in this sample, where women in both the low moderate improving to mild 
and high moderate improving fatigue classes experienced a similar number of days with 
moderate to severe disturbed sleep that was statistically different from the mild 
improving fatigue severity class.  The significant relationship between fatigue and sleep 
disturbance suggests a synergistic effect that warrants further study. 
 Fatigue class membership was also significantly related to the number of days 
with moderate to severe depressed mood in both cycles, with women in the high 
moderate improving fatigue class experiencing the most days of moderate to severe 
depressed mood.  The mean days of moderate to severe depressed mood was particularly 
high during cycle 2 in the high moderate improving fatigue class (mean = 4.11 days, SD 
= 3.77) when compared to both the mild improving fatigue class (mean = .74 days, SD = 
1.66) and the low moderate improving to mild fatigue class (mean = 1.54 days, SD = 




moderate improving fatigue class (mean = 1.02 days, SD = 3.11) was significantly 
decreased when compared to the low moderate improving to mild fatigue class (mean = 
1.28 days, SD = 2.87) in cycle 3, although with a smaller mean difference.  It is unknown 
whether individuals with increased depressed mood during cycle 2 sought and were 
provided treatment that may have alleviated the number of days they experienced 
moderate to severe days of depressed mood during cycle 3.  Several studies have reported 
on a significant relationship between fatigue and depression during chemotherapy and the 
possible existence of a symptom cluster including both fatigue and depression with other 
symptoms, such as disturbed sleep and pain (Ancoli-Israel et al., 2006; Bender et al., 
2005; Bower et al., 2011; Byar et al., 2006; Dragomir & Fodoreanu, 2013; Gaston-
Johansson et al., 1999; Goldstein et al., 2012; Huang et al., 2014; Jacobsen et al., 1999; 
Kim et al., 2008; Liu et al., 2009; Nieboer et al., 2005; Prigozin et al., 2010; Von Ah et 
al., 2008).   
 There was also a positive relationship between the number of days with moderate 
to severe depressed mood and moderate worsening disturbed sleep class membership 
during cycle 2, suggesting women experienced both depressive symptom and sleep 
symptoms concurrently.  Others have found depressive symptoms predict or are 
positively related to difficulty with sleeping (Ancoli-Israel, 2006; Bender et al., 2005; 
Berger et al., 2010; Colagiuri et al., 2011; Kim et al., 2008; Liu et al., 2009).  Colagiuri et 
al. (2011) suggest that there may be a reciprocal relationship between sleep difficulty and 
depressive symptoms, where sleep difficulty may results from increased depressive 
symptoms and/or sleep difficulty may lead to increasing depressive symptoms.  Not 




along with fatigue and pain, in women undergoing treatment for breast cancer (Dodd, 
Cho Cooper, & Miaskowski, 2010; Liu et al., 2009). 
 In both cycles, the number of days with moderate to severe nausea and vomiting 
was increased in the high moderate improving fatigue class when compared to the mild 
improving fatigue class.  While those in the mild improving fatigue class experienced less 
than one day with moderate to severe nausea and vomiting, those in the high moderate 
improving fatigue class experienced 3 to 4 days of nausea and vomiting at moderate to 
severe levels.  There are several reports of a positive association between fatigue and 
chemotherapy-induced nausea and vomiting during treatment for cancer, even with use of 
appropriate antiemetic therapies (Jacobsen et al., 1999; Miaskowski et al., 2014; Osoba et 
al., 1997; Poon et al., 2013).  Poon et al. (2013) found that individuals who suffer from 
fatigue are 1.57 times less likely to have good control over chemotherapy-induced nausea 
and vomiting. While the biological mechanism that supports this relationship is not well-
understood, it is possible that cytokine induction and dysregulation of neurotransmitters 
may contribute to the development of both symptoms simultaneously (Poon et al., 2013).  
Regardless of the etiology, individuals who suffer from higher levels of nausea and 
vomiting during chemotherapy may be at risk for increased fatigue severity.   
 During cycle 2, the number of days with moderate to severe levels of anxiety 
were increased for those in the high moderate improving fatigue class (mean = 3.11 days, 
SD = 4.14) when compared to those in the mild improving fatigue class (mean = .49 days, 
SD = 1.13).  This relationship was not found during cycle 3, where the number of days 
with moderate to severe levels of anxiety had decreased to an average of 1.38 (SD = 2.28) 




to co-occur in women with breast cancer (Bender et al., 2005; Byar et al., 2006; 
Dragomir & Fodoreanu, 2013; Prigozin et al., 2010).  It is unknown whether individuals 
who were experiencing anxiety in cycle 2 sought and received treatment and thus 
manifested reduced anxiety during subsequent cycles or if anxiety declines as treatment 
progresses and the associated stress and uncertainty diminish as the nervousness 
surrounding unknown expectations decreases.  Previous reports suggest that anxiety is 
persistent during treatment with chemotherapy in women with breast cancer, but may be 
highest before the first chemotherapy infusion (Bistrup et al., 2015; Lim, Devi, & Ang, 
2011).  Future research may investigate whether anxiety diminishes, even slightly, over 
time through each cycle of chemotherapy or whether the difference in anxiety between 
cycles 2 and 3 was unique to our sample.    
 We were surprised to observe that pain was statistically significantly more severe 
for those in the low moderate improving to mild fatigue class, as compared to those in the 
high moderate improving or mild improving fatigue classes.  It is unknown why this was 
found in our sample, although pain and fatigue are reported to co-occur in women with 
breast cancer (Bender et al., 2005; Gaston-Johansson et al., 1999; Jacobsen et al., 1999; 
Kim et al., 2005; Nieboer et al., 2005). 
 Trouble thinking was significantly related to fatigue and disturbed sleep class 
during cycle 3 only. This is consistent with others’ findings that cognitive function is 
related to fatigue and disturbed sleep during treatment with chemotherapy.  The lack of 
association among these symptoms during cycle 2 may relate to the smaller, subsample of 
data used in this analysis, as not all women in our sample reported on severity of trouble 




2015).   
Increases in overall symptom severity during cycle 2 predicted a higher severity 
class for fatigue and disturbed sleep during cycle 3.  Several studies have reported on the 
consistency of individual symptoms and symptom clusters over multiple cycles of 
chemotherapy (Jacobsen et al., 1999; Liu et al., 2009; Payne et al., 2006; Savard et al., 
2009; Tchen et al., 2003).  The findings of this study indicate that women who experience 
significant symptom severity during cycle 2 may be at risk for increased severity of 
fatigue and disturbed sleep during cycle 3.  
 There were some limitations to this study.  Because this was a secondary analysis 
of existing data, a number of variables were not fully explored, including co-morbidities 
or significant medical history, symptom management strategies, and fatigue-associated 
factors, such as nutritional status, cachexia, and daily activity or exercise.  Additionally, 
reports of disturbed sleep were based on subjective report, without objective measures for 
study.  Finally, the sample was fairly homogenous in demographic variables, including 
marital status and ethnicity.  Findings may not generalize to other populations of women 
receiving initial chemotherapy treatment for breast cancer. 
 Caution should be used in interpreting our results with regards to the model 
identified class and extracted predicted class memberships.  Given the use of daily 
symptom severity reporting to define our symptom trajectory classes, it is likely there is 
more variability around the parameter means than what is described in the models.  
Predicted class memberships are based on probabilities, and while treated as observed 
variables in the reported analyses, are truly unobserved variables.   




including the risk for increased measurement error when compared to measures using 
multiple items.  Single-items measures are practical and useful in the clinical setting and 
have reported good reliability and validity (Cleeland & Mendoza, 2011; Mooney et al., 
2014).   
Conclusions 
 While few demographic or clinical factors were associated with fatigue and 
disturbed sleep trajectory classes, the presence of other symptoms at moderate to severe 
levels was associated with membership in higher fatigue and disturbed sleep classes.  
There was a trend towards an association between membership in the high moderate 
improving fatigue class and more hours spent lying down and more days of missed work.  
Overall symptom severity in cycle 2 may predict both fatigue and disturbed sleep class 
membership in cycle 3.  Clinicians need to be aware that women who present with 
significant symptoms during an early cycle of chemotherapy are at risk for continued 
severity of fatigue and disturbed sleep in subsequent cycles.  Interventions aimed at 
reducing symptoms may have an impact on activity level and ability to continue 
employment, as well as reduction of symptoms during future cycles of chemotherapy and 
into survivorship.  Further study is needed to determine whether higher severity of fatigue 
and disturbed sleep can predict poorer outcomes related inactivity and loss of 
employment.  Additionally, future studies might explore the long-term relationship 
between overall symptom severity during earlier cycles of chemotherapy and class 
membership during later cycles of chemotherapy.  Finally, well-designed longitudinal 
studies are needed to determine if there are genetic or molecular markers that may be 
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ANTECEDENTS, CO-OCCURING SYMPTOMS, AND OUTCOMES  
OF DISTINCT TRAJECTORIES OF THE SYMPTOMS OF  
MOOD DISTURBANCE IN WOMEN WITH  
BREAST CANCER 







 The purpose of this study was to examine if membership in differing trajectory 
classes for depressed mood and anxiety during chemotherapy for breast cancer is 
determined by demographic, clinical, or symptom characteristics.   
 A secondary analysis was utilized to explore data collected from 166 women who 
self-reported on the severity of 10 symptoms through daily phone calls to an automated 
system while undergoing chemotherapy for breast cancer.  Tests of mean differences 
were used to distinguish between classes with previously identified distinct trajectories of 
depressed mood and anxiety on demographic, clinical, and symptom variables. 
 Participants in this study had a mean age of 52.91 years, were mostly Caucasian 
(91.46%), and the largest proportion of the sample was diagnosed with Stage II disease 
(40.36%).  During cycle 3, for both depressed mood (cycle 3: = 7.21, p < .01), and 
anxiety (cycle 3: = 4.53, p = .04), women who received Doxorubicin were more likely 
to be in the higher severity classes.  Additionally, for anxiety during cycle 3, women with 
no college experience were more likely to be in the moderate class (= 9.70, p = .03). 
Membership in the moderate severity class for anxiety was associated with increased 
hours spent lying down during cycle 2 (t(162) = -2.21, p = .03).  Membership in the 
moderate severity anxiety class was associated with fatigue (cycle 2: t(162) = 18.99, p < 
.001; cycle 3: t(153) = 18.14, p < .001), disturbed sleep (cycle 3: t(153) = 14.39, p < 
.001), and depressed mood (cycle 2: Welch t(8.27) = 18.46, p < .01; cycle 3: Welch 
t(12.14) = 16.76, p < .01).  Membership in the moderate severity depressed mood class 
was associated with fatigue (cycle 2: t(162) = 9.02, p < .01), disturbed sleep (cycle 3: 




t(8.1) = 8.95, p = .02), and nausea and vomiting (cycle 2: Welch t(26.9) = 2.68, p < .01; 
cycle 3: t(153) = 4.23, p = .04).  The summative number of days with moderate to severe 
total symptoms during cycle 2 was associated with a higher severity class membership 
during cycle 3 for both depressed mood (t(153) = 16.40, p < .001) and anxiety (t(153) = 
21.85, p < .001). 
 Clinicians should be aware that chemotherapy regimen and the presence of other 
symptoms is associated with depressed mood and anxiety during chemotherapy for breast 
cancer. Additionally, higher severity of psychological symptoms during early cycles may 
continue during subsequent cycles and warrant early intervention to decrease 
psychological distress.   
Background 
There is an abundance of literature supporting a high prevalence of disturbing 
symptoms during chemotherapy in women with breast cancer.   Among these highly 
prevalent symptoms are depression (24-54%) (Bower et al., 2011; Gaston-Johansson, 
Fall-Dickson, Bakow, & Kennedy, 1999; Kim, Barsevick, Tulman, & McDermott, 2008; 
Liu et al., 2009; So et al., 2009) and anxiety (6-74%) (Bender, Ergun, Rosenzweigh, 
Cohen, & Sereika, 2005; Browall, Persson, Ahlberg, Karlsson, & Danielson, 2009; So et 
al., 2009).  Depression and anxiety are more common in oncology patients than in the 
general population and are often assessed together and referred to as psychological 
distress (Gold et al., 2016).  Mood disturbance may be related to anxiety, diagnostic 
testing, worries about disease progression, concern about an inability to perform usual 
functions, and concerns about the future (Gaston-Johansson et al., 1999).  Chemotherapy 




morbidity, leading to increased psychological distress (Gaston-Johansson et al., 1999).  
Additionally, increases in mood disturbance may be associated with shorter recurrence-
free periods and overall survival in survivors of breast cancer (Groenvold et al., 2007).  
Worth noting is evidence that mood disturbance in oncology patients may result in 
treatment non-adherence, increased time in the hospital, impairment in quality of life, 
poor prognosis, and increased mortality (Gold et al., 2016; Jones et al., 2015; Mitchell et 
al., 2011). 
Mood disturbance has been associated with previous treatment for mood 
disturbance, lack of an intimate confiding relationship, younger age, and stressful non-
cancer life experiences (Burgess et al., 2005; Dunn et al., 2011; Gold et al., 2016).  
Depressed mood and anxiety in women with breast cancer are often associated with the 
presence of other symptoms in symptom clusters, such as fatigue, cognitive impairment, 
pain, sleep disturbance, and hot flashes (Berger & Higginbotham, 2000; Berger, Wielgus, 
Hertzog, Fischer, & Farr, 2010; Bower et al., 2011; Broeckel, Jacobsen, Horton, 
Balducci, & Lyman, 1998; Gaston-Johansson, Fall-Dickson, Bakow, & Kennedy, 1999; 
Jacobsen et al., 1999; Kim, Barsevick, Tulman, & McDermott, 2008; Liu et al., 2009; So 
et al., 2009; Tchen et al., 2003).  These symptom cluster studies often involve a cross-
sectional design and include symptoms in a cluster based on prevalence, as opposed to 
severity or distress, using mostly variable-oriented analysis methods. 
More recently, seven reported studies have included a subgroup analysis of 
classes of women with breast cancer experiencing similar trajectories of mood 
disturbance and potential correlates of class membership (Bistrup et al., 2015; DeShields, 




Henselmans et al., 2010; Lam et al., 2012; Lam, Shing, Bonanno, Mancini, & Fielding, 
2014; Wang, Chang, Chen, Chen, & Hsu, 2014).  These reports have identified 3-5 
classes with distinct trajectories of mood disturbance across various time-points in the 
breast cancer treatment spectrum.  Potential correlates of class membership included 
quality of life and state/trait anxiety measures, younger age, type of surgery, employment, 
education, and social support (Bistrup et al., 2015; DeShields et al., 2006; Dunn et al., 
2011; Helgeson et al., 2004; Henselmans et al., 2010; Lam et al., 2012; Lam et al., 2014; 
Wang et al., 2014).  Importantly, while longitudinal in design, each of studies evaluated 
symptoms of psychological distress and correlates at specific time-points, ranging from 
3-7 times over 6-55 months, but did not examine the patterns that begin during 
chemotherapy treatment.   
Given the significant burden of treatment-associated symptoms, and their 
association with inferior long-term outcomes relative to adherence, functional status, 
employment and mortality, identification of those at risk for moderate to severe levels of 
mood disturbance during chemotherapy treatment for breast cancer is important (Gold et 
al., 2016; Jones et al., 2015; Mitchell et al., 2011).  Using Latent Growth Mixture 
Modeling (LGMM), we previously observed two distinct patterns of depressed mood; the 
majority (91% of respondents in cycle 2 and 94% in cycle 3) with a minimal level of 
depressed mood and a small class with a moderate level of depressed mood (9% of 
respondents in cycle 2 and 6% in cycle 3).  Two latent trajectories of anxiety were also 
revealed using a LGMM model, including a minimal anxiety class (95% of respondents 
in cycle 2 and 92% in cycle 3) and a moderate anxiety class (5% of respondents in cycle 




occurring symptoms, and outcomes are associated with class membership for the mood 
disturbance responses of depressed mood and anxiety. 
Methods 
Participants and Setting 
 Data from 3 longitudinal studies that utilized the automated telephone-linked-care 
system for data collection were used in this secondary analysis.  Participants were 
recruited from 6 settings, including clinics in the southeast, western, and midwestern 
United States.  Studies 1 and 2 were both randomized clinical trials and Study 3 involved 
no intervention or study group assignment.  While in both Study 1 and Study 2, 
participants were assigned to a usual care and a symptom management intervention 
group, only those in Study 2 were found to have differences in reported symptoms 
between the groups.  All data from eligible participants in Study 1 and Study 3 and those 
in the usual care group in Study 2 were included in this secondary analysis.  Across all 3 
parent studies, data were available for cycle 2 and cycle 3.  Eligibility requirements for 
this secondary analysis included being a woman diagnosed with breast cancer beginning 
initial treatment with chemotherapy and completed study measures through cycle 2 and 
cycle 3. 
A cohort of 259 women with a breast cancer diagnosis and receiving initial 
treatment with chemotherapy were pooled from the three parent studies.  Of these, 80 
women who were randomized to the intervention group for Study 2 along with 13 women 
who did not complete study measures through cycles 2 and 3 were excluded.  A total 
sample of 166 women completed study measures through cycles 2 (n=165) and 3 (n=155) 





All 3 parent studies utilized similar instrumentation.  Demographic and disease-
related data were collected at baseline and included age, gender, race/ethnicity, 
employment status, education, extent of disease and details of the chemotherapy protocol.  
Single-item indicators were used to assess each symptom.  Conditional branching was 
used, where participants were asked, “During the past 24 hours did you experience 
(symptoms)?”  A no response was scored as zero and a yes response elicited further 
questioning using a 1 to 10 Likert scale for the severity of that particular symptom.  The 
investigator-developed instrument is further described by Mooney, Beck, Friedman, 
Farzanfar, and Wong (2014).  Symptoms assessed included fatigue, disturbed sleep, 
depressed mood, anxiety, pain, nausea/vomiting, sore mouth, and diarrhea across all three 
parent studies.  Two additional symptoms, distress associated with changing appearance 
and trouble thinking, were assessed in Studies 2 and 3.  A subsample was used in 
analyses that included those 2 symptoms, consisting of participants enrolled in those 2 
parent studies only.   
Daily hours spent lying down and whether or not employed participants were able 
to attend work were collected.  To account for varying cycle lengths, only data from the 
first 14 days of each cycle were included in the analyses. 
Study Procedures 
This study was reviewed by Institutional Review Board (IRB) at the University of 







 The Software Statistical Package for the Social Sciences (SPSS), version 23.0 was 
used for data management and data analysis.  P values less than .05 were considered 
statistically significant and because this was a hypothesis-generating study, there was no 
adjustment for multiplicity.   
 Descriptive statistics and frequency distributions were generated on the sample 
characteristics.  Using the models previously described for depressed mood and anxiety 
in both cycles, the model predicted class membership was obtained for each individual on 
each symptom during each cycle using posterior probabilities.  While there is uncertainty 
in predicted class membership, the entropy and posterior probabilities as previously 
reported for our models suggest a strong model fit and predicted class membership was 
treated as an observed variable for the purposes of this analysis (Jung & Wickerama, 
2008).  Class membership assignment was then used to test for mean differences and 
associations among the categories across the classes on antecedents, co-occurring 
symptoms, and outcomes.  Fisher’s exact chi-square was used to account for small cell 
sizes, a conservative test that allows for tests of associations among categories when cell 
sizes had an expected frequency of five or less.  In cases where classes did not display 
homogeneity of variance, the Welch statistic, a robust test that allows violation of this 
assumption, was used.  The analysis proceeded to answer four specific aims. 
 Aim 1 was to determine whether differing symptom trajectory profiles for 
depressed mood and anxiety are associated with variations in demographic and clinical 
characteristics.  After establishing the classes for the severity of each individual symptom 




chemotherapy regimen were compared to class membership across the classes for 
depressed mood and anxiety for each cycle using chi-square (stage of disease, education, 
employment, marital status, and chemotherapy regimen) and independent-samples t  tests 
(age).  Because of the large diversity of chemotherapy regimens and the sample size, it 
was not statistically possible to interpret comparison between the individual regimens.  
Instead, tests were conducted on two agents of interest, whether or not women received 
Doxorubicin as part of their regimen and whether or not women received a Taxane as 
part of their regimen.   
 Aim 2 was to determine whether differing symptom trajectory profiles for 
depressed mood and anxiety are associated with variations in outcome measures, such as 
average hours spent lying down and days of missed work.  Daily measures of hours spent 
lying down were averaged for each individual for each cycle 2 and 3.  Days of missed 
work were summed for all employed participants for each cycle 2 and 3.  To answer this 
aim, tests of mean differences across the classes were conducted on the outcome 
variables using independent-samples t tests.  Only those participants who were employed 
were included in the test of mean differences across the classes for days of missed work.   
 Aim 3 was to determine whether differing symptom trajectory profiles for 
depressed mood and anxiety are associated with variations in the severity of other 
symptoms, such as fatigue, disturbed sleep, pain, nausea and vomiting, and trouble 
thinking.  These symptoms were studied because they were both prevalent in the sample 
and previously reported to relate with depressed mood and/or anxiety.  Tests of mean 
differences across classes on the number of moderate to severe days reported for each 




scores for each symptom included the number of days subjects scored 4 or higher on 
severity of fatigue, disturbed sleep, depressed mood, anxiety, pain, nausea, and trouble 
thinking within the first 14 days of each cycle.  These summative scores were then 
compared to class membership for depressed mood and anxiety in cycles 2 and 3 using 
independent-samples t tests.   
 Aim 4 is to determine whether differing symptom trajectory profiles for depressed 
mood and anxiety during cycle 3 are associated with variations in the overall symptom 
severity during cycle 2.   Overall symptom severity for cycle 2 included the number of 
days where subjects scored 4 or higher on severity of fatigue, disturbed sleep, depressed 
mood, anxiety, pain, and nausea and vomiting.  These symptoms were studied because 
they were both prevalent in the sample, with data from all participants, and previously 
reported to relate with depressed mood and/or anxiety.  The total number of moderate to 
severe days was then compared to the extracted class membership for depressed mood 
and anxiety in cycle 3 using independent-samples t tests.   
Results 
 
 A total of 166 women with breast cancer participated in the study.  Subject 
demographic and clinical characteristics are summarized in Table 4.1.  Women ranged in 
age from 24 to 80 years (mean age = 52.91, SD = 10.8).  Most women were White 
(91.46%), married (75%), and not currently working (62.8%).  The majority of the 
sample had some education beyond high school (75.3%) and 40.36% of women in the 
sample were diagnosed with Stage II breast cancer.  Participants received over 12 
different regimens of chemotherapy during the study period.  The prevalence of 




Table 4.1 Sample Demographic and Clinical Characteristics (n =166) 
Characteristic Mean SD 
Age (in years) 52.90 10.8 
Characteristic n % 
Ethnicity 
   Non-Hispanic 
   Hispanic 










   Partnered 
   NonPartnered 










   Full-time 
   Part-time 
   Not Employed 












   High school          
   Some College  
   Associate Degree 
   Bachelor Degree 
   Postgraduate  
















   Less than  $9,999 
   $10,000-29,999 
   $30,000-49,000 
   $50,000-69,000 
   $70,000 or More      
   Unknown 

















Stage of Disease 
   Stage I 
   Stage II 
   Stage III 
   Stage IV 













Chemotherapy Regimen   
   Cyclophosphamide with Doxorubicin 68 41.0% 
   Docetaxel 23 13.9% 
   Cyclophosphamide with Methotrexate and 5-FU 16 9.6% 
   Docetaxel with Carboplatin 13 7.8% 
   Cyclophosphamide with Docetaxel 12 7.2% 
   Cyclophosphamide with Doxorubicin and 
Docetaxel 9 5.4% 
   Cyclophosphamide with Doxorubicin and 5-FU 6 3.6% 
   Cyclophosphamide with 5-FU 4 2.4% 





Table 4.2 Symptom Prevalence and Mean Number of Days at Moderate to Severe Levels 
 
Symptom Cycle 






than 0 at 
Least Once 
Mean no. Days 











than 3 at 
Least Once 
Mean no. Days 





















Fatigue a 2 153 (92.7%) 7.53 (3.69), 1-14 115 (69.7%) 5.09 (3.47), 1-14 659 (36.4%) 1152 (63.6%) 585 (32.3%) 3 148 (94.9%) 7.09 (3.93), 1-14 105 (67.3%) 4.95 (3.70), 1-14 654 (38.4%) 1050 (61.6%) 520 (30.5%) 
Disturbed 
Sleep a 
2 126 (76.4%) 3.63 (2.56), 1-13 103 (62.4%) 2.87 (2.07), 1-13 1354 (74.8%) 457 (25.2%) 296 (16.3%) 
3 110 (70.5%) 3.40 (2.64), 1-13 85 (54.5%) 2.46 (1.76), 1-11 1330 (78.1%) 374 (21.9%) 209 (12.3%) 
Pain a 2 124 (75.2%) 4.55 (3.20), 1-14 75 (45.5%) 3.51 (2.95), 1-13 1247 (68.9%) 564 (31.1%) 263 (14.5%) 3 104 (66.7%) 5.16 (3.74), 1-14 66 (42.3%) 4.15 (3.33), 1-14 1167 (68.5%) 537 (31.5%) 274 (16.1%) 
Nausea and 
Vomiting a 
2 116 (70.3%) 3.90 (2.92), 1-13 78 (47.3%) 2.66 (2.28), 1-11 1359 (75.0%) 542 (29.9%) 208 (11.5%) 
3 111 (71.2%) 4.05 (3.31), 1-14 63 (40.4%) 3.14 (2.63), 1-12 1254 (73.6%) 450 (26.4%) 198 (11.6%) 
Diarrhea a 2 69 (41.8%) 2.13 (1.53), 1-8 30 (18.2%) 1.83 (0.87), 1-4 1664 (91.9%) 147 (8.1%) 55 (3.0%) 3 49 (31.4%) 2.63 (1.82), 1-10 23 (14.7%) 2.17 (1.53), 1-6 1575 (92.4%) 129 (7.6%) 49 (2.9%) 
Sore Mouth a 2 68 (41.2%) 3.62 (2.34), 1-11 38 (23.0%) 3.11 (2.29), 1-10 1565 (86.4%) 246 (13.6%) 118 (6.5%) 3 68 (43.6%) 3.32 (2.61), 1-13 38 (24.4%) 2.66 (2.72), 1-13 1478 (86.7%) 216 (12.7%) 91 (5.3%) 
Trouble 
Thinking b 
2 46 (27.9%) 2.67 (1.97), 1-11 28 (17.0%) 2.50 (2.19), 1-10 884 (93.2%) 64 (6.8%) 37 (3.9%) 
3 31 (19.9%) 3.26 (2.11), 1-9 21 (13.5%) 1.95 (1.07), 1-5 776 (94.1%) 46 (5.6%) 20 (2.4%) 
Appearance b 2 38 (23.0%) 3.32 (2.57), 1-12 25 (15.2%) 3.16 (2.37), 1-9 882 (93.0%) 66 (7.0%) 42 (4.4%) 3 15 (9.6%) 3.27 (3.97), 1-13 10 (6.4%) 3.50 (4.50), 1-12 801 (97.1%) 24 (2.9%) 17 (2.1%) 
Mood Disturbance Symptoms 
Depressed 
Mood a 
2 99 (60.0%) 3.60 (3.21), 1-13 70 (42.4%) 3.23 (2.84), 1-12 1455 (80.3%) 356 (19.7%) 226 (12.5%) 
3 83 (53.2%) 3.47 (3.11), 1-14 55 (35.3%) 2.87 (2.86), 1-13 1416 (83.1%) 288 (16.9%) 158 (9.3%) 
Anxiety a 2 77 (46.7%) 3.34 (3.17), 1-13 47 (28.5%) 2.91 (2.83), 1-11 1544 (85.3%) 267 (14.7%) 147 (8.2%) 3 62 (39.7%) 3.56 (3.62), 1-13 40 (25.6%) 2.65 (2.56), 1-9 1483 (87.0%) 221 (13.0%) 106 (6.2%) 
a n=165, cycle 2; n=156, cycle 3; 1811(78.4%) days reported cycle 2, 1704(78.0%) days reported cycle 3; 499(21.6%) days missing cycle 2, 480(22.0%) days missing cycle 3 




the most prevalent symptom, followed by disturbed sleep, depressed mood, anxiety, pain, 
and nausea and vomiting.  
Aim 1 
Results of the tests of mean differences and associations among categories across 
classes on the demographic variables are presented in Table 4.3 for the depressed mood 
classes and Table 4.4 for the anxiety classes.  Only the comparison of education to class 
membership for anxiety during cycle 3 and the comparison of whether or not women 
received Doxorubicin were related to class membership for both depressed mood and 
anxiety during cycle 3.  In this cycle only, high school graduates were more likely to be 
in the moderate anxiety class and those with an undergraduate degree were more likely to 
be in minimal anxiety class.  Also, those in the moderate severity class for both 
symptoms were more likely to have received Doxorubicin.  All respondents in the 
moderate severity class for depressed mood during cycle 3 received Doxorubicin and 
83.3% of respondents in the moderate class for anxiety during cycle 3 received 
Doxorubicin.  
Aim 2 
   For both symptoms, the t tests for both hours spent lying down and days of missed 
work were nonsignificant (see Tables 4.3 and 4.4), with the exception of hours spent 
lying down and anxiety class membership during cycle 2.  Women in the moderate 
anxiety class reported statistically significantly higher average daily hours spent lying 






Table 4.3 Tests of Mean Differences and Associations Among Categories for 
Antecedents and Outcomes of Depressed Mood Class Membership 
 








Age (in years)  52.29 
(11.01) 
50.66 (8.95) t(159) = 
1.23, 
p = .27 
Education    
  = 0.88, 
p = .98 
 Less than high school 6 (4.4%) 0 (0.0%) 
 High school 25 (18.4%) 5 (20.8%) 
 Undergraduate/Technical 
School 
88 (64.7%) 16 (66.7%) 
 Postgraduate 17 (12.5%) 3 (12.5%) 
Marital Status      = 1.27, 
p = .50  Married 105 (76.1%) 16 (66.7%)  Not Married 33 (23.9%) 8 (33.3%) 
Employment      = 1.88, 
p = .46  Employed 54 (39.1%) 6 (25.0%)  Not Employed 84 (60.9%) 18 (75.0%) 
Stage    
  = 2.43, 
p = .64 
 I 15 (11.0%) 5 (20.8%) 
 II 58 (42.6%) 9 (37.5%) 
 III 31 (22.8%) 6 (25.0%) 
 IV 32 (23.5%) 4 (16.7%) 
Doxorubicin      = 1.13, 
p = .34  Yes 63(47.7%) 7(35.0%)  No 69(52.3%) 13(65.0%) 
Taxane     = .43, 
p = .61  Yes 43(32.6%) 8(40.0%)  No 89(67.4%) 12(60.0%) 
Hours Spent 
Lying Down 
 10.57 (2.63) 10.33 (3.82) t(27) = 0.30, 
p = .77 
Days Missed 
Work (n=20) 
 2.28 (1.81) 4.0 (0.00) t(18) = 1.73, 





Table 4.3 continued 
 














p = .82 
Education    
 = 2.01, 
p = .68 
 Less than high school 5 (3.5%) 0 (0.0%) 
 High School 24 (16.9%) 3 (33.3%) 
 Undergraduate/Technical 
School 
94 (66.2%) 5 (55.6%) 
 Postgraduate 19 (13.4%) 1 (11.1%) 
Marital Status      = 2.55, 
p = .32  Married 109 (75.7%) 5 (55.6%)  Not Married 35 (24.3%) 4 (44.4%) 
Employment      = 0.78, 
p = 1.00  Employed 57 (39.6%) 3 (33.3%)  Not Employed 87 (60.4%) 6 (66.7%) 
Stage    
  = 1.58, 
p = 0.84 
 I 19 (13.3%) 0 (0.0%) 
 II 60 (42.0%) 5 (55.6%) 
 III 33 (23.2%) 2 (22.2%) 
 IV 31 (21.8%) 2 (22.2%) 
Doxorubicin      = 7.21, 
p < .01*  Yes 74(51.4%) 8(100.0%)  No 70(48.6%) 0(0.0%) 
Taxane      = 1.68, 
p = .27  Yes 50 (34.7%) 1(12.5%)  No 94 (65.3%) 7(87.5%) 
Hours Spent 
Lying Down 
 10.59 (2.72) 10.24 (4.15) t(150) = 
0.36, 
p = .72 
Days Missed 
Work (n=27) 
 1.56(1.71) 1.00(0.00) t(25) = 0.21, 





Table 4.4 Tests of Mean Differences and Associations Among Categories for 
Antecedents and Outcomes of Anxiety Class Membership 
 







Age (in years)  52.53 
(10.72) 
59.13 (9.76) t(159) = 
3.25, 
p = .07 
Education    
 = 6.45, 
p = .13 
 Less than high school 5 (3.3%) 1 (11.1%) 
 High school 26 (17.2%) 4 (44.4%) 
 Undergraduate/Technical 
School 
99 (65.6%) 4 (44.4%) 
 Postgraduate 21 (13.9%) 0 (0.0%) 
Marital Status     = 0.73, 
p = 1.00  Married 114 (74.5%) 7 (77.8%)  Not Married 39 (25.5%) 2 (22.2%) 
Employment     = 6.76, 
p = .05  Employed 60 (39.2%) 0 (0.0%)  Not Employed 93 (60.8%) 9 (100.0%) 
Stage    
 = 4.21, 
p = .36 
 I 20 (13.2%) 0 (0.0%) 
 II 65 (43.0%) 2 (14.3%) 
 III 33 (21.9%) 3 (21.4%) 
 IV 33 (21.9%) 9 (64.3%) 
Doxorubicin    Χ2 = 1.51, 
p = .29  Yes 76 (52.8%) 6 (75.0%)  No 68 (47.2%) 2 (25.0%) 
Taxane     = 0.28, 
p = .72  Yes 49 (34.0%) 2 (25.0%)  No 95 (66.0%) 6 (75.0%) 
Hours Spent 
Lying Down 
 10.41 (2.77) 12.53 (3.03) t(162) = -
2.21, 
p = .03* 
Days Missed 
Work (n=20) 





Table 4.4 continued 
 








Age (years)  52.69 
(10.90) 
53.87 (8.73) t(150) = .13, 
p = .72 
Education     = 9.70, 
p = .03* 
 Less than high school 4 (2.9%) 1 (7.7%)  
 High school 22 (15.8%) 5 (38.5%)  
 Undergraduate/Technical 
School 
95 (68.3%) 5 (38.5%)  
 Postgraduate 18 (12.9%) 2 (15.4%)  
Marital Status     = 3.52, 
p = .24 
 Married 107 (76.4%) 7 (53.8%)  
 Not Married 33 (23.6%) 6 (46.2%)  
Employment     = 3.90, 
p = .15 
 Employed 56 (39.7%) 4 (33.3%)  
 Not Employed 85 (60.3%) 8 (66.7%)  
Stage     = 2.85, 
p = .58 
 I 19 (13.7%) 0 (0.0%)  
 II 60 (43.2%) 5 (38.5%)  
 III 31 (22.3%) 4 (30.8%)  
 IV 29 (20.9%) 4 (30.8%)  
Doxorubicin     = 4.53, 
p = .04* 
 Yes 72 (51.4%) 10 (83.3%)  
 No 68 (48.6%) 2 (16.7%)  
Taxane     = 1.67, 
p = .23 
 Yes 49(35.0%) 2(16.7%) 
 No 91(65.0%) 10(83.3%) 
Hours Spent 
Lying Down 
 10.44 (2.75) 11.87(3.20) t(150) = -
1.77, 
p = .08 
Days Missed 
Work (n=27) 
 1.46(1.67) 2.00(1.73) t(25) = 0.28 








 Results of the independent samples t tests comparing class membership with the 
number of moderate to severe days of individual symptom are presented in Tables 4.5 
and 4.6.  Women in the moderate depressed mood class reported a statistically 
significantly greater number of days with moderate to severe fatigue (p < .01*), anxiety 
(p < .01*), and nausea and vomiting (p = .04*) during cycle 2 and disturbed sleep (p = 
.01*), anxiety (p = .02*), and nausea and vomiting (p = .04*) during cycle 3 when 
compared to women in the minimal depressed mood class.  Pain and trouble thinking 
were not related to depressed mood class membership.  Women in the moderate anxiety 
class reported statistically significantly greater number of days with moderate to severe 
fatigue (p < 001*) and depressed mood (p < .01*) during cycle 2 and fatigue (p < 001*), 
disturbed sleep (p < .01*), and depressed mood (p < .01*) during cycle 3 when compared 
to women in the low anxiety class.  Pain, nausea and vomiting, and trouble thinking were 
not associated with anxiety class membership.    
 Aim 4 
 For both depressed mood (F(1,153) = 16.404, p < 001*) and anxiety (F(1, 153) = 
21.849, p < 001*), the overall symptom severity in cycle 2, the total number of days 
where subjects scored 4 or higher on severity of fatigue, disturbed sleep, depressed mood, 
anxiety, pain, and nausea and vomiting was associated with class membership in cycle 3.  
For depressed mood, means for the minimal (10.12, SD = 9.47) and moderate (23.22, SD 
= 8.61) classes suggest that those in the moderate class for depressed mood during cycle 
2 reported statistically higher overall symptom severity in cycle 2 when compared to the 




Table 4.5 Tests of Mean Differences for Co-occurring Symptoms With Depressed Mood 
Class Membership 
 
Depressed Mood Class Mean Days SD Omnibus Test 
Cycle 2 
Fatigue t(162) = 9.02, p < .01* 
Consistently Mild 3.21 3.53  
Consistently Low Moderate 5.63 4.20  
Disturbed Sleep t(162) = 0.99, p = .32 
Consistently Mild 1.74 2.15  
Consistently Low Moderate 2.21 2.17  
Anxiety Welch t(24.3) = 11.76, p < .01* 
Consistently Mild 0.49 1.38  
Consistently Low Moderate 2.92 3.43  
Pain t(162) = 0.50, p = .48 
Consistently Mild 1.66 2.75  
Consistently Low Moderate 1.25 1.96  
Nausea and Vomiting Welch t(26.9) = 2.68, p < .01* 
Consistently Mild 1.13 1.90  
Consistently Low Moderate 2.08 2.75  
Trouble Thinking t(80) = 0.49, p = .49 
Consistently Mild 0.82 1.73  
Consistently Low Moderate 1.33 1.97  
Cycle 3
Fatigue Welch t(8.5) = 8.49, p = .06 
Consistently Mild 3.13 3.63  
Consistently Low Moderate 2.20 5.20  
Disturbed Sleep t(153) = 6.31, p = .01* 
Consistently Mild 1.26 1.79  
Consistently Low Moderate 2.78 1.20  
Anxiety Welch t(8.1) = 8.95, p = .02* 
Consistently Mild 0.46 1.22  
Consistently Low Moderate 4.33 3.87  
Pain t(153) = 0.05, p = .83 
Consistently Mild 1.78 2.98  
Consistently Low Moderate 1.56 3.25  
Nausea and Vomiting t(153) = 4.23, p = .04* 
Consistently Mild 1.18 2.23  
Consistently Low Moderate 2.78 2.64  
Trouble Thinking  
Consistently Mild 0.53 1.03  
Consistently Low Moderate 0.00 0.00  
Total Cycle 2 Days Moderate/Severe Symptoms t(153) = 16.40, p < .001* 
Consistently Mild 10.12 9.46  




Table 4.6 Tests of Mean Differences for Co-occurring Symptoms With Anxiety Class 
Membership 
 
Anxiety Class Mean Days SD Omnibus Test 
Cycle 2 
Fatigue t(162) = 18.99, p < .001* 
Consistently Mild 3.28 3.54  
Consistently Moderate 8.56 3.36  
Disturbed Sleep t(162) = 0.19, p = .66 
Consistently Mild 1.79 2.15  
Consistently Moderate 2.11 2.26  
Depressed Mood Welch t(8.27) = 18.46, p < .01* 
Consistently Mild 1.08 2.01  
Consistently Moderate 6.44 3.71  
Pain t(162) = 0.32, p = .57 
Consistently Mild 1.63 2.69  
Consistently Moderate 1.11 2.03  
Nausea and Vomiting t(162) = 1.20, p = .28 
Consistently Mild 1.23 2.03  
Consistently Moderate 2.00 2.60  
Trouble Thinking  
Consistently Mild .86 1.75  
Consistently Moderate .00 .00  
Cycle 3 
Fatigue t(153) = 18.14, p < .001* 
Consistently Mild 2.98 3.62  
Low Moderate to Mild 7.46 3.82  
Disturbed Sleep t(153) = 14.39, p < .001* 
Consistently Mild 1.19 1.71  
Low Moderate to Mild 3.08 1.80  
Depressed Mood Welch t(12.14) = 16.76, p < .01* 
Consistently Mild .59 1.14  
Low Moderate to Mild 5.69 4.48  
Pain t(153) = 0.34, p = .56 
Consistently Mild 1.73 2.91  
Low Moderate to Mild 2.23 3.83  
Nausea and Vomiting t(153) = 2.94, p = .09 
Consistently Mild 1.18 2.23  
Low Moderate to Mild 2.31 2.59  
Trouble Thinking t(75) = -1.35, p = .18 
Consistently Mild .51 1.03  
Low Moderate to Mild 1.50 .71  
Total Cycle 2 Days Moderate/Severe Symptoms t(153) = 21.85, p < .001* 
Consistently Mild 9.82 9.24  




SD = 9.65) classes suggest that those in the moderate class for anxiety during cycle 2 
reported statistically higher overall symptom severity in cycle 2 when compared to the 
minimal class. 
Conclusions 
 Identifying factors that contribute to symptom trajectories allows clinicians to 
target those at risk for increased symptom experiences during chemotherapy.  Various 
demographic and clinical characteristics were examined as possibly distinguishers of 
depressed mood and anxiety class membership.  None of the demographic or clinical 
characteristics were found to be associated with depressed mood or anxiety class 
membership, with the exception of education.  During cycle 3, women with no college 
experience were likely to be in the moderate anxiety class when compared to women with 
a college degree.  This finding, in combination with findings reported by Lam et al. 
(2010) of an association between education and psychological distress trajectory, suggest 
that higher education may be protective against anxiety during chemotherapy treatment.  
While several studies have correlated younger age with higher mood disturbance, a 
relationship between age and class membership was not found in this sample (DeSheilds 
et al., 2006; Dunn et al., 2011; Gold et al., 2016; Lam et al., 2010).  Importantly, during 
cycle 3, women in the moderate class for both depressed mood and anxiety were more 
likely to have received Doxorubicin as part of their chemotherapy regimen than not.  One 
explanation for this may be that women who received Doxorubicin also reported higher 
levels of fatigue (see previous reports).  Given a known relationship between fatigue and 
mood disturbance (Berger & Farr, 1999; deJong, Kester, Schouten, Abu-Saad, & 




fatigue, it would also correlate with symptoms of mood disturbance. 
 While stage of disease was not associated with class membership for anxiety in 
either cycle, examination of the moderate anxiety class for both cycles revealed that all 
women in this class reported Stage II or greater disease.  Worries about disease 
progression and concerns about the future are reported to relate to mood disturbance, but, 
in our study, particularly to anxiety, as the moderate depressed mood did not trend with 
the same relation to stage of disease (Gaston-Johansson et al., 1999). Unfortunately, we 
were underpowered to test differences among the classes in disease stage.  In a larger 
sample, with a greater class count for the moderate anxiety class, these subtle differences 
may have been statistically different. 
 During cycle 2 only, women in the consistently moderate anxiety class reported 
statistically significant greater average daily hours spent lying down (mean hours = 
12.53, SD = 3.03) when compared to women in the consistently mild anxiety class (mean 
hours = 10.41, SD = 2.77).  No reports were found where differences in activity level or 
resting hours were compared with severity of anxiety during treatment for breast cancer 
and it is unknown why this difference among the classes was not found during cycle 3 in 
our sample.  
 None of the other demographic or clinical variables were associated with class 
membership in this sample.  There are a couple of possible explanations for this.  First, 
the number of women who experienced a moderate to severe trajectory for depressed 
mood (9% of respondents in cycle 2 and 6% in cycle 3) and anxiety (5% of respondents 
in cycle 2 and 8% of respondents in cycle 3) was low.  Additionally, more half of the 




Henselmans et al. (2010) also found a large group of women who experienced no mood 
disturbance during chemotherapy, suggesting that not all women, or even a great 
percentage of women experience these symptoms.  In our sample, in particular, the low 
class counts for the moderate trajectory classes for depressed mood and anxiety may have 
decreased the power and ability to detect differences among the classes on these potential 
correlate variables.  Second, class trajectories may be predicted by variables other than 
demographic and clinical determinants, such as genetic and molecular factors.  Cleeland 
et al. (2003) and Miaskowski et al. (2014) propose that a lack of association between 
demographic characteristics and symptom presentation may be related to a possible 
relationship between biologic mechanisms and genetic and epigenetic determinants with 
symptom experience rather than demographic and clinical determinants.  Further study is 
needed to determine whether these variables may distinguish class membership for 
symptoms of mood disturbance.   
 Membership in the moderate latent classes for both depressed mood and anxiety 
was overwhelmingly related to fatigue.  This is not surprising, as fatigue has been 
associated with symptoms of mood disturbance in both cross-sectional correlation and 
symptom cluster studies (Bender et al., 2005; Gaston-Johansson, 1999; Kim et al., 2008; 
Liu et al., 2009; Savard et al., 2009; So et al., 2009; Von Ah, Kang, & Carpenter, 2008).  
The finding that increases in the severity of disturbed sleep is associated with depressed 
mood and anxiety during cycle 3 is consistent with reports that sleep difficulty and 
depression and anxiety are associated and may cluster (Colagiuri et al., 2011; Onselen et 
al., 2012). 




was not found in our sample (Poon et al., 2013).  One explanation may be that the 
relationship between anxiety and nausea reported by Poon et al. (2013), was specific to 
anticipatory anxiety measured prior to receiving chemotherapy, not a trajectory of anxiety 
over the course of chemotherapy.  While the results of this study are congruent with those 
reported by Osoba et al. (1997), the data we had do not allow for exploration of specific 
types of nausea, including anticipatory or delayed nausea.  Interestingly, nausea and 
vomiting was increased for those in the moderate depressed mood class during both 
cycles.  To our knowledge, this finding has not been reported in women with breast 
cancer, but suggests that mood disturbance may be associated with physical symptoms, 
such as nausea and vomiting. 
 In our study, as within other studies, we found a close relationship between the 
symptoms of mood disturbance.  The relationship between both symptoms of mood 
disturbance is well studied (Colagiuri et al., 2011; Dunn et al., 2011; Gold et al., 2016; 
Lam et al., 2012).  Gold et al. (2016) report on a collective of combined anxiety and 
depression syndrome (CADS), suggesting that these symptoms often occur together and 
that elucidating etiology for one symptom may explain the other and developing 
interventions aimed at managing one, may assist in management of the other. 
 Increases in overall symptom severity during cycle 2 were associated with 
membership in the moderate class for both depressed mood and anxiety.  This finding is 
consistent with several studies that have reported on the consistency of individual 
symptoms and symptom clusters over multiple cycles of chemotherapy (Jacobsen et al., 
1999; Liu et al., 2009; Payne, Piper, Rabinowitz, & Zimmerman, 2006; Savard et al., 




experience significant symptom severity during cycle 2 may be at risk for increased 
severity in the symptoms of mood disturbance during cycle 3.  Early intervention may 
improve long-term symptom experiences during chemotherapy.     
 A major limitation of this study is a lack of data for several relevant variables of 
interest, including history of psychological illness or distress and comorbidities.  One of 
the strongest correlates of symptoms of mood disturbance during cancer treatment is a 
history of psychological illness, poor coping, or distress prior to initiation of treatment 
(Gold et al., 2016).  Because of the nature of our study, data for these variables were 
unavailable and psychological history could not be controlled for.   
Another limitation is the relatively homogenous sample in marital status (74.1% 
married).  It is unknown whether married women receive more support than nonmarried 
and potentially influenced the degree to which symptoms of mood disturbance were 
experienced.  Of the reviewed literature, only Helgeson et al. (2004) reported on social 
support as a predictive correlate of trajectories of psychological adjustment.  Further 
study is needed with diverse samples to determine whether marital status and/or social 
support can explain differences in the trajectories of mood disturbance. 
The use of a single-item measure for symptom severity has limitations, including 
the risk for increased measurement error when compared to measures using multiple 
items.  Single-items measures are useful in the clinical setting for practical purposes and 
have reported good reliability and validity (Cleeland, Fisch, & Dunn, 2011; Mooney et 
al., 2014). 
Caution should be used in interpreting our results with regards relative to 




reporting to define our symptom trajectory classes, there may be more variability within 
the classes around the parameter estimates than what is described in the models.  In 
addition, predicted class memberships are based on probabilities, and while treated as 
observed variables in these analyses, care should be used to over-extend the 
interpretation.   
 Future research should focus on the identification of potential correlates for class 
membership, including genetic and molecular determinants.  Additionally, results of this 
study should be replicated in larger samples to determine whether these same classes are 
consistent and if, with larger class counts, correlates and long-term outcomes may be 
attributed to class membership.  Clinicians should have awareness that symptoms of 
mood disturbance may co-occur and may relate to fatigue, disturbed sleep, and nausea 
and vomiting.  Interventions should be developed to assist women with symptoms of 
mood disturbance throughout chemotherapy, targeting those women at who report 
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DISCUSSION AND CONCLUSIONS 
Introduction 
 
 Women with breast cancer undergoing treatment with chemotherapy experience 
persistent symptoms related to both tumor and treatment (Kim, Barsevick, Tulman, & 
McDermott, 2008; Payne, Piper, Rabinowitz, & Zimmerman, 2006; Wood, Nail, Gilster, 
Winters, & Elsea, 2006).  The change in the presence and severity of a symptom over 
time, or the trajectory of the symptom, is dynamic throughout the course of treatment and 
survival (Payne, 2002).  General symptoms, such as fatigue, disturbed sleep, depressed 
mood, and anxiety, are particularly distressing, as the specific etiology is often unknown, 
making it difficult for healthcare providers to manage (Kim, McGuire, Tulman, & 
Barsevick, 2005; National Comprehensive Cancer Network, 2010; Ware, Kosinski, & 
Keller, 1996).  The existence of these symptoms during treatment is also related to 
inferior outcomes, including decreases in functional status, reduced occupational 
functioning, treatment nonadherence, increased hospitalization and, during survival, 
increased recurrence and mortality (Beck et al., 2010; Cleeland et al., 2000; Lee et al., 
2004). 
 Previous studies have identified that the challenges of studying symptoms include 
difficulty separating tumor burden effects or disease-related symptoms from treatment-




controlling for confounding variables, such as comorbidities and medications (Wood et 
al., 2006).  Previous studies of symptoms experienced by women with breast cancer 
undergoing chemotherapy have focused on the prevalence of symptoms, as opposed to 
the severity of symptoms.  Additionally, theoretically important time points, such as 
baseline, nadir, and end of cycle, are often used for data collection, ignoring the 
potentially dynamic existence of symptoms on a daily basis.  Understanding the severity 
of symptoms, as they exist on a daily basis, and the correlates of daily symptom 
experiences, will assist clinicians in identifying women who may be at risk for symptom 
development or increased symptom severity prior to or during early cycles of 
chemotherapy.  Those women at highest risk for elevated symptom burden may be 
targeted for self-management support, pharmacological intervention, and more intensive 
provider surveillance during chemotherapy to improve outcomes, and address issues such 
as treatment adherence, functional losses, and increased rates of hospital admission. 
 The objectives of this study were to identify subgroups of women experiencing 
similar symptom trajectories while undergoing chemotherapy for breast cancer and to 
determine if demographic, clinical, and symptom variables are associated with specific 
symptom classes. 
Sample 
 This was a secondary analysis of pooled data collected as part of two longitudinal, 
randomized controlled trials that tested the use of an automated telephone-linked-care 
system for monitoring symptoms and intervening in the presence of symptoms during 
chemotherapy: “Telephone-linked Care for Cancer Symptoms Management (TLC-




“Symptom Care at Home (SCH),” which was funded by the NIH/DHHS (R01 CA120558 
Mooney, PI).  Additionally, data were included from a nonrandomized, longitudinal 
study utilizing the same automated telephone-linked-care system for data collection of 
the presence of symptoms during chemotherapy: “Symptom Care by Phone (SCP2)” 
(Mooney, PI). 
The sample consisted of 166 women, ages 18 and older, diagnosed with breast 
cancer and undergoing initial treatment with cycles 2 and 3 of chemotherapy.  Women 
were primarily middle-aged (mean age 52.91 years, SD = 10.8), mostly White (91.46%), 
mostly married (75%), and mostly not employed (62.8%).  Women in the sample 
received any of 12 different chemotherapy regimens consisting of differing combinations 
and dosing of chemotherapy agents, such as Adriamycin with Cyclophosphamide 
(41.7%), Docetaxel or Paclitaxel alone (12.8%), Cyclophosphamide with 5Flourouracil 
(12.8%), Cyclophosphamide with Docetaxel (7.1%), Docetaxel with Adriamycin and 
Cyclophosphamide (5.1%), Docetaxel with Carboplatin (7.7%), Adriamycin with 
Cyclophosphamide and 5Flourouracil (3.8%), and others (6.4%).  Eighty-two (52.6%) 
women received Doxorubicin as part of their regimen and 51 (32.7%) women received 
Paclitaxel or Docetaxel.   
Study Findings 
 The first aim of this study was to determine the trajectory classes reflecting the 
severity of 10 symptoms (fatigue, pain, disturbed sleep, depressed mood, anxiety, nausea 
and vomiting, diarrhea, distress about appearance changes, sore mouth, and trouble 
thinking) reported by women undergoing cycles 2 and 3 of chemotherapy for breast 




the severity of individual symptoms reported by women undergoing chemotherapy for 
breast cancer during cycle 2 and during cycle 3? 2) What are the trajectory classes, if any, 
associated with the severity of individual symptoms reported by women undergoing 
chemotherapy for breast cancer during cycle 2 and cycle 3? 3) Do the trajectory classes 
associated with the severity of individual symptoms differ between cycle 2 and cycle 3 of 
chemotherapy?  Symptoms were measured by self-report on a 0-10 response scale, daily 
during cycle 2 and cycle 3 of breast cancer treatment with chemotherapy.  To 
accommodate for varying cycle lengths, only the first 14 days of symptom reports during 
each cycle were used for the analysis of symptom trajectories.   
 Common symptoms, with their prevalence (i.e., occurring at least once) during 
cycle 2 and cycle 3, included fatigue (prevalence of 92.7% and 94.9%), disturbed sleep 
(prevalence of 76.4% and 70.5%), depressed mood (prevalence of 60% and 53.2%), 
anxiety (prevalence of 46.7% and 39.7%), pain (prevalence of 75.2% and 66.7%), and 
nausea and vomiting (prevalence of 70.3% and 71.2%).  Sore mouth (prevalence of 
41.2% and 43.6%), distress associated with change in appearance (prevalence of 23% and 
9.6%), diarrhea (prevalence of 41.8% and 31.4%), and trouble thinking (prevalence of 
27.9% and 19.9%) were less prevalent.  All 10 individual symptoms were modeled over 
14 days of each cycle in a 1-class model and then latent class mixture models of distinct 
patterns of variation over time were evaluated for each symptom.  These models defined 
classes of women who experienced a similar symptom trajectory over the first 14 days of 
each cycle of chemotherapy.  Of the 10 symptoms, latent classes were recovered for 
fatigue, disturbed sleep, depressed mood, and anxiety.  Of the remaining symptoms, 




warnings, but with low class counts.  For the other 5 symptoms, there were warnings in 
the output that indicated the multiclass models were not trustworthy.  Exploration of 
further multiclass models for these 6 symptoms in this sample was terminated with the 2-
class solution.  We were likely underpowered to detect latent classes for these six 
symptoms and it is possible that in a larger sample, multiclass models might have been 
retained.  During both cycles of treatment, a majority of respondents reported a severity 
of zero for many of the symptoms, including sore mouth, trouble thinking, diarrhea, and 
distress associated with change in appearance.  These symptoms were reported on fewer 
days overall during cycle 2 and cycle 3 and may have limited the ability to recover 
classes.  Logically, it may be that latent classes with homogenous trajectories for these 
symptom were not recovered because these symptoms were simply not reported 
frequently enough to model multiple homogenous trajectories.  Less prevalent symptoms 
may be better studied using cross-sectional designs or modeling data from specific 
theoretically relevant time-points when the symptom is expected to be present.  
 Fatigue was the symptom with the greatest prevalence (92.7% during cycle 2 and 
94.9% during cycle 3) and 67.3% of women during cycle 2 and 69.7% of women during 
cycle 3 reported a moderate to severe level of fatigue at least once during each cycle.  A 
3-class model provided the best fit to the data with acceptable fit indices and class 
proportions.  This model reflected three distinct trajectories: mild improving, low 
moderate improving to mild, and high moderate improving fatigue severity.  Fatigue 
severity improved across the first 14 days of each cycle for all classes.  While the 
majority of subjects were in the mild improving fatigue class (59% for cycle 2 and 64% 




improving fatigue classes reported persistent fatigue during both cycles.  In both cycles, 
11% of respondents were in the high moderate improving fatigue class.  Additionally, the 
growth factors and visualization of the trajectories over the two cycles of chemotherapy, 
suggests that fatigue in cycle 2 did not differ in pattern during cycle 3, similar to 
previously reported findings of fatigue patterns over multiple courses of chemotherapy 
(Berger, 1998; Jacobsen et al., 1999).   
Disturbed sleep was highly prevalent (70.5% during cycle 2 and 76.4% during 
cycle 3) and at moderate to severe levels (62.4% during cycle 2 and 54.5% during cycle 
3) in the sample.  A two-class model was described that included the following classes: 
mild improving disturbed sleep during both cycles and moderate worsening disturbed 
sleep (11% of respondents) during cycle 2 and mild worsening disturbed sleep (19% of 
respondents) during cycle 3.  Only those women in the worsening disturbed sleep classes 
had an increase in severity during the 14 days.  This suggests that identification of 
women at risk for disturbed sleep early in the course of treatment, and subsequent 
intervention, may improve sleep later in the course of treatment. 
The prevalence of depressed mood (53.2% during cycle 2 and 60% during cycle 
3) and anxiety (39.7% during cycle 2 and 46.7% during cycle 3) was similar to 
previously reported findings (Bower et al., 2011; Gaston-Johansson, Fall-Dickson, 
Bakos, & Kennedy, 1999; Kim et al., 2008; Liu et al., 2009; So et al., 2009).  Depressed 
mood and anxiety were also prevalent at moderate to severe levels in the sample (42.4% 
during cycle 2 and 35.3% during cycle 3, 28.5% during cycle 2 and 25.6% during cycle 
3, respectively).  Two-class models were retained for both depressed mood and anxiety.  




cycle 2 and 94% in cycle 3) and a consistently moderate depressed mood class (6% of 
respondents) during cycle 2 and a moderate improving depressed mood class ( 9% of 
respondents) during cycle 3 were identified.  While the mean severity in the consistently 
mild depressed mood classes was less than 1 over both cycles, the mean severity in the 
consistently moderate and moderate improving depressed mood classes were 4 or higher 
across both cycles.  During cycle 3, these women experienced a slight improvement in 
depressed mood, but remained with moderate severity.  Symptoms of mood disturbance 
have been reported to increase from baseline, but generally remain stable over time 
(Nieboer et al., 2005).  Our findings suggest that women who report a higher severity of 
depressed mood early in a cycle of chemotherapy may retain the symptom throughout the 
cycle of chemotherapy.  A 2-class model was retained for anxiety that fit the data with 
consistently mild anxiety classes during both cycles (92% of respondents in cycle 2 and 
95% in cycle 3) and a consistently moderate anxiety class (5% of respondents) during 
cycle 2 and a low moderate improving to mild anxiety class (8% of respondents) during 
in cycle 3.  Similar to depressed mood, the mean daily severity in the moderate anxiety 
class was greater than 3 across both cycles, with mean severity levels slightly higher 
during cycle 2 when compared to cycle 3. 
 While not large, a group of women existed in our sample who experienced 
fatigue, disturbed sleep, depressed mood, and anxiety at moderate to severe levels during 
chemotherapy treatment.  The growth factors and visualization over the two cycles of 
chemotherapy are presented in see Table 5.1.  Only fatigue is reported in the literature 
having similar patterns over multiple courses of chemotherapy (Berger, 1998; Jacobsen et 




Table 5.1 Growth Factor Means and Predicted Frequencies for Each Class 
 







Mild Improving 2.25* -0.26* 0.01* 97.94 
Low Moderate Improving to 
Mild 3.21* 0.32 -0.03* 51.46 
High Moderate Improving 5.66* 0.34 0.01 18.26 
Cycle 3 
Mild Improving 1.76* -0.12 0.00 106.24 
Low Moderate Improving to 
Mild 2.52* 0.65* -0.06* 41.50 
High Moderate Improving 5.43* 0.60* -0.06* 18.26 
Disturbed Sleep 
Cycle 2 
Mild Improving 1.74* -0.20* 0.01 145.85 
Moderate Worsening 3.76* -0.28 0.03 18.15 
Cycle 3 
Mild Improving 0.87* -0.07 0.00 133.65 
Mild Worsening 1.66* 0.14 0.00 31.35 
Depressed Mood 
Cycle 2 
Consistently Mild 0.78* -0.04 0.00 148.50 
Consistently Moderate 4.04* 0.22 -0.01 14.85 
Cycle 3 
Consistently Mild 0.27 0.13 -0.01 155.10 
Moderate Improving 4.82* 0.23 -0.02* 9.90 
Anxiety 
Cycle 2 
Consistently Mild 0.69* -0.10* 0.01* 156.75 
Consistently Moderate 4.90* 0.03 0.00 8.25 
Cycle 3 
Consistently Mild 0.34* -0.03 0.00 156.75 
Low Moderate Improving to 






over multiple cycles of chemotherapy.  However, even the reports of fatigue are based on 
a single aggregate trajectory and further study is needed to discover whether individuals 
differ in their class membership across multiple cycles of chemotherapy.  Cross-
tabulations and Chi square were used to compare whether extracted predicted class 
memberships varied within individuals between cycle 2 and cycle 3 for these four 
symptoms of interest.  Of those in the mild improving fatigue class during cycle 2, 6.8% 
moved to the low moderate improving to mild fatigue class and 1.1% moved to the high 
moderate improving fatigue class during cycle 3.  Of those in the low moderate 
improving to mild fatigue class during cycle 2, 25% moved to the mild improving fatigue 
class and 18.8% moved to the high moderate improving fatigue class during cycle 3.  Of 
those in the high moderate improving fatigue class during cycle 2, 22.2% moved to the 
mild improving fatigue class and 33.3% moved to the low moderate improving to mild 
fatigue class during cycle 3.  Of those in the mild improving disturbed sleep class during 
cycle 2, 6.9% moved to the mild worsening disturbed sleep class during cycle 3 and 64% 
moved from the moderate worsening disturbed sleep class during cycle 2 to the mild 
improving disturbed sleep class during cycle 3.  There was no movement from the 
consistently mild depressed mood class to the moderate improving depressed mood class 
between cycles, but 57.1% of those in the consistently moderate depressed mood class 
during cycle 2 moved to the consistently mild depressed mood class during cycle 3.  
Finally, while only 5.4% of those in the consistently mild anxiety class during cycle 2 
moved to the low moderate improving to mild anxiety class during cycle 3, 37.5% of 
those in the low moderate improving to mild anxiety class during cycle 2 moved to the 




and more importantly, the small class counts for the moderate and severe symptom 
classes across all four symptoms make it difficult to tease out potential moderating 
factors for class movement, such as age, stage of disease, or chemotherapy regimen.  
Additionally, because this was a secondary analysis, data related to symptom 
management strategies used during cycle 2 could not be controlled for to adjust a study of 
class movement.  Research is needed, with larger samples, to determine if these patterns 
of movement do exist and potential correlates of movement between classes.  Possible 
methods include both visualization and statistical repeated-measures longitudinal 
analysis.  
 The second aim was to identify multisymptom trajectory classes of women 
undergoing cycles 2 and 3 of chemotherapy for breast cancer.  A multisymptom model 
was not identified in this sample. Because individual symptom multiclass models were 
not retained for trouble thinking, sore mouth, distress with changing appearance, 
diarrhea, nausea and vomiting, or pain, these symptoms were excluded from a 
multisymptom model analysis.  Even with only including symptoms with retained 
multiclass models, a multisymptom model using fatigue, disturbed sleep, depressed 
mood, and anxiety was likely underpowered given the modest sample size and large 
variability in the number of days with reported symptoms.  There are two likely 
explanations for this lack of findings.  First, it is possible that a model explaining the 
trajectory of multiple symptoms in women receiving chemotherapy for breast cancer does 
not exist.  However, this is unlikely, as several recent reports suggest that symptoms may 
exist in combination during chemotherapy and individuals may be at risk for these 




Farr, 1999; Berger & Higginbotham, 2000; Bower et al., 2011; Broekel, Jacobsen, 
Horton, Balducci, & Lyman, 1998; Jacobsen et al., 1999; Byar, Berger, Bakken, & Cetek, 
2006; Dodd, Cho, Cooper, & Miaskowski, 2010; Gaston-Johannson et al., 1999; Liu et 
al., 2009; Liu et al., 2012; Molassiotis, Yam, Yung, Chan, & Mok, 2002; Osoba et al., 
1997; Poon et al., 2013; So et al., 2009).  These studies report the existence of concurrent 
symptoms among those symptoms that are more commonly prevalent, such as fatigue, 
disturbed sleep, depressed mood, anxiety, pain, and nausea and vomiting.  In our sample, 
there was marked within-class variability in the growth factor parameters.  While a 
mixture distribution may well represent the diversity in these symptoms, we did not have 
the sample size needed to recover classes.  Future designs may be more successful with 
larger samples and the addition of model constraints to address these highly variable 
symptom experiences and increase statistical power. 
 With the second aim unanswered, an exploratory analysis was undertaken to 
determine whether various demographic, clinical, and symptom characteristics were 
predictive of class membership for each individual symptom of fatigue, disturbed sleep, 
depressed mood, and anxiety.  Aim three was to determine if demographic, clinical and 
symptom variables predict membership in distinct individual symptom trajectory classes.  
The specific research question was the following: To what extent are differing symptom 
trajectory profiles associated with variations in age, chemotherapy regimen, stage of 
disease, marital status, employment, education, and the presentation of other symptoms at 
moderate to severe severity? 
For all four symptoms, univariate tests of mean differences among classes on 




regimen and education.  For fatigue, depressed mood, and anxiety, women who received 
Doxorubicin as part of their chemotherapy regimen were more likely to be in the higher 
severity classes.  These findings cannot be verified with previous reports, as the effect of 
chemotherapy type on symptom presentation is understudied and inconsistently reported 
in the literature (Berger, 1998; Berger & Farr, 1999; DeJong, Kester, Schouten, Abu-
Saad, & Courtens, 2006).  Across the sample, more than 12 different chemotherapy 
combinations were reported, making it difficult to adequately address the question of how 
chemotherapy regimen was associated with class membership.  Further study is needed to 
determine whether the use of Doxorubicin places women at risk for higher fatigue, 
depressed mood, and anxiety and whether this effect is dose-dependent or related to other 
agents received in combination with Doxorubicin.  Additionally, for anxiety, women with 
no college education were more likely to be in the moderate symptom severity class when 
compared to women with a college degree.  This finding, in combination with previous 
reports, suggests that higher educational attainment may be associated with lower anxiety 
during chemotherapy, although further research is needed to replicate these observations 
(Lam et al., 2010).    
Inconsistencies between our findings and previously reported findings of the 
relationship between demographic and clinical characteristics and symptoms may be 
related to limited variability in the sample with respect to demographic characteristics, 
and the relatively small sample size in the present study.  The number of women who 
were predicted in the higher severity classes for all symptoms was low and this may have 
decreased the power to detect differences among the classes on these variables.  Further 




distinct symptom classes. 
 Membership in higher fatigue classes was associated with increased number of 
days of moderate to severe disturbed sleep, depressed mood, nausea and vomiting, 
anxiety, and trouble thinking.  The relationship between fatigue and disturbed sleep is not 
surprising and is consistent with previous reports (Berger & Farr, 1999; Berger & 
Higginbotham, 2000; Bower et al., 2011; Broekel et al., 1998; Jacobsen et al., 1999; Liu 
et al., 2009; Onselen et al., 2012).  Similarly, an increase in the number of days with 
moderate to severe fatigue was associated with membership in the moderate severity 
class for both depressed mood and anxiety.  Relationships among depressive symptoms, 
trouble sleeping, psychological distress, and fatigue have been reported by other 
investigators (Bender et al., 2005; Byar et al., 2006; Dodd et al., 2010; Gaston-Johannson 
et al., 1999; Kim et al., 2008; Liu et al., 2009; Niebor et al., 2005; So et al., 2009; Von 
Ah & Carpenter, 2008).  The finding that there is an association between sleep and mood 
disturbances during cycle 3 is consistent with observations about the co-occurrence of 
sleep difficulties, anxiety and depressed mood (Colagiuri et al., 2011; Onselen, Cooper et 
al., 2012).  Additionally, the number of days with moderate to severe levels of nausea and 
vomiting was increased in the severe fatigue class when compared to the minimal fatigue 
class.  There are several reports of a positive association between fatigue and 
chemotherapy-induced nausea and vomiting, even with use of appropriate anti-emetics 
(Molassiotis et al., 2002; Osoba et al., 1997; Poon et al., 2013).  In addition, the 
relationships between both fatigue and disturbed sleep with trouble thinking has been 
previously reported (Bender et al., 2005). 




associated with the moderate severity class for anxiety and depressed mood, respectively.  
The relationship between both symptoms of mood disturbance is well studied and 
commonly known as co-occurrence of anxiety and depressive symptoms or CADS 
(Colagiuri et al., 2011; Dunn et al., 2011; Gold et al., 2016; Lam, Shing, Bonanno, 
Mancini, & Fielding, 2012).  The co-existence of these symptoms suggests that etiology 
for one may explain the other and developing interventions aimed at managing one may 
assist in management of the other.  Unfortunately, data for several potential moderators 
of class membership for depressed mood and anxiety were not available on participants 
in this sample, including history of mood disturbance, measures of trait anxiety, and 
baseline measures of psychological health.  Future research should attempt to capture the 
potential relationship between depressed mood and anxiety and class membership for 
these co-existing symptoms.  
 Finally, for all four symptoms, across both cycles, the total number of days with 
moderate to severe symptoms, including fatigue, disturbed sleep, depressed mood, 
anxiety, nausea and vomiting, and pain during cycle 2, was associated with a higher 
severity class membership during cycle 3.  This suggests that the overall symptom 
experience during an earlier cycle may predict the occurrence of fatigue, disturbed sleep, 
depressed mood, and anxiety during a later cycle.  These results suggest that individuals 
with an increased overall symptom experience during an early cycle of chemotherapy 
may be targeted for increased symptom management in an effort to improve the symptom 
experience during subsequent cycles.   
 Aim four was to determine if distinct symptom trajectory classes were associated 




spent lying down during cycles 2 and 3 of chemotherapy for breast cancer.  The specific 
research question for this aim was the following: To what extent are differing symptom 
trajectory profiles associated with variations in change in functional status, days of 
missed work, and hours spent lying down as reported by women undergoing 
chemotherapy for breast cancer? 
We could not evaluate the association between change in functional status and 
latent class membership because of a large amount of missing data, and thus a change 
score for functional status could only be calculated for 12 women.   
Potential consequences of latent class membership for fatigue, disturbed sleep, 
depressed mood, and anxiety were studied and included average daily hours spent lying 
down and days of missed work.  Results of the significant outcomes are presented in 
Tables 5.2 and 5.3.  For fatigue, women in the high moderate improving class reported an 
average of 12.36 hours spent lying down, which was statistically significantly higher 
when compared to women in the mild improving class who reported an average of 10 
hours spent lying down during cycle 2. This is consistent with other studies that have 
found that higher fatigue is associated with lower activity levels (Berger & Farr, 1999; 
Berger & Higginbotham, 2000; deJong, Cantel, Shouten, Abu-Saad, & Courtens, 2004; 
Downie, Fan, Houede-tchen, Yi, & Tannock, 2006).  However, in cycle 3, there was no 
association between hours spent lying down and fatigue class membership, and the mean 
hours spent lying down were nearly identical across the three fatigue classes.  Further 
examination with larger samples may better highlight this association.  During cycle 2 
only, women in the consistently moderate anxiety class, as compared to women in the 



























Lying Down 10.00 (2.54) 10.79 (2.64) 12.36 (3.77) 
F(2, 44) = 2.03,
p = .02* 
Days Missed 
Work (n=20) 1.9 (1.52) 3.13 (2.03) 2.5 (2.12) 
F(2, 17) = 1.05,
p = .37 
Cycle 3 
Hours Spent 
Lying Down 10.44 (2.94) 10.71 (2.51) 10.05 (2.51) 
F(2, 150) = 0.35,
p = .70 
Days Missed 
Work (n=27) 1.33 (1.50) 1.43 (1.72) 2.20 (1.65) 
F(2, 24) = 0.51,
p = .61 





Mean Hours (SD) 
Consistently 
Moderate 
Mean Hours (SD) 
Independent-
Samples t test 
Hours Spent Lying 






Mean Hours (SD) 
Low Moderate 
Improving to Mild 
Mean Hours (SD) 
Independent-
Samples t test 
Hours Spent Lying 
Down 10.44 (2.75) 11.87 (3.20) 
t(150) = -1.77, 






 (mean hours 12.53 vs. 10.41).  No prior research has identified an association between 
inactivity and anxiety.  
All other tests of mean differences among the classes on the outcomes for hours 
spent lying down and days of missed work were nonsignificant.  While the omnibus test 
was nonsignificant during both cycles, the mean days of missed work increased as fatigue 
severity class increased.  Unfortunately, only 37.2% of the sample was employed either 
part or full-time and we were statistically underpowered to detect differences in missed 
work days among the fatigue latent classes.  The relationships between fatigue and days 
of missed work deserves exploration in a cohort with more employed participants.   
Limitations 
While LGMM is a useful technique for identifying subgroups of individuals who 
experience similar symptom trajectories, there are inherent limitations, including the 
assumption that classes represent unobserved population subgroups (Colder et al., 2002; 
Ialongo, 2010; Sterba & Bauer, 2010).  This is particularly problematic in cases with 
small sample sizes, a large number of assessments or measurement time points, and 
highly variable data.  Care should be taken to consider whether the size and nature of the 
data allowed the researcher to find multiple classes when they actually exist (Ialongo, 
2010).  While several subgroups were identified in this analysis of symptoms reported by 
women with breast cancer, the existence of latent class subgroups should not be over-
interpreted.  Ialongo (2010) suggests five steps that can be utilized to build the case for 
the existence of latent class subgroups, including providing a rationale for the chosen 
statistical approach, using substantive theory to hypothesize about subgroup existence, 




models, and considering sample size and the nature of the data.  These five steps are 
discussed in relation to our findings below. 
Providing Rationale for Approach 
Our selected approach for modeling the daily symptom reports was LGMM, 
which is well suited for symptom studies, where longitudinal patterns are of interest and 
models can identify homogeneous subgroups of individuals with similar symptom 
experiences.  The categorical latent variables correspond to the person-oriented 
component in that they represent a category or class that describes subgroups of 
individuals who are relatively homogeneous within that class and are heterogeneous 
across classes (Muthen & Muthen, 2000). LGMM also allows estimation of the 
relationship between class membership and antecedent or outcome variables (Muthen & 
Muthen, 2000).  A limitation of LGMM is the requirement for multiple measurement 
time points, with at least 4 or 5 time points preferred (Muthen & Muthen, 2000).  With 
this, comes the requirement for larger sample sizes to achieve adequate statistical power 
and allow for the assumed attrition rates.  While there is no general rule for determining 
sample size applicable to all situations in growth modeling, the Monte Carlo method has 
been recommended.  Assuming data are missing at random, the Monte Carlo method, 
which does consider the number of measurement time points, estimated a sample size 
requirement of between 150 and 250 participants for our study.  Our sample size of 166 
women was therefore at the lower limit of those estimates, adequate, but given the nature 
of symptom data, where some symptoms are highly variable among women and across 
days and other symptoms are often reported at a severity of zero, and the use of a large 




larger sample size would provide greater power to support our confidence in the 
existence of the identified latent classes.  In addition, greater power, through a larger 
sample size, may have allowed us to conclude that there were only single-class models 
for the 6 symptoms where we were unable to identify multiclass models.  
Use of Substantive Theory 
 Substantive theory assists in building the case for the existence of subgroups 
(Ialongo, 2010).  Comparison of our results to the few other studies reporting symptom 
trajectory subgroups revealed conflicting findings and therefore do not help to confirm 
our subgroup findings.  Several recent studies of the symptoms of mood disturbance and 
one study of disturbed sleep where growth mixture techniques were used, identified 
models with a greater number of classes when compared to our findings (Bistrup et al., 
2015; Dunn et al., 2015; Gold et al., 2016; Helgeson et al., 2004; Henselmans et al., 
2010; Lam et al., 2010; Onselen et al., 2012; Wang et al., 2014).  Differing findings 
among these subgroup studies and our study may be attributed to differing sample 
demographic and clinical characteristics, differing measurement time points, and 
differences in the instruments used to measure varying symptoms.  Additional research 
employing these kinds of longitudinal latent variable methods is warranted to better 
understand the trajectory of symptoms experienced during breast cancer.   
Tests of Antecedents and Consequences 
 Testing whether theoretically relevant covariates predict class membership 
probabilities and establishing the predictive value of classes can reassure researchers of 
the existence of classes (Ialongo, 2010).  Certainly, the identification of antecedents to 




argument for the existence of the identified classes, although these associations were 
limited to chemotherapy regimen, education, and hours spent lying down and were not all 
replicated during both cycles.  In addition, the identification of co-occurring symptoms 
within classes supports the existence of the identified classes.  The use of covariates as 
evidence of class existence is particularly relevant when the associated antecedents, co-
occurring symptoms, and outcomes are reported to relate to fatigue, disturbed sleep, 
depressed mood, or anxiety in the literature.  For example, we found that women in the 
low moderate improving to mild anxiety class during cycle 3 had lower educational 
attainment.  Consistent with these observations, Lam et al. (2010) noted that education 
was protective against psychological distress.  In this case, our finding was consistent 
with previous reports and serves as a support for the existence of the latent classes for 
anxiety we identified.  However, some of our significant associations have not been well-
studied and could not be substantiated in the published literature.  For example, we found 
that women in the consistently moderate anxiety class during cycle 2 reported higher 
average daily hours spent lying down when compared to women in the consistently mild 
anxiety class.  However, no reports were found in the literature where differences in 
activity level or resting hours were associated with the severity of anxiety during 
treatment, and we were unable to verify our finding with those of previous studies.  Here, 
our significant association between an outcome and class membership for anxiety is not 
as helpful in supporting the existence of the latent classes.  There were several non-
significant associations in our sample that have been reported to exist in the literature, 
including the reported relationship between age and disturbed sleep.  Additionally, some 




either conflicting or are inconsistently reported.  For example, we found that women in 
the higher severity classes for fatigue, depressed mood, and anxiety were more likely to 
have receiving Doxorubicin as part of their chemotherapy regimen.  Unfortunately, we 
were unable to verify these findings with previous reports, as the effect of chemotherapy 
type on symptom presentation is understudied and inconsistently reported.  Again, our 
finding of an association between an antecedent and class membership for fatigue, 
depressed mood, and anxiety was not supported in the literature, and is not as helpful in 
building confidence towards the existence of the identified latent classes.  One possibility 
is that differences between our findings and those previously reported may be related to 
our small sample size and resultant low statistical power, or to low proportions in some of 
the classes.  For example, Table 5.4 presents the model predicted class counts for the 
identified latent classes of fatigue, disturbed sleep, depressed mood, and anxiety.  The 
class proportions are low in the higher severity classes for all symptoms, and particularly 
for the symptoms of mood disturbance.  Tests of between-group differences among the 
classes may have had attenuated power, resulting in differences between our results and 
those reported by other investigators. As such, there remains the possibility that the 
classes we identified do not completely represent the symptom trajectories experienced 
during cycles 2 and 3 of treatment for breast cancer.  The findings reported here should 
not be over-interpreted, and continued study of this important aspect of the treatment 
experience is warranted.   
Comparing Alternative Models 
 Comparing the results of an alternative modeling approach and model fit can also 




Table 5.4 Class Counts for Fatigue, Disturbed Sleep, Depressed Mood, and Anxiety 
Class Class Count 
Fatigue 
Cycle 2 
Mild Improving 97.94 
Low Moderate Improving to Mild 51.46 
High Moderate Improving 18.26 
Cycle 3 
Mild Improving 106.24 
Low Moderate Improving to Mild 41.50 
High Moderate Improving 18.26 
Disturbed Sleep 
Cycle 2 
Mild Improving 145.85 
Moderate Worsening 18.15 
Cycle 3 
Mild Improving 133.65 
Mild Worsening 31.35 
Depressed Mood 
Cycle 2 
Consistently Mild 148.50 
Consistently Moderate 14.85 
Cycle 3 
Consistently Mild 155.10 
Moderate Improving 9.90 
Anxiety 
Cycle 2 
Consistently Mild 156.75 
Consistently Moderate 8.25 
Cycle 3 
Consistently Mild 156.75 







that this method uses a formal statistical procedure to test whether the hypothesized 
trajectories actually emerge from the data rather than assume the existence of a particular 
number of trajectories or classes (Andruff, Carraro, Thompson, Gaudreau, & Louvet, 
2009).  The simplest assumption, a single-class model, was hypothesized first.  Classes 
were added to the model to determine the solution, or the number of classes, that best fit 
the data.  Intercepts, slopes, and possibly quadratic or cubic functions were determined 
for each class.  In our study, multiple model fit indices guided the determination of the 
number of classes retained.  Of primary interest were the Bayesian Information Criterion 
(BIC) and entropy, along with the Akaike Information Criterion (AIC), Bootstrapped 
Likelihood Ratio Test (BLRT), and the Vuong-Lo-Mendell-Rubin Test (VLMR).  The 
BIC was used to evaluate improvement in model fit as additional classes were added.  
Smaller BIC values suggested a better model fit (Colder et al., 2002; Muthen & Muthen, 
2000).  If the addition of a class resulted in a reduction in the BIC value relative to the 
BIC from the previous model (without the added class), then the new model was 
considered an improvement and the model was retained.  The addition of classes 
continued until the BIC did not decrease with the addition of a class.  Additionally, 
entropy was used to evaluate the probabilities of membership in each class for each 
individual.  Entropy is a summary measure of classification accuracy based on these 
probabilities that ranges from 0 to 1.0 (Colder et al., 2002).  The closer entropy values are 
to 1.0, the better the classification.  Model selection was determined by multiple 
additional criteria, including the “K” versus “K-1” class models to determine whether a 
model with K classes fit the data better than a model with “K-1” classes using the 




Likelihood Ratio Tests (VLMR) (Dunn et al., 2011; Jung & Wickerama, 2008; Nylund, 
Asparouhov, et al., 2007; Nylund, Bellmore, et al., 2007).  Finally, to determine the best-
fitting model, the distribution of subjects in each class (class proportions) were examined, 
and the class-specific trajectories were graphed and visually inspected to determine if the 
predicted trajectories were clinically meaningful and theoretically interpretable (Onselen, 
et al., 2012).  The retained models were those that produced the best fit indices relative to 
the other tested models, with class proportions of greater than 5% of the sample.  For 
fatigue, the 3-class model was retained because it produced a lower BIC and higher 
entropy when compared to the 2-class model, but was more parsimonious and clinically 
relevant when compared to the 4-class model during both chemotherapy treatment cycles.  
Additionally, one of the classes in the 4-class model during treatment cycle 3 had class 
proportions of less than 5%.  For disturbed sleep, depressed mood, and anxiety, 2-class 
models were retained because the 3-class models had class counts of 5% or less for at 
least one class.  Use of model fit indices for selecting the best fitting model in 
comparison to other models helps to strengthen our confidence in the existence of the 
identified classes. 
Considering Sample Size and the Nature of the Data 
 In our study, steps were taken to build the case for subgroup existence in our 
sample, including use of parsimony and substantive theory as well as use of model fit 
indicators, but the sample size and nature of the data available limit the usefulness of 
LGMM.  This study was limited in sample size to the participants in the primary studies 
who met the criteria for this secondary analysis.  Certainly a larger sample size would be 




and stability of class definitions (Colder et al., 2002).   This may be especially true in 
cases of relatively low base rate outcomes, such as rarer symptoms or symptoms often 
reported at a severity level of zero (Ialongo, 2010).  While our sample of 166 women was 
minimally acceptable to apply LGMM for subgroup identification, the degree of 
variability in women’s symptom trajectories potentially warranted a larger sample to 
identify classes that could be described with confidence.  
 Particular care should be given to the nature of the data in our study and the 
usefulness of LGMM in modeling symptom trajectories with daily reporting.  In our 
identified models, and given the use of daily symptom severity reporting, it is likely that 
there is more variability within the classes than the presented growth factors adequately 
represent.  As an example of this, examination of spaghetti plots of a random sample of 
10 women drawn from each of the severity classes for fatigue during cycle 2 
demonstrates the degree of variability and inability to visually discern patterns among 
women with predicted membership in the same classes (see Figure 5.1).  Additionally, 
because symptoms peak and ebb, there was a large number of days where women 
reported zero severity on symptoms.  The reliance on aggregated means with many daily 
reports of zero may have decreased the aggregate means for the growth factors and 
therefore may not well-represent the actual severity pattern of the symptoms (see Table 
5.5).  Examination of a random sample of 10 women predicted in each of the fatigue 
severity classes (see Figure 5.2-5.4) during cycle 2 demonstrates the effect of the days 
with zero severity on the fitted line plots for individuals.  The prevalence of days with 
zero severity on the reported symptom may reduce the overall mean severity for 







Figure 5.1 Spaghetti plots demonstrating high variability in trajectories of fatigue across 








Table 5.5 Number of Days Symptoms Reported at Various Severity Levels 
 
Symptom Cycle 
No. Days (%) 
Symptom 
Reported Level 0 








Fatigue a 2 659 (36.4%) 1152 (63.6%) 585 (32.3%) 3 654 (38.4%) 1050 (61.6%) 520 (30.5%) 
Disturbed Sleep a 2 1354 (74.8%) 457 (25.2%) 296 (16.3%) 3 1330 (78.1%) 374 (21.9%) 209 (12.3%) 
Pain a 2 1247 (68.9%) 564 (31.1%) 263 (14.5%) 3 1167 (68.5%) 537 (31.5%) 274 (16.1%) 
Nausea and 
Vomiting a 
2 1359 (75.0%) 542 (29.9%) 208 (11.5%) 
3 1254 (73.6%) 450 (26.4%) 198 (11.6%) 
Diarrhea a 2 1664 (91.9%) 147 (8.1%) 55 (3.0%) 3 1575 (92.4%) 129 (7.6%) 49 (2.9%) 
Sore Mouth a 2 1565 (86.4%) 246 (13.6%) 118 (6.5%) 3 1478 (86.7%) 216 (12.7%) 91 (5.3%) 
Trouble Thinking b 2 884 (93.2%) 64 (6.8%) 37 (3.9%) 3 776 (94.1%) 46 (5.6%) 20 (2.4%) 
Appearance b 2 882 (93.0%) 66 (7.0%) 42 (4.4%) 3 801 (97.1%) 24 (2.9%) 17 (2.1%) 
Depressed Mood a 2 1455 (80.3%) 356 (19.7%) 226 (12.5%) 3 1416 (83.1%) 288 (16.9%) 158 (9.3%) 
Anxiety a 2 1544 (85.3%) 267 (14.7%) 147 (8.2%) 3 1483 (87.0%) 221 (13.0%) 106 (6.2%) 
a 1811(78.4%) days reported cycle 2, 1704(78.0%) days reported cycle 3; 499(21.6%) days missing cycle 2, 
480(22.0%) days missing cycle 3 
b 948 (80.6%) days reported cycle 2, 825 (79.6%) days reported cycle 3; 228 (19.4%) days missing cycle 2, 211 
(20.4%) days missing cycle 3 
 



















Figure 5.3 Fitted line plots for random sample of 10 women in the low moderate 














Figure 5.4 Fitted line plots for random sample of 10 women in the high moderate 










The result would be to systematically underestimate symptom severity. 
Naming of the classes in our models was qualitatively achieved using 
visualization of the mean class trajectories.  Class names were based on common 
category nomenclature for symptom severity, none (0), mild (0-3), moderate (4-7), and 
severe (7-10) for the intercept and a description of the slope and quadratic terms, whether 
consistent, improving, or worsening within the same severity threshold or moving 
between categories.  These labels might be misleading as average severities were 
influenced by the zero severity reports and this impact is greater in symptoms that occur 
less frequently.  Trajectories that varied greater than one severity degree during the 14 
days were considered to be improving or worsening, depending on their directionality.  If 
the change moved to a differing severity category, it was indicated in the name.  
Examination of the standard errors for the parameter estimates in our models revealed 
large confidence intervals in many cases, indicating the range of possible values that were 
likely to include the population parameter.  In cases where the range included the 
possibility of zero, those growth parameters were considered not statistically significant.  
For example, during cycle 2, the slopes for both the low moderate improving to mild 
fatigue class and the high moderate improving classes were nonsignificant (see Table 
5.6).  However, visualization of the trajectories revealed an improvement in the severity 
of fatigue during the chemotherapy cycle (see Figure 5.5).  Here, improvement was 
indicated in the class names, even with confidence intervals suggesting a range of values 
that could include zero.  Caution should be considered in determining the validity and 
statistical significance of the growth parameters and in the methods used for naming the 



































*p < .05 
 





Of additional concern is the nature of the data collection procedures with regards 
to the days where all symptoms were reported at a severity of zero.  For all days, women  
had the option of reporting that they had no symptoms in a single response measure.  This 
allowed women to be compliant in calling and indicate quickly no symptoms, but there 
remains the possibility that women used this option when they may have been 
experiencing symptoms, wanted to comply with the daily calling, but only had time for a 
brief call.  Table 5.7 provides an example of the number of days where 30 women, taken 
as random samples of 10 women from each fatigue class during, reported zero on fatigue 
during cycle 2, the number of days where women reported zero on all symptoms using 
the single response option compared to the number of days where fatigue was scored as 
zero while other symptoms were reported individually at severities above zero.  From this 
random subsample, it does appear that there were days where women used the single 
response score to indicate a fatigue severity of zero, and it is possible that in some cases, 
this response may not have accurately reflected the symptom severity, but rather the need 
to shorten the call length.  Caution should be used when interpreting the results of our 
study, especially with regards to the number of days women reported zero severity and 
the effect of those zeros on the symptom trajectories and parameter means.  
Limitations related to sample size and the nature of our data result because this 
was a secondary data analysis using previously collected data.  We were constrained in 
sample size to those women who met the inclusion criteria and were available for this 
secondary analysis.  Additionally, the sample was fairly homogenous in ethnicity and 
marital status, possibly limiting the generalizability of the findings.  Several variables, 




Table 5.7 Example of Days With Reported Zero Severity on Fatigue for Random Sample 
of 10 Women From Each Fatigue Severity Class During Cycle 2 
 
Fatigue Class  
Random Sample 
(n=30) 
Total Days Zero on 
All Symptoms  
(Single Score) 
Total Days Zero on 
Fatigue (Reported 
Severity on Some 
Other Symptom)  
Total Days Zero on 
Fatigue  
(Total) 
Mild Improving 17 38 55 
Low Moderate 
Improving to Mild 13 21 34 
High Moderate 
Improving 9 7 16 
 
 
   





unavailable, including history of psychological illness or distress, comorbidities, and the 
use symptom management strategies. 
Reported chemotherapy regimens varied in cycle length and dosing.  For 
consistency in capturing the symptom trajectories over a similar period of time for each 
participant, only data collected during the first 14 days of each cycle were included in the 
analysis.  While this limits the interpretability of the results to the first 14 days of each 
cycle, it does capture acute phase following chemotherapy administration and only 
negates the period of time where symptoms may return to a precycle baseline in cases of 
longer cycles.  In addition, some women may have received weekly chemotherapy 
treatments, which means they potentially received two doses of chemotherapy during the 
14 day period of interest.  Future work should focus on capturing the entire cycle of 
chemotherapy, regardless of length, to determine whether and how these symptoms 
trajectories differ among the classes within and after the first 14 days. 
 Given the limitations of LGMM, particularly with reference to our sample size 
and the nature of our data, care should be given in the interpretation of our findings and 
the application to further research and practice.  A next step would certainly involve 
consideration of other analytic methods for describing the variation in symptom 
trajectories among women receiving chemotherapy for breast cancer.  Other potentially 
useful methods may include visualization and pattern-based methods and less-restrictive 
variable-oriented methods such as Latent Growth Curve Modeling, which is used to 
model quantitative individual differences in developmental change, but does not predict 
class existence (Sterba & Bauer, 2010).  Additionally, Latent Class Growth Analysis may 




trajectories are identified, but without variability within the classes (Sterba & Bauer, 
2010).  Finally, attempts to replicate the findings of our study using LGMM, should 
consider larger sample sizes to strengthen the confidence in the existence of latent 
trajectory classes, expecting large variability among the reported symptom severities.    
Recommendations for Future Research 
 This study contributes to a growing body of cancer-related symptom literature, 
including the development of a person-focused nursing symptom science congruent with 
person-centered nursing practice (Henly, Wyman, & Findorff, 2011).  A unique 
contribution of this study is the modeling of change over time, using a health trajectory 
perspective that is dynamic, idiographic, and person focused (Henly et al., 2011).  
Additionally, this study tested for associations between various theoretically relevant 
variables and latent class membership for fatigue, disturbed sleep, depressed mood, and 
anxiety.  Given the limitations described above with regards to the usefulness of LGMM 
and cautions related to sample size and the nature of the data, future research should first 
seek to determine whether LGMM is the best method for describing patterns of change in 
symptom presentation where daily severity data are available and many days are reported 
as mild or zero severity for many symptoms.  While we were unable to identify subgroup 
models for many of the individual symptoms, these symptoms were still present in our 
sample and warrant discussion in the symptom literature.  Methods that include 
visualization of the data may assist in better understanding the unique patterns with 
which many symptoms present.  Building off the reported findings of this study, future 
research should focus on determining whether these classes are replicable and stable 




covariates, or long-term outcomes of class membership, including genetic and molecular 
factors.  
Although we were able to find changes in class membership between cycles, 
because of methodological limitations, including sample size, we were unable to test for 
factors unique to those who switched class. Methodological advancements are needed to 
better understand this phenomenon, with the possible use of visual techniques and 
advanced statistical methods.  Future research should consider varying methods for 
studying movers and stayers between consecutive cycles of chemotherapy.   
 This study utilized constructs shared across four symptom theories: the 
multiplicative nature of symptoms and the existence of antecedents and consequences to 
the symptoms (Barsevick, 2007; Cleeland et al., 2003; Dodd et al., 2001; Parker, Kimble, 
Dunbar, & Clark, 2005).  In addition, this study assumed that symptoms co-occur in 
individuals in such a way that those individuals can be subclassified based on their 
unique symptom trajectories.  Potential covariates of class membership were studied, 
including various demographic and clinical factors.  While symptoms did, in fact, co-
occur throughout both cycles of chemotherapy in ways unique to the symptom class, the 
theorized antecedents did not associate with class membership in most cases. 
 Unfortunately, we were unable to describe a multisymptom latent class model in 
this sample.  Future work should focus on the co-existence of multiple symptoms, 
attempting to understand the etiological pathways that lead to multisymptom 
presentation.  When designing studies using complex longitudinal data, care should be 
taken to ensure the sample size accommodates for rare events and variability in severity 




multisymptom trajectory classes.  Accounting for these issues in symptom reporting may 
include methodological considerations such as the use of measures of prevalence versus 
severity or distress and the use of unique statistical methods for analysis, including 
visualization, growth modeling with constraints, and cluster analysis. 
 For all four symptoms, there were differences in class membership based on the 
presence of other symptoms at moderate to severe levels, suggesting a co-occurrence or 
co-existence of symptoms.  It is unknown whether these symptoms develop as a result of 
class membership or if class membership is predictive of symptom presentation.  One 
possible explanation for the co-existence of multiple symptoms is that interindividual 
variability in symptom expression may be related to genetic and molecular factors.  This 
would also explain the lack of relationship between the classes we identified and 
demographic and clinical factors, where those demographic and clinical factors do not 
adequately explain genetic differences among individuals (Miaskowski et al., 2014).  
There is significant evidence to support the role of cytokines and inflammation in 
symptom production.  Cleeland et al. (2003) suggest the concept of sickness behavior, 
which has been demonstrated in animal models, as an explanation for disease-related 
symptom presentation.  Sickness behavior in animals includes many symptoms that are 
similar to those experienced by cancer patients.  Proinflammatory cytokines, including 
interleukin -1, tumor necrosis factor-alpha, IFN-alpha, and IL-2, trigger cascade 
responses that produce symptoms, such as pain, fatigue, cognitive impairment, psychosis, 
and depressed mood.  Clinical evidence suggests that symptoms experienced during 
cancer treatment may be mediated by cytokines acting on the central and peripheral 




multiple symptoms in a variety of cancer populations with biologic markers of symptom 
mechanisms simultaneously collected.  Potential associations between symptoms 
presentation can then be studied, including the possibility that specific biomarkers will 
correlate with symptom class membership.  
 Through furthering our understanding of symptom presentation in this unique 
patient population, we can begin to develop and study potential symptom management 
strategies to support those who fall into the higher symptom severity classes and those 
who move into the higher symptom severity classes from a lower class during a previous 
cycle.  We can develop the evidence-base needed to understand women who may be at 
risk for higher severity of symptoms during chemotherapy and identify factors that may 
allow early intervention, including education, monitoring, and pharmacological 
management as needed.  By identifying women who may be at increased risk for higher 
severity of symptoms during chemotherapy and managing those symptoms as 
appropriate, those women may avoid poor outcomes known to be associated with 
increased symptom presentation, such as decreases in functional status, loss of 
employment and productivity, problems with treatment adherence, use of emergency 
room and hospitalization, and poor outcomes through survivorship (Beck et al., 2010; 
Bradley, Neumark, Luo, & Schenk, 2007; Byar et al., 2006; Cleeland et al., 2000). 
Recommendations for Clinical Practice 
 The findings of this study suggest that clinical practice must incorporate 
assessment and management of multiple symptoms early during the course of 
chemotherapy.  Forty-one percent of women reported fatigue at moderate to severe 




women reported depressed mood at moderate to severe levels, and 5% of women reported 
anxiety at moderate to severe levels during cycle 2.  Thirty-six percent of women 
reported fatigue at moderate to severe level, 19% of women reported disturbed sleep at 
moderate to severe levels, 6% of women reported depressed mood at moderate to severe 
levels, and up to 8% of women reported anxiety at moderate to severe levels during cycle 
3.  Recognizing the existence of a percentage of women who experience individual 
symptoms at moderate to severe levels across multiple cycles of chemotherapy is 
important, as not all women will need the same level of symptom management.  Of 
importance, the identified trajectory classes suggest that women who report an initial 
value of moderate or greater severity of fatigue, disturbed sleep, depressed mood, or 
anxiety may continue with the symptom at some severity.  Many of the classes showed an 
improvement in trajectory, but not always to a mild level.  In addition, the worsening 
disturbed sleep class trajectories suggest that these women, who reported an initial 
severity of moderate level, experienced an increase in the symptom during the 14 days.  
Clinicians should be aware that women who report an initial symptom severity on the 1st 
day of chemotherapy at moderate to severe levels may benefit from increased symptom 
surveillance and management. This small percentage of women who reported symptoms 
at moderate to severe levels were at increased risk for development of a variety of co-
existing symptoms, including fatigue, disturbed sleep, depressed mood, anxiety, nausea, 
and pain.  Additionally, these women may have been at increased risk for poorer 
outcomes, including decreased activity and missed work.  Understanding that the 
presence of severe symptoms during cycle 2 may predict symptom presentation during 




chemotherapy.  Practitioners need to assess for and be aware of symptoms early in the 
course of chemotherapy, as the results of this study suggest that symptoms persist from 
one cycle to the next.  Patient and caregiver education should be directed at not only self-
care and pharmacological management strategies but also at recognizing and reporting 
the existence of symptoms to practitioners.  Additionally, practitioners need to be aware 
that symptoms often co-occur and that the dynamic process of multiple symptoms may be 
influenced by management of a single symptom.  Symptom management, as derived from 
the evidence-base, needs to be aimed at those women most at-risk for the development of 
significant symptom severity. 
Summary 
 Results of this study add to our knowledge of the symptoms experienced by 
women undergoing chemotherapy treatment for breast cancer.  This study demonstrates 
that symptoms are highly prevalent, often at moderate to severe levels and that symptom 
trajectories are dynamic.  Additionally, this study points to the existence of distinct 
classes of women who experience moderate to severe levels of fatigue, disturbed sleep, 
depressed mood, and anxiety.  While the majority of women experience low to moderate 
levels of symptoms, a small, but significant percentage of women experience symptoms 
at moderate to severe levels throughout two cycles of chemotherapy.  While demographic 
factors were not related to symptom trajectory class, the type of chemotherapy and the 
presence of other symptoms was.  Finally, higher overall symptom severity during cycle 
2 predicted the presence of individual symptoms at moderate to severe levels during 
cycle 3.  Further research is needed to support the existence of these classes, with larger 




class membership across multiple cycles is needed.  Further examination of co-existing 
symptoms over multiple cycles of chemotherapy, using longitudinal data reporting on the 
severity of symptoms in needed.  Future research designs may consider the usefulness of 
LGMM in capturing the dynamic nature of the symptom experience, with inherent 
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